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Abstract 
Protein acyltransferases (PATs), a group of enzymes catalysing fatty acylation of a variety of 
proteins, play an important role in protein sorting and signalling in the cell. In the Hedgehog 
(Hh) signalling pathway the PAT Hedgehog acyltransferase (Hhat) is responsible for addition 
of a palmitic acid to the N-terminal cysteine of Hh proteins. This modification is necessary 
for proper packaging and release of Hh ligands from the signalling cell and for transmitting a 
potent signal to the receiving cell. Hh signalling regulates cell growth and differentiation. 
Improper activation of the Hh signalling pathway in cancer arises either through an 
upregulation of ligand-dependent autocrine or paracrine signalling, or oncogenic mutations 
in the signal receiving cell. To date, drug therapies targeting the pathway in cancer have 
been directed at pathway regulators downstream of ligand binding. In this thesis, I 
investigate the potential of Hhat as a therapeutic target in lung cancer cell lines that express 
Sonic hedgehog (Shh). Studies of lung cancer cell lines A549, H209 and H82 treated with Shh 
pathway inhibitors showed no autocrine dependence on Shh signalling. Nonetheless, A549 
cells were capable of inducing a Shh signal response in C3H10T½ cells in co-culture in a 
juxtacrine/paracrine fashion indicating that Shh in lung cancer cells may be involved in 
juxtacrine/paracrine signalling to the surrounding stroma. This effect was effectively 
attenuated by siRNA-mediated Hhat knock-down confirming the potential of Hhat as 
therapeutic target in cancer. I further provide a membrane topology model of Hhat which 
will aid in understanding the molecular mechanism of this enzyme. Membrane topology 
determination resulted in a topology model where Hhat consists of 11 transmembrane 
regions with the signal peptide preserved in the mature protein. Surprisingly, the suggested 
catalytic site, a conserved His, is localised in a transmembrane region near the cytosol away 
from the site of Hh palmitoylation which occurs in the lumen of the endoplasmic reticulum. 
Taken together, my results provide a firm basis for further investigation of the mechanism 
of action of Hhat and its role as a potential drug target in multiple human cancers. 
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1 Introduction 
Cells in a multi-cellular organism communicate with each other by means of intercellular 
small molecule or protein signals to coordinate tissue development, tissue homeostasis, 
immune responses and tissue repair after injury. These signals can be transferred by direct 
cell-cell contact (juxtacrine signalling), by spreading over distances of several cell diameters 
(paracrine signalling) or by systemic transfer in the blood reaching the entire organism 
(endocrine signalling). Hedgehog (Hh) proteins are highly conserved signalling molecules 
involved in embryonic development of all metazoans. In recent years, they have also been 
shown to function as important regulators of adult tissue homeostasis and tissue repair 
after injury. The complex orchestration of these events is tightly regulated and while the 
entire mechanism is not yet fully understood, several key regulatory features of Hh 
signalling have been elucidated. One of these features includes the dual lipidation of Hh 
proteins during signal production. Hh proteins are modified with a cholesteroyl moiety at 
the C-terminus and a palmitoyl moiety at the N-terminus and these modifications are 
necessary to produce a functioning signal. Disregulation of the Hh signal during 
embryogenesis leads to a variety of developmental malformations, while inappropriate 
pathway upregulation in adults can contribute to tumour development. While 
cholesteroylation is an autocatalytic process, palmitoylation is catalysed by Hedgehog 
acyltransferase (Hhat), a multispanning membrane protein. The importance of Hhat for 
proper Hh signalling has been demonstrated in numerous in vitro models as well as in 
developmental mouse models. However, Hhat as a potential drug target in cancers 
dependent on aberrant Hh signalling has not yet been assessed. It is therefore of interest to 
provide proof-of-concept that Hhat is a viable pharmacological target in cancer cells and to 
explore this enzyme in more detail. This has been the focus of my thesis studies. 
1 Introduction 
28 
1.1 Hh signalling 
1.1.1 Hh in development and homeostasis 
Morphogens are secreted signalling molecules which emanate from a restricted region of a 
tissue and spread away from the source to form a concentration gradient inducing specific 
responses at distinct concentrations. Hh proteins act as morphogens to regulate cell 
proliferation, differentiation and tissue patterning during embryonic development. The Hh 
gene was first discovered during genetic studies of embryonic development in Drosophila 
melanogaster (Nusslein-Volhard and Wieschaus, 1980). To identify genes involved in larval 
development, Nusslein-Volhard and Wieschaus looked at the segmentation pattern of the 
larval body which is comprised of eleven segments marked with a polarised band of 
denticles on its anterior side and a band of naked cells on its posterior side. After disruption 
of the Hh locus, mutant larvae were considerably smaller in size and had lost their segment 
polarity as well as the band of naked cells normally present in each segment. This resulted in 
an irregular lawn of denticles resembling the spikes of a hedgehog giving the gene its name 
(Figure 1.1). 
 
Figure 1.1 Segment polarity in normal Drosophila larva and larva with deleted Hh locus. 
Normal larvae consist of three thoracic (T1-3) and eight abdominal (A1-8) segments marked by 
denticles on their anterior side. Compared to normal larvae (left), Hh deletion mutants lose 
segment polarity and are considerably smaller in size (right). Adapted from Nusslein-Volhard 
and Wieschaus, 1980. Reprinted by permission from Macmillan Publishers Ltd. 
1 Introduction 
29 
More than a decade later, three mammalian Hh homologues encoded by separate genes 
were identified; Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh) 
(Echelard et al., 1993). Shh, Dhh and Ihh are highly similar in their peptide sequence where 
Shh and Ihh share 90% sequence identity with each other and further 80% identity with 
Dhh. Dhh is most similar to Drosophila Hh. Although they are differentially distributed in the 
body, they are all processed in the same way and share all known interaction partners. Since 
their discovery, Hh proteins have been found to be involved in embryonic patterning 
throughout the animal kingdom (Ingham et al., 2011). Only the commonly used model 
organism Caenorhabditis elegans has so far been found to lack Hh homologues (Hao et al., 
2006).  
The Hh pathway is one of a handful of central signalling pathways responsible for early 
embryonic development. Others include the Wnt, Notch and transforming growth factor-β 
(TGF-β) signalling pathways. These pathways work in concert to create specific responses in 
surrounding cells controlling the cell fate in developing tissues by regulating target gene 
expression. Shh is the most studied of the three mammalian Hhs and is also the most 
broadly expressed. During early vertebrate embryogenesis, Shh is expressed in midline 
tissues controlling the development of the neural tube and the patterning of the left-right 
and dorso-ventral (top-bottom) axes of the embryo (Varjosalo and Taipale, 2008, Ingham 
and McMahon, 2001). Later during embryogenesis, it is involved in the patterning of the 
limbs and the development of epithelial tissues in most organs such as the lung, gut, 
pancreas, taste buds, smooth muscles and eye. Ihh is predominantly involved in early 
vasculogenesis of the embryo and the formation of bone and cartilage. Dhh is the least 
widely expressed homologue and has only been found during the development and 
maturation of the testis and the ovary (Varjosalo and Taipale, 2008, Ingham and McMahon, 
2001). 
In adults, the Hh signal is only active in stem cell-like progenitor cells responsible for 
maintenance and regeneration of epithelial tissues in need of constant renewal, e.g. taste 
bud (Miura et al., 2001), gut (van den Brink, 2007), lung (Watkins et al., 2003) and hair 
follicle (St-Jacques et al., 1998). The pathway is also upregulated in tissue regeneration after 
injury, e.g. in the lung (Watkins et al., 2003) and after bone breakage (Miyaji et al., 2003). 
Shh has more recently been implicated in the maintenance of the blood-brain barrier 
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(Alvarez et al., 2011, Amankulor et al., 2009) and brain tissue repair after injury (Amankulor 
et al., 2009).  
1.1.2 Hh signalling in disease 
Disregulation of the Hh signal during embryogenesis leads to a variety of developmental 
malformations (Cohen, 2010). These include various forms of holoprosencephaly, a 
condition in which the forebrain fails to divide in two halves during development where the 
most severe form is cyclopia and less severe forms are cleft lip and milder facial 
malformations. Other malformations include polydactyly (additional fingers or toes) and 
polysyndactyly (fusion of two or more fingers or toes). Inherited mutations in Ptch1, the 
gene encoding the Hh receptor, may also lead to nevoid basal cell carcinoma syndrome 
(Gorlin syndrome), a condition involving skin malformations often resulting in multiple basal 
cell carcinomas. Further, somatic pathway mutations and inappropriate expression of Hh 
ligands are known to lead to tumour development in adults (discussed in detail in Section 
1.1.4).  
1.1.3 The Hh signalling pathway 
1.1.3.1 Hh expression and processing 
Hh proteins are expressed as 50 kDa proproteins composed of a signal peptide directing 
them to the endoplasmic reticulum (ER), a 19 kDa N-terminal signalling domain and a 28 kDa 
C-terminal autoprocessing domain (Lee et al., 1994). On their way through the secretory 
pathway, Hh proteins undergo extensive post-translational modifications. On entry into the 
ER the signal peptide is cleaved off exposing a conserved N-terminal Cys residue. This Cys is 
modified by covalent attachment of a palmitate (a 16-carbon saturated fatty acid, C16:0), a 
reaction catalysed by Hhat using palmitoyl-CoA as a substrate (Pepinsky et al., 1998, Buglino 
and Resh, 2008). Palmitoylation may proceed through a thioester intermediate, with 
spontaneous S-to-N shift resulting in an amide linkage (Pepinsky et al., 1998), which in 
contrast to thioester-linked palmitoylation is an irreversible type of covalent bond. 
Alternatively, as S-palmitoylation cannot be detected during in vitro palmitoylation of Shh, 
direct N-palmitoylation has also been proposed (Buglino and Resh, 2008). 
Hh also goes through autocleavage of the full-length protein catalysed by its C-terminal 
domain to yield Shh-N and Shh-C (Lee et al., 1994, Porter et al., 1995), see Figure 1.2. The 
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cleavage occurs between a Gly and a Cys residue where a thioester intermediate undergoes 
nucleophilic attack by cholesterol resulting in covalent attachment of cholesterol to the 
terminal Gly residue of Shh-N (Porter et al., 1996). Palmitoylation is not necessary for 
autocleavage to occur (Buglino and Resh, 2008). Hh proteins are the only proteins known to 
date to be modified by cholesterol, although a number of unidentified proteins have been 
observed in whole cell lysate screens using radioactive or fluorescent cholesterol probes 
(Porter et al., 1996, Heal et al., 2011, also Magee/Tate groups, unpublished results).  
 
Figure 1.2 Post-translational processing of human Shh. 
The primary sequence of Shh is composed of a signal peptide (residues 1-23), the signalling 
domain (residues 24-197) and the autoprocessing domain (residues 198-424). Upon 
translocation into the ER lumen the signal peptide is cleaved off exposing an N-terminal Cys 
residue which is palmitoylated by Hhat. An initial palmitoyl thioester has been proposed to 
spontaneously shift to an irreversible amide linkage. The Shh also goes through autocleavage 
catalysed by the C-terminal domain where cholesterol is attached to the C-terminus of the N-
terminal signalling domain. 
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1.1.3.2 The role of palmitoylation and cholesteroylation of Hh proteins 
The lipid modifications of Hh proteins are crucial for formation of multimeric complexes of 
Hh proteins which are necessary for a regulated spread of the signal in the extracellular 
space, stability in the extracellular matrix and inducing long-range Hh signalling by creating a 
concentration gradient (Callejo et al., 2006). Both the cholesterol modification and 
palmitoylation of Hhs are required for stable membrane anchoring and for formation of 
soluble multimeric complexes (Zeng, 2001, Goetz et al., 2006, Gallet et al., 2003). These 
requirements were demonstrated by imaging of cells expressing a truncated form of Shh, 
Shh-N, which cannot be cholesteroylated, and Shh-C25S or Shh-C25A in which the 
palmitoylation site has been removed (Lewis et al., 2001, Gallet et al., 2006, Li et al., 2006, 
Callejo et al., 2006). Lack of cholesterol on Shh-N does not impede Shh-N binding to its 
receptor Patched (Ptch); however, failure to create soluble multimeric complexes alters the 
spread of Hh creating low local concentrations resulting in poor activation of high-level 
targets (Li et al., 2006). These observations have led to a model for morphogen spreading as 
a result of its lipid modifications. After secretion, non-lipidated Hh spreads from the source 
by simple diffusion to rapidly generate an even and low concentration of Hh across the 
surrounding field of cells. Fully processed Hh, on the other hand, spreads over restricted 
distances from the source creating a controlled concentration gradient across neighbouring 
cells (Figure 1.3).  
 
Figure 1.3 The effect of lipid modifications on the spreading of Hh. 
Non-lipidated Hh moves in a diffusion dependent manner resulting in a rapid spread from the 
source giving an even and low concentration of Hh across the surrounding field of cells. Lipid 
modified Hh (Hh*), on the other hand, is constrained in its movement by spreading over a 
restricted distance from the source and creating a concentration gradient across neighbouring 
cells. 
Hh*
Hh
P
ro
te
in
 l
e
v
e
l
Distance from source
1 Introduction 
33 
The palmitoyl modification is needed for proper packaging of the multimeric protein 
structure as well as to fully potentiate the Shh signal (Kohtz et al., 2001, Chen et al., 2004). 
In several in vitro studies, palmitoylation of Hh proteins has been shown to greatly increase 
the potency of the Hh signal transduction (Taylor et al., 2001, Pepinsky et al., 1998). In Hhat 
knock-out studies in vivo, it is absolutely required for activity in Drosophila segmental 
patterning and development of the wing disc (Dawber et al., 2005, Amanai and Jiang, 2001, 
Lee et al., 2001b, Chamoun et al., 2001, Micchelli et al., 2002). In the mouse, the 
palmitoylation requirement is less strict for short range targets, but necessary for proper 
long-range signalling (Chen et al., 2004). Using a homozygous Hhat deletion mouse model, 
Hhat-/-, palmitoylation of Hh proteins has been shown to be crucial for proper patterning 
and development (Chen et al., 2004). The Hhat-/- embryos showed defects resembling the 
Shh-/- mutant, including smaller size and prosencephaly. Although the features were less 
pronounced than in the Shh-/- mutant, they clearly suggest a decrease in Hh signal potency  
 
Figure 1.4 Effects of Hhat gene knock-out (here denoted Skn) on mouse development. 
The upper panel shows external morphology of wt and mutant mouse embryos at 10.5 days 
post-coitum (dpc). The lower panel shows skeleton staining at 18.5 dpc. The Skn-/- embryos 
showed defects such as smaller size and prosencephaly reminiscent of the Shh-/- mice, though 
less pronounced. They also exhibited short-limb dwarfism similar to Ihh-/- mutants. The effects 
in mice with unpalmitoylated Shh, ShhC24S, are less pronounced than in Skn-/- mice indicating a 
combined impact of Hhat deletion on all three Hh homologues. Adapted from Chen et al., 
2004. Reprinted by permission from Cold Spring Harbor Laboratory Press.  
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in Hhat-/- mutants. On the other hand, the effects in mice where the Shh palmitoylation site 
had been removed, ShhC24S, are less pronounced than in Hhat-/- mice indicating a combined 
impact of Hhat deletion on all three Hh homologues; in addition to Shh-/- features, Hhat-/- 
mutants exhibited short-limb dwarfism, a phenotype similar to Ihh-/- mutants. The Hhat-/- 
mice are born but die shortly after birth. 
1.1.3.3 Hh secretion and gradient formation 
After reaching the plasma membrane, Hh proteins have been found to associate with sterol-
rich membrane microdomains (also known as lipid rafts). Studies in Drosophila and the 
mouse have shown that the release of Hh into the extracellular space is dependent on 
Dispatched (Disp), a 12-transmembrane protein with a sterol-sensing domain (SSD) found in 
lipid microdomains of the plasma membrane (Burke et al., 1999, Kawakami et al., 2002). In 
the absence of Disp, Hh is accumulated at the surface of the producing cells but cannot be 
released, rendering Disp necessary for paracrine, but not juxtacrine, Hh signalling (Caspary 
et al., 2002, Ma et al., 2002, Kawakami et al., 2002, Tian et al., 2005, Etheridge et al., 2010). 
The interaction of Disp with Hh proteins depends on the latter’s cholesterol modification as 
Hh lacking cholesterol is readily secreted from Disp mutant cells (Burke et al., 1999, Ma et 
al., 2002), probably by reduced levels of palmitoylation anchoring, or, in case of 
palmitoylation being present, by simple dissociation from the membrane. Further, Disp has 
been implicated in polarising Hh secretion from apical to basolateral membranes in 
polarised cells (Callejo et al., 2011), and involvement in the regulation of vesicular trafficking 
necessary for transcellular Hh transport (Etheridge et al., 2010). However, its mechanism of 
action is not yet known.  
After reaching the cell surface of the signal producing cells, apart from interacting with Disp, 
Hhs interact with heparin sulphate proteoglycans (HSPGs). HSPGs are a group of molecules 
present on the cell surface and in the extracellular matrix (ECM) consisting of heparan 
sulphate (HS) glycosaminoglycan (GAG) chains attached to a protein core. They are classified 
into three families: syndecans, glypicans and perlecans. Syndecans have a membrane-
spanning protein core with HS and chondroitin sulphate side chains; glypicans are 
glycosylphosphatidylinositol (GPI)-anchored with a globular core protein stabilised by 
disulphide bonds carrying HS chains; perlecans are secreted core proteins carrying HS chains  
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Figure 1.5 Three main classes of HSPGs. 
(A) Syndecans have a membrane-spanning protein core with HS and chondroitin sulphate side 
chains. (B) Glypicans are GPI-anchored with a globular core protein stabilised by disulphide 
bonds. (C) Perlecans are secreted core proteins carrying HS chains. Adapted from Yan and Lin, 
2009. Reprinted by permission from Cold Spring Harbor Laboratory Press. 
(Figure 1.5). Hh proteins were first discovered to bind HSPG though involvement of a basic 
motif, the Cardin-Weintraub motif, which binds a negatively charged region of HSPGs (Rubin 
et al., 2002). Recently, Hhs have also been found to bind HSPGs in regions outside the 
Cardin-Weintraub motif (Chang et al., 2011). The HSPG binding of Hh is required for 
multimer formation, stability in the ECM and release as well as signalling activity in the 
receiving cell by acting as co-receptors for Hh (Yan and Lin, 2009).  
Several models for formation of morphogen gradient have been proposed. These include 
the restricted diffusion and lipoprotein transfer models (Yan and Lin, 2009). Restricted 
diffusion is dependent on formation of Hh multimers on the cell surface. By interaction with 
HSPGs on the cell surface and in the extracellular matrix, the Hh multimers are propelled 
across neighbouring cells by restricted diffusion achieved by continuous binding to HSPGs 
(Figure 1.6 A). The morphogen spreading is eventually terminated by binding and 
sequestration of Hh by its receptor and co-receptors on the signal receiving cells. Work done 
in Drosophila has implicated the involvement of large macromolecular complexes known as 
lipoproteins in the intercellular transport of Hh (Panakova et al., 2005). These structures are 
poorly defined and have been proposed to consist of exosomes carrying lipid-modified  
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Figure 1.6 Models for morphogen gradient formation in Hh signalling. 
(A) Restricted diffusion model is based on Hh multimers interacting with HSPGs which restrict 
their spread across the field of cells. (B) Lipoprotein transfer model is based on Hh binding of 
lipoprotein particles which spread in a restricted fashion. The transfer between cells and 
lipoprotein particles is proposed to occur by reversible binding of Hh lipid modifications. 
Adapted from Yan and Lin, 2009. Reprinted by permission from Cold Spring Harbor Laboratory 
Press. 
proteins or lipoprotein particles such as low-density lipoprotein (LDL). Knock-down (KD) of 
lipophorin, the protein constituent of Drosophila lipoprotein particles, reduces long-range 
Hh signalling indicating a role for lipoprotein particles in Hh transfer. Although a decrease in 
lipophorin decreases Hh spreading, it does not appear to affect its release from the 
producing cell. The intercellular transport is proposed to occur through reversible binding of 
Hh using its lipid modifications to lipoprotein particles which are able to move across cells 
(Figure 1.6 B).  
In the restricted diffusion model, the lipids have been proposed to drive a micellar type of 
aggregation, while in the lipoprotein model, the lipids are believed to anchor Hh to the lipid 
bilayer of the vesicle. Recent reports, however, suggest that after multimerisation, both lipid 
modifications are removed by enzymatic cleavage with a disintegrin and metalloprotease 
(ADAM) resulting in soluble and biologically active morphogenic multimers (Dierker et al., 
2009, Ohlig et al., 2011). In this model, the flexible lipid-modified N-terminus of Shh-N is 
suggested to block Shh from binding its receptor Ptch. ADAM-mediated cleavage, which is 
proposed to be dependent on the palmitoylation of Shh, removes the flexible C- and N-
termini, allowing Shh multimers to be released from the producing cell and Shh to bind its 
receptor Ptch by exposing its zinc coordination site. This site has been shown to be the 
Restricted diffusion Lipoprotein transfer
A B
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binding site for both receptors Ptch and Hedgehog interacting protein, Hhip (Bosanac et al., 
2009, Bishop et al., 2009). 
1.1.3.4 Hh signal transduction 
Hh signal transduction in mammals is dependent on the primary cilium (Huangfu et al., 
2003, Huangfu and Anderson, 2005, Liu et al., 2005), an organelle present in most 
mammalian cells which is a small protrusion (up to 10 µm) on the cell surface forming a 
compartment distinct from the rest of the membrane and cytoplasm. It is made up of a 
centrosome called the basal body, from which nine double microtubule doublets protrude. 
Protein transport along the cilium depends on a microtubule-based transport system called 
intraflagellar transport (IFT, Tasouri and Tucker, 2011). Hh signalling in Drosophila does not 
depend on the primary cilium and therefore, the following description of Hh signal 
transduction will be based on Shh signalling in mammals. 
Upon reaching the receiving cell, Shh binds to its receptor Ptch. Ptch is a 12-spanning 
membrane protein containing an SSD and is a homologue to Disp involved in Shh release 
from signal producing cells. Two homologues of Ptch exist in mammals, Ptch1 and Ptch2, 
both with similar binding affinity for Hh proteins. Ptch is present adjacent to the basal body 
of the primary cilium (Chamberlain et al., 2008, Rohatgi et al., 2007) where it in the absence 
of Hh inactivates Smoothened (Smo). Ptch does not regulate Smo by direct physical 
interaction. Instead, oxysterols have been linked to regulation of Smo (Corcoran and Scott, 
2006) and, as Ptch has an SSD, it is believed to indirectly regulate Smo by oxysterol transport 
across the plasma membrane (Taipale et al., 2002). Smo is a 7-transmembrane protein with 
homology to G protein-coupled receptors (GPCRs), which while inactivated is confined to an 
intracellular compartment. When Shh binds Ptch, inhibition of Smo is released and the 
compartmentalised Smo moves into the primary cilium where it fuses with the plasma 
membrane, while the Hh-Ptch complex is internalised for degradation in the endosomal 
pathway (Corbit et al., 2005, Kovacs et al., 2008). 
After entry into the primary cilium Smo is relocated to the distal end of the cilium by the IFT 
machinery where it interacts with Glioma-associated oncogene homologue (Gli) 
transcription factors . Three Gli transcription factors are present in mammals: Gli1, Gli2 and 
Gli3 (Kinzler et al., 1987, Kinzler and Vogelstein, 1990). They all contain DNA-binding Zn-
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finger motifs and while Gli1 only can act as an activator, Gli2 and Gli3 can take on active (Gli-
A) or repressive (Gli-R) forms. The full-length Gli protein acts as a transcriptional activator, 
while the repressor form is produced by partial proteasomal degradation of Gli2 and Gli3. 
While Gli2 is mostly in the activator form, Gli3 is mostly present in its repressor form. The 
relative levels of Gli-R and Gli-A have been suggested to reflect the signal strength which in 
turn governs which target genes are expressed (Altaba, 1999, Stecca and Ruiz i Altaba, 
2010). Binding of Hh ligands to Ptch activates Smo leading to an accumulation of the 
activator form of Gli (Gli-A) which induces target gene expression. Smo activation and 
translocation into the primary cilium result in simultaneous translocation of Gli to the distal  
 
Figure 1.7 Hh signal transduction in the signal receiving cell. 
(A) In the absence of Shh, Ptch located at the base of the primary cilium acts as a suppressor of 
Smo which is located in an intracellular compartment. Gli transcription factors are processed 
into their repressor form Gli-R by partial proteasomal cleavage and act on target genes by 
repressing their transcription. (B) When Hh is present it binds to Ptch and inactivates its 
inhibition of Smo. Activated Smo relocates to the plasma membrane at the base of the primary 
cilium and is transported to its distal end resulting in activation of Gli transcription factors. Gli 
proteins are converted to Gli-A and are translocated to the nucleus where they activate target 
gene expression. Hhip acts as a suppressor of the Shh signal by competing with Ptch for 
binding of Hh. Cdo, Gas1 and Boc serve as signal enhancers by stimulating binding of Shh to 
Ptch. 
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end of the cilium where its activation takes place. The movement of the ciliary kinesin 
protein Kif7, a homologue to Cos2 in Drosophila, has been shown to occur simultaneously 
with Smo movement through the primary cilium and is able to regulate Gli proteins by direct 
interaction (Endoh-Yamagami et al., 2009, Liem et al., 2009, Cheung et al., 2009). While Smo 
activates Gli, Suppressor of Fu (SuFu) acts to suppress Gli activity, either by regulating the 
Gli-A:Gli-R ratio or by controlling Gli entry into the nucleus (Jia et al., 2009, Chen et al., 
2009b, Lauth et al., 2010). 
Apart from binding the receptor Ptch, mammalian Hh proteins are also able to bind other 
cell surface membrane-anchored proteins to modulate signal transduction. Hedgehog 
interacting protein (Hhip), growth arrest specific 1 (Gas1) protein, cell adhesion molecule-
related/down-regulated by oncogenes (Cdo), and brother of Cdo (Boc) have all been shown 
to bind Hh proteins. Hhip binding of Hh proteins results in a negative effect on the signal 
transduction likely by competition with Ptch for ligand binding. It also acts to restrict the 
spread of the Hh gradient as it binds and sequesters the ligands (Chuang and McMahon, 
1999). Gas1 is a GPI-anchored protein (Stebel et al., 2000) which acts as a positive 
component of Shh signalling and its expression is negatively regulated by Hh signalling (Lee 
et al., 2001a, Martinelli and Fan, 2007, Allen et al., 2007). Binding of Shh to Cdo and Boc also 
has a positive effect on Hh signalling (Tenzen et al., 2006); however, if they cooperate with 
Ptch for binding is not yet clear. 
1.1.3.5 Hh signal target genes 
The Hh signal upregulates a variety of genes of which three are present in the Hh pathway 
itself. Upregulation of Ptch, Hhip and Gli1 results in the restriction of the signal spreading by 
sequestration of the ligand by upregulated expression of Ptch and Hhip as well as 
amplification of the signal transduction through a feedback loop created by upregulated 
expression of Gli1. Other direct and indirect targets of Hh signalling include transcription 
factor genes FoxA2, FoxF1 and N-myc, the anti-apoptotic regulator Bcl2, a variety of cyclin 
genes which regulate cell-cycle progression, and other genes involved in DNA damage 
response, DNA replication and DNA repair (Yoon et al., 2002, Eichberger et al., 2006, Kasper 
et al., 2006, Shi et al., 2010). Hh further promotes epidermal growth factor (EGF) signalling 
in Drosophila, platelet-derived growth factor (PDGF) signalling in mouse fibroblasts and 
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tumour cells (Pasca di Magliano and Hebrok, 2003), and regulates expression of a variety of 
Wg/Wnt pathway molecules (Vestergaard et al., 2005).  
1.1.4 Hh signalling in cancer 
For cancers to develop, cells need to acquire a range of capabilities to overcome the control 
systems of an organism and become malignant. These capabilities were summarised by 
Hanahan and Weinberg and collectively called the hallmarks of cancer (Hanahan and 
Weinberg, 2011). The hallmarks of cancer include the capabilities to resist cell death, sustain 
proliferative signalling, evade growth suppressors, induce angiogenesis, enable replicative 
immortality and activate invasion and metastasis. Collected evidence supports that the Hh 
signalling pathway in cancer is able to govern cell proliferation, regulate apoptosis, recruit 
blood supply, and aid metastasis. 
1.1.4.1 Modes of Hh signalling in cancer 
The Hh pathway in cancer has been shown to have a role in tumour initiation in basal cell 
carcinoma (BCC), medulloblastoma (MB) and rhabdomyosarcoma (RMS), tumour 
maintenance in colon and pancreatic cancers, and an as yet undefined role in lymphoma, 
prostate and lung cancers (Barakat et al., 2010, Teglund and Toftgard, 2010). Hh signalling in 
cancer is either Hh ligand-dependent or Hh ligand-independent (Figure 1.8). Ligand-
independent cancers arise through loss-of-function mutations in tumour-suppressor genes 
of the pathway (Ptch, SuFu) or by gain-of-function mutations in proto-oncogenes (Smo, Gli), 
both of which permanently activate the pathway. Ligand-dependent cancers can either 
depend on autocrine or paracrine Hh ligand signalling. In the autocrine signalling system, 
the cancer cell is self-sufficient in Hh ligands which induce cell proliferation in the same cell. 
Ligand-dependent paracrine signalling occurs between cancer and normal stromal cells 
within the cancer microenvironment to stimulate cells to produce growth factors benefiting 
cancer growth. In the most commonly found form of paracrine signalling, ligand production 
occurs in cancer cells to stimulate the surrounding stroma (Teglund and Toftgard, 2010, 
Rubin and de Sauvage, 2006). Work using xenograft as well as transgene mouse models of a 
variety of Shh- and Ihh-expressing tumours has shown pathway activation in cancer cells 
with signalling response in the adjacent stromal tissue rather than in the tumour tissue itself 
(Teglund and Toftgard, 2010, Rubin and de Sauvage, 2006). Stromal activation may lead to 
production of growth and survival factors, fibrotic tissue formation or increased 
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vascularisation (Harris et al., 2011). In the reverse paracrine signalling model, tumour cells 
respond to Hh ligands produced in the adjacent stroma. This form of signalling may be 
involved in experimental models of glioma and some B cell malignancies, but appear 
generally less common (Teglund and Toftgard, 2010, Lindemann, 2008). 
 
 
Figure 1.8 Modes of Hh signalling in Hh pathway-dependent cancer. 
(A) Ligand-independent signalling. Arises by loss-of-function in tumour-suppressing genes or 
gain-of-function mutations in proto-oncogenes. (B) Ligand-dependent autocrine signalling. The 
cancer cell is self-sufficient in Hh ligands which induces cell proliferation in the same cell. 
(C) Ligand-dependent paracrine signalling occurs between cancer and normal stromal cells in 
the cancer microenvironment. 
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1.1.4.2 Oncogenic mutations in the Hh pathway 
Hh pathway activity in cancer was first identified in patients with the Gorlin syndrome 
where hereditary inactivating mutations of Ptch lead to constitutive activation of the signal 
pathway manifested as skin malformations often resulting in development of multiple BCC 
during childhood. Somatic inactivation of Ptch and to a lesser extent activating mutations in 
Smo (10% of cases) lead to sporadic BCC, the most common tumour among Caucasians 
(Epstein, 2008). Activating mutations in the Hh pathway seem to be required and are 
possibly also sufficient for the development of BCC (Epstein, 2008).  
A subset of MBs (malignant childhood brain tumours), glioma (the most frequent central 
nervous system (CNS) tumour), and RMS (tumour originating from skeletal muscle precursor 
cells), have all been found to harbour activating mutations in the Hh pathway (summarised 
in Table 1.1). After BCC, MB has the strongest connection to aberrant Hh signalling. 
However, it still remains to be seen if Hh pathway inhibition is clinically relevant in all these 
cancer types (Teglund and Toftgard, 2010). 
Table 1.1 Hh-activating mutations in human tumours (Teglund and Toftgard, 2010). 
Gene Mutation type Tumour type 
Ptch1 Loss-of-function BCC 
MB 
RMS 
Smo  Gain-of-function BCC 
MB 
SuFu Loss-of-function MB 
Prostate cancer 
RMS 
Gli1 Amplification 
 
 
Translocation 
Missense mutation* 
Glioma 
MB 
RMS 
Pericytoma 
Breast cancer 
Pancreatic cancer 
Gli2 Amplification Squamous cell carcinoma 
MB 
Gli3 Missense mutation* Colorectal cancer 
Pancreatic cancer 
    *Unverified function.  
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1.1.4.3 Overexpression of Hh ligands 
While activating mutations in the Hh pathway are mainly responsible for progression of BCC, 
MB and RMS, involvement of overexpressed Hh ligands has been implicated in other types 
of cancer (Table 1.2). Although the mechanisms are not always clear, ligand-dependent 
signalling has been linked to tumour maintenance in a variety of cancers where the Hh 
signalling pathway has been shown to be active during development, e.g. colon (Berman et 
al., 2003, Qualtrough et al., 2004), pancreatic, prostate (Fan et al., 2004, Sanchez et al., 
2004) and lung cancers (Watkins et al., 2003, Yuan et al., 2007, Yauch et al., 2008).  
Table 1.2 Hh ligand expression in human cancers and cancer cell lines. 
Tumour type Gene Reference 
Colon cancer  Shh 
Ihh 
(Berman et al., 2003, Qualtrough et al., 2004) 
Digestive tract tumours Shh 
 Ihh 
(Berman et al., 2003) 
Glioma Shh (Dahmane et al., 2001) 
PDAC Shh 
Ihh 
(Berman et al., 2003, Thayer et al., 2003, Kayed 
et al., 2004, Yauch et al., 2008) 
Prostate cancer Shh (Fan et al., 2004, Sanchez et al., 2004) 
NSCLC Shh (Yuan et al., 2007, Yauch et al., 2008) 
SCLC Shh (Watkins et al., 2003, Yauch et al., 2008) 
 
In pancreatic ductal adenocarcinoma (PDAC), both Shh and Ihh have been shown to be 
expressed in cancer cell lines and Gli1 and Ptch1 have been shown to be expressed in 
primary tumours (Berman et al., 2003, Thayer et al., 2003, Kayed et al., 2004, Yauch et al., 
2008). Hh pathway inhibition in experiments performed on cancer cell lines, xenograft 
mouse models and various transgenic mice overexpressing Shh against different 
backgrounds have collectively shown that the Hh pathway is involved in PDAC most likely by 
a paracrine signalling loop (Teglund and Toftgard, 2010, Barakat et al., 2010). 
Subsets of both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cell lines 
have been shown to overexpress Hh pathway components including Shh without any 
apparent oncogenic mutations being involved (Watkins et al., 2003, Yuan et al., 2007). 
Although the subject has been widely studied both in cell lines and in primary tumours, the 
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evidence provided for Hh pathway involvement in lung cancer is less clear-cut than for 
pancreatic cancer. The involvement of the Hh pathway in lung cancer is discussed in more 
detail in Section 1.1.5. 
1.1.4.4 The cancer stem cell 
Developmental signalling pathways, e.g. Hh, Wnt, Notch and bone morphogenic protein 
(BMP) pathways, are involved in maintenance of stem cell pools during adulthood. Adult 
stem cells are a distinct type of cells able to self-renew and further differentiate into more 
specialised cell types within the tissue. Tumours have long been considered to arise from 
disregulated adult stem cells which transform or give rise to cancer stem cells (CSCs). CSCs 
are multipotent cells which are able to reconstitute a tumour by propagating in a malignant 
manner and which need to be eradicated in full in order to cure cancer (Nguyen et al., 2012, 
Lobo et al., 2007). Generally, tumours are phenotypically heterogeneous and display various 
stages of differentiation similarly to normal cells in the tissue they are derived from. This 
raises the question if CSCs could be responsible for the full range of cell types seen in 
cancer. Targeting of developmental pathways has thus been proposed as a therapeutic 
strategy to eradicate the CSC population in cancers which seem to be dependent on CSCs. 
Although the concept of a CSC has for decades been under strong debate, the current 
consensus is that only a subset of cancers depends on CSCs, while other cancers may 
contain a high load of mutations making every cell capable of stem cell-like renewal (Nguyen 
et al., 2012, Lobo et al., 2007). Therefore, in cancers where CSCs are responsible for tumour 
regeneration, therapies targeting developmental pathways may be sufficient to completely 
stop tumour growth making inhibition of Hh signalling and other developmental pathways 
in cancers highly attractive.  
1.1.5 Hh signalling in lung cancer 
1.1.5.1 Lung cancer incidence and aetiology 
Lung cancer is the most common type of cancer in the world today accounting to 12% of all 
new cancer cases each year. About 85% of lung cancers occur in past or current smokers 
with 11% of lifetime heavy smokers developing cancer. Smoking in Western Europe and 
North America is in decline; however, a smoking epidemic in China and Eastern Europe 
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continues to maintain a high number of incidents worldwide (van Meerbeeck et al., 2011, 
Minna et al., 2002).  
Lung cancer is subdivided into SCLC and three types of NSCLC – adenocarcinoma, squamous 
cell carcinoma and large-cell carcinoma – as well as other less differentiated variants. Both 
NSCLC and SCLC have a very poor prognosis as few treatment options are available. The 
prognosis is usually worsened by late diagnosis as about 80% of newly diagnosed patients 
have already developed regional or distant metastasis (Minna, 2000). The prognosis is highly 
dependent on the stage of the disease with an overall survival of 15% over 5 years. About 
13% of all lung cancers are SCLCs (van Meerbeeck et al., 2011). SCLC grows rapidly and has a 
poorer prognosis than NSCLC as it can only be treated with radiotherapy and combined 
chemotherapy. NSCLC, on the other hand, when confined to the chest, can often be 
removed by lung resection in addition to treatment with radio- and chemotherapy (Minna 
et al., 2002).  
Although a variety of genes and pathways involved in the carcinogenesis of the lung have 
been identified, no major causative mutations have been shown to induce lung 
carcinogenesis in either NSCLC or SCLC. The most common oncogenic mutations in NSCLC 
include mutations in the EGF receptor gene (EGFR) and KRas and are present in 10-30% of 
NSCLC cases (Janku et al., 2011). Other genes affected at lower frequencies include MET, 
PIK3CA, HER2 and BRAF. Targeted therapy using drugs against EGFR and VEGF receptor 
(VEGFR) have recently been put to use in clinical treatment of NSCLC. The molecular biology 
of SCLC is still too unclear for targeted therapy. However, SCLC clearly differs from NSCLC by 
rarely displaying mutation in EGFR and KRas (van Meerbeeck et al., 2011). The upregulated 
expression of Hh pathway components in SCLC indicates a role for Hh signalling. As the Hh 
pathway is active both during tissue maintenance and regeneration, its upregulation in lung 
cancer has thus been proposed to be an effect of chronic tissue injury by cigarette smoke 
(Beachy et al., 2004).  
1.1.5.2 Hh signalling in lung cancer 
The involvement of the Hh signalling pathway in lung cancer has been studied both in 
primary tumours and in cancer cell lines. A first study of Hh signalling in SCLC and NSCLC cell 
lines conducted by Watkins et al. (2003) showed that a majority (5 of 7) of SCLC cell lines 
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expressed both Shh and Gli1, while NSCLC expressed Shh but not Gli1 indicating that Hh 
signalling was more prevalent in SCLC. Growth of some SCLC cell lines was inhibited using a 
Shh-blocking antibody as well as cyclopamine, a Smo inhibitor, suggesting that these cells 
required paracrine Shh signalling for growth. Further, these cell lines appeared to express 
wild-type Ptch1 demonstrating that the pathway activation is not due to loss of Ptch activity 
as is seen in BCC. When grown as xenografts in nude mice, the SCLC cell line H249 
responsive to Hh pathway inhibitors further proved to be sensitive to cyclopamine 
treatment in vivo (Watkins et al., 2003).  
NSCLC cell lines, although they did not express Gli1 nor responded to Hh pathway inhibitors, 
were nonetheless able to induce a Hh signalling response in co-culture with Shh-LIGHT2 
reporter cells which respond to Shh signalling by activating Gli-responsive luciferase 
expression (Watkins et al., 2003). A similar study in a different set of 60 NSCLC cell lines 
showed that a higher proportion of NSCLC cell lines than reported by Watkins et al. 
expressed Hh pathway components. However, only a sub-set of these were sensitive to Hh 
pathway inhibitors (Yuan et al., 2007) and the combined results still show that the activation 
of the Shh pathway is more prevalent in SCLC than in NSCLC. Interestingly, studies in 
primary SCLC and NSCLC show significantly higher frequency of Gli1 expression than in 
established cell lines (Vestergaard et al., 2006, Yuan et al., 2007). Active Hh signalling in 
primary NCSLCs is not reflected in the sensitivity of NSCLC cell lines to Hh signalling 
inhibitors (Yuan et al., 2007). Together, these observations indicate that studies in lung 
cancer cell lines may represent an underestimation of Hh pathway activity in lung cancer 
where cells grown in culture lose their dependency on Shh.  
Studies of an acute lung injury mouse model treated with naphthalene showed that Hh 
signalling was activated during tissue regeneration, suggesting that Hh pathway activation in 
cancer may originate from the same progenitor cells which are responsible for Hh pathway 
activation during injury (Watkins et al., 2003). Subsequently, an in vitro study of human 
bronchial epithelial cells showed that the cells were transformed after treatment with 
cigarette smoke and could form tumours in xenograft mice. They displayed Hh pathway 
activity and their growth was inhibited both in vivo and in vitro by cyclopamine (Lemjabbar-
Alaoui et al., 2006). The apparent lack of activating mutations in the Hh pathway in lung 
cancer samples suggests that Hh pathway activation solely is not able to initiate 
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carcinogenesis, but rather that the active Hh pathway is a cancer-supporting mechanism 
activated in the tumour microenvironment. However, one mouse lung cancer model has 
shown that human cyclin E-induced pulmonary adenocarcinoma expressed Shh and Gli1 in 
the majority of tumours, but not surrounding cells, indicating an autocrine Hh signal loop 
(Ma et al., 2007). 
A more recent report of Hh signalling in a variety of cancers including SCLC and NSCLC has 
muddied the waters of studies of Hh signalling involvement in lung cancer by showing that 
cyclopamine treatment has negative off-target effects on a variety of cancer cell lines 
previously shown to be dependent on Hh signalling (Yauch et al., 2008). In a panel of 42 
NSCLC and 20 SCLC cell lines it was shown that growth inhibition by cyclopamine treatment 
did not correlate with a decrease in Gli1 expression indicating off-target effects of 
cyclopamine and challenging the Hh dependence results in cell lines obtained in previous 
studies. These findings outline the need to study the Hh pathway in lung cancer in more 
detail and the necessity for using alternative models to cell lines for studying the interaction 
of paracrine signalling models such as the Hh pathway. 
1.1.6 Small-molecule inhibitors of Hh signalling 
The involvement of the Hh pathway in various types of cancer has made it an attractive 
target for therapeutic intervention in the clinic. Over the past decade, an array of synthetic 
pathway inhibitors, most targeting Smo, has been developed (Stanton and Peng, 2010), see 
Figure 1.9. The field exploded after the discovery that the long-known plant-derived 
teratogens cyclopamine and jervine were causing birth defects by inhibiting the Hh pathway 
(Incardona et al., 1998, Cooper et al., 1998). Cyclopamine and jervine are found in the 
California corn lily Veratrum californicum, a plant native to the highlands of north-west 
North America, and were discovered after a link was made between high occurrence of 
holoprosencephaly and cyclopia in local sheep populations and grazing of the plant by 
pregnant mothers. Cyclopamine and jervine are steroidal alkaloids and inhibit the Hh signal 
by antagonising Smo (Cooper et al., 1998, Incardona et al., 1998). The more potent 
cyclopamine displays a relatively low affinity for Smo, has poor oral bioavailability and 
suboptimal pharmacokinetics. Therefore, great efforts have been made to produce 
cyclopamine derivatives; KAAD-cyclopamine has a 10- to 20-fold higher potency than 
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cyclopamine (Taipale et al., 2000) and IPI-926 is in phase I clinical trials after displaying 
better oral bioavailability and improved half-life (Tremblay et al., 2009).  
Other compounds not derived from cyclopamine have also been found to inhibit Smo. These 
include CUR-61414 (Williams et al., 2003), GDC-0449 (Rudin et al., 2009), and SANT-1, -2, -3 
and -4 (Chen et al., 2002). While CUR-61414 phase I trials of topical treatment of patients 
with BCC showed low efficacy and have been halted, GDC-0449 has shown good oral 
bioavailability and is progressing to phase II clinical trials (LoRusso et al., 2011). 
Hh pathway inhibitors not targeting Smo include GANT-58 and GANT-61 which inhibit Hh 
signalling downstream of SuFu at the level of Gli and have been shown to be effective in 
reducing growth of human prostate cancer xenografts in mice (Lauth et al., 2007). 
Robotnikinin is a compound which binds Shh directly blocking Hh signalling upstream of Ptch 
and may prove effective in the treatment of Hh ligand-dependent cancers (Stanton et al., 
2009). A similar Shh-blocking effect can be achieved using the monoclonal antibody 5E1 
(MAb-5E1) which binds Shh and thus prevents it from binding its receptor Ptch (Ericson et 
al., 1996). MAb-5E1 has proved to be a valuable instrument in the laboratory for inhibiting 
Shh ligand-dependent signalling in cell assays. 
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Figure 1.9 Structures of Hh pathway inhibitors classified according to their molecular targets. 
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1.2 Protein palmitoylation 
Palmitoylation of proteins is a post-translational modification where a 16-carbon saturated 
(C16:0) fatty acid palmitate is attached to a Cys residue. It confers hydrophobicity to the 
protein allowing it to associate with membranes, regulating protein trafficking, stability, 
membrane microorganisation and protein-protein interactions (Salaun et al., 2010). The 
membrane association of proteins by palmitoylation alone is only transient as one single 
palmitate is not enough to permanently anchor the protein to the membrane (Zeng, 2001). 
Palmitoylation is often preceded by other protein lipid modifications in the vicinity of the 
palmitoylation site which together confer stable membrane anchoring. These include N-
myristoylation and prenylation. N-myristoylation is addition of a 14-carbon saturated 
(C14:0) fatty acid myristate onto an N-terminal Gly residue by N-myristoyltransferase 
(Martin et al., 2011). Prenylation involves addition of an isoprenoid, 15-carbon farnesyl or 
20-carbon geranylgeranyl, via a thioether linkage to a Cys residue in a C-terminal CaaX (also 
CC and CXC) motif where “C” represents Cys, “a” represents any aliphatic amino acid and 
the residue in the X position specifies the type of isoprenoid added. These modifications are 
catalysed by farnesyltransferase (FT) and geranylgeranyltransferases (GGTI and II), 
respectively, and followed by endoproteolytic removal of -aaX by a prenyl-CaaX-specific 
protease, Rce1, with subsequent methylation of the newly exposed isoprenylcysteine by a 
carboxylmethyl transferase, Icmt (Casey and Seabra, 1996). Other lipid modifications include 
GPI-anchor modification and cholesteroylation. Apart from palmitoylation, acylation of 
proteins can occur with a variation of acyl chain lengths and linkages including O-
palmitoleoylation (C16:1 fatty acid) and O-octanoylation (C8:0 fatty acid), see Figure 1.10. 
While palmitoylation of mammalian proteins has been known for over 30 years (Schlesinger 
et al., 1980), the enzymes which catalyse the reaction have been known for less than a 
decade. Palmitoylation is catalysed by protein acyltransferases (PATs), a group of proteins 
which fall into two distinctly different protein families, the DHHC protein family 
characterised by a catalytically important Asp-His-His-Cys (DHHC) motif, and the membrane-
bound O-acyltransferase (MBOAT) protein family. Although both families consist of multi-
spanning membrane proteins they are structurally unrelated and differ further by the 
localisation of their targets – DHHC PATs act on cytosolic targets while MBOAT PATs act on  
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Figure 1.10 Structures of common protein lipid modifications highlighting the type of covalent 
attachment to the protein.  
targets within the secretory pathway. The properties of both protein families and their 
targets are discussed in more detail below. 
1.2.1 DHHC protein family 
The DHHC family of PATs consists of seven members in yeast (Roth et al., 2006) and 23 
DHHC-coding genes in humans (Fukata et al., 2004). They are multispanning membrane 
proteins characterised by a 50 residue long conserved cysteine-rich domain (CRD) with the 
conserved DHHC motif which has been shown to be necessary for palmitoylation (Roth et 
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al., 2006). In addition, DHHC proteins (subsequently abbreviated DHHCs) have been shown 
to be autopalmitoylated, a process dependent on the DHHC motif, possibly representing a 
reaction intermediate form of the enzymes (Fukata et al., 2004). Apart from ankyrin repeats 
found at the N-terminal extensions of some DHHCs, there is little homology in the regions 
flanking the CRD. Topological studies of yeast DHHCs combined with computational studies 
across species suggest that they consist of 4-6 transmembrane (TM) regions with the DHHC 
motif and the N- and C- termini localised on the cytosolic side of the membrane (Politis et 
al., 2005), see Figure 1.11 B. A study in HEK293 cells showed that while most DHHCs are 
localised in the ER and the Golgi, a few can be found in the plasma membrane (Ohno et al., 
2006). It is, however, not yet clear how they are targeted to their destinations. While most 
lipid modifications are irreversible, the thioester bond between the palmitoyl group and the 
target protein catalysed by DHHC PATs is a reversible modification. Its removal is catalysed 
by acyl protein thioesterases (APTs) resulting in retrograde trafficking back to the Golgi 
where the protein can enter a new palmitoylation cycle (Baekkeskov and Kanaani, 2009). 
The palmitoylation cycling has been shown to have critical importance for the regulation of 
S-palmitoylated proteins, governing intercompartmental trafficking of lipid-anchored 
proteins or association with lipid microdomains of palmitoylated membrane-spanning 
proteins, thus regulating protein activity (Baekkeskov and Kanaani, 2009, Iwanaga et al., 
2009). 
DHHC PATs have been shown to be promiscuous in their substrate specificity by being able 
to act on several different target proteins without guidance by any defined consensus motif 
on the target apart from a Cys residue. Also, the same target may be palmitoylated by 
different DHHCs. This redundancy in activity is as yet poorly understood; however, it has 
become clear that factors such as the type of preceding prenylation modification on the 
target protein, the basicity of the sequence surrounding the palmitoylation site and the 
proximity of the palmitoylation site to the membrane may play a role determining which 
proteins are palmitoylated by DHHCs (Salaun et al., 2010). Certain target specificity has been 
found for a number of yeast DHHCs (Roth et al., 2006) and studies of mammalian DHHCs 
suggest that some DHHCs have a broad substrate specificity while others are more selective. 
As no evidence has yet been provided that substrate specificity is encoded in the CRD 
domain of DHHC proteins, it has been suggested that features outside this domain, such as 
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the ankyrin-repeats of DHHC13 and DHHC17, may be more important in providing substrate 
specificity (Greaves and Chamberlain, 2011). 
Mutations in the DHHC gene family have been implicated in a variety of diseases, including 
cancer, schizophrenia, X-linked mental retardation, and Huntington’s disease (Baekkeskov 
and Kanaani, 2009). Particularly well studied areas of involvement of DHHC proteins in 
 
Figure 1.11 Phylogenetic tree and membrane topology of the DHHC protein family. 
(A) Unrooted tree showing phylogenetic distances between human acyltransferases in the 
DHHC protein family. (B) Experimentally determined topology of yeast DHHC protein Akr1 
shows six TM domains with the DHHC motif on the cytosolic side alongside its C- and N-termini 
(left). Other DHHC proteins are predicted to have the same localisation of the DHHC motif and 
their termini, containing 4-6 TM regions (right). 
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disease include palmitoylation of Ras proteins – small GTPases involved in driving 
proliferation of a variety of cancers, and palmitoylation of Huntingtin – a protein involved in 
Huntington’s disease, by HIP14 (DHHC17) in neuronal cells. 
1.2.2 MBOAT protein family 
The MBOAT protein family consists of enzymes catalysing acyl attachment onto a variety of 
molecules and is defined by a region of sequence similarity called the MBOAT domain 
(Hofmann, 2000). Although the overall sequences are quite divergent, all family members 
are predicted to have 8-12 TM domains and share a highly conserved His residue imbedded 
in a long TM domain which is believed to be responsible for their catalytic activity. Only 
three MBOAT family members are known to be involved in palmitoylation of protein targets 
– Hhat, Porcupine (Porc) and ghrelin O-acyltransferase (GOAT) – while the remaining 
members transfer acyl groups onto membrane-embedded lipid molecules or have unknown 
functions (Table 1.3). Glycerol uptake/transporter 1 homologue (Gup1) is highly similar to 
Hhat (also known as Hhat-like), but lacks the conserved His residue. Although its exact role 
has not been defined, studies suggest that it acts as a negative regulator of Shh 
palmitoylation (Abe et al., 2008).  
In contrast to DHHC PATs, the three MBOAT PATs present in the MBOAT family act on 
substrates destined for secretion and have highly restricted substrate specificity. In 
Table 1.3 Members of the MBOAT protein family found in humans. 
Gene Description 
ACAT1 Acyl-coenzyme A:cholesterol acyltransferase 1 
ACAT2* Acyl-coenzyme A:cholesterol acyltransferase 2 
DGAT1 Diacylglycerol O-acyltransferase 1 
GOAT Ghrelin O-acyltransferase 
Hhat Hedgehog acyltransferase 
Gup1* Glycerol uptake/transporter 1 homologue 
MBOAT1* Lysophospholipid acyltransferase 1 
MBOAT2* Lysophospholipid acyltransferase 2 
MBOAT5 Lysophospholipid acyltransferase 5 
MBOAT7 Lysophospholipid acyltransferase 7 
Porc Porcupine (Wg/Wnt acyltransferase) 
* Evidence only at transcript level in humans, activity assigned by homology. 
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mammals, Hhat, also known as Sightless (Sit), Skinny Hedgehog (Ski/Skn), Central missing 
(Cmn) and Raspberry (Rasp), is the only PAT responsible for palmitoylation of Hh proteins 
(Lee and Treisman, 2001, Chamoun et al., 2001, Micchelli et al., 2002, Buglino and Resh, 
2008). Hhat is a membrane spanning protein predicted to have 8-12 TM regions localised in 
the ER and the Golgi (Buglino and Resh, 2008). In mammals, Hhat appears to act only on Hh 
proteins, whereas in Drosophila it is also able to palmitoylate Spitz, an EGFR ligand, 
increasing its membrane association and activity (Miura et al., 2006, Miura and Treisman, 
2006, Buglino and Resh, 2008). Both Spitz and Hhs are palmitoylated at an N-terminal Cys 
residue (revealed after signal peptide cleavage) and Hhat is the only known PAT that acts on 
a terminal Cys. The N-terminal Cys of Hh proteins is a part of a pentapeptide CGPGP which is 
conserved in all Hh homologues across phyla. In vitro palmitoylation experiments have 
shown that the 11 N-terminal amino acids of Shh are sufficient for Hhat to palmitoylate the 
terminal Cys (Buglino and Resh, 2008). Uniquely to Hh proteins, the palmitoyl is attached by 
an amide linkage, most likely forming through a spontaneous S-to-N shift of an initial 
thioester on the Cys side chain to an amide bond at the terminal backbone N (Pepinsky et 
al., 1998). It has also been proposed that Hhat can directly N-palmitoylate Shh (Buglino and 
Resh, 2008) but the evidence for this is circumstantial.  
As in Hh signalling, the palmitoylation of Wnt ligands in the Wnt signalling pathway is 
required for receptor binding and signal activation (Chang and Magee, 2009). Almost all Wnt 
proteins are dually acylated at internal residues – murine Wnt-3a is S-palmitoylated at Cys77 
and O-palmitoleoylated at Ser209 (Willert et al., 2003, Takada et al., 2006). Although Porc 
has not been directly linked to acylation of Wnt proteins, indirect evidence show that both 
acylation reactions are dependent on it. While O-palmitoleoylation of Ser209 can occur 
independently of S-palmitoylation, S-palmitoylation of Cys77 appears to be dependent on O-
palmitoleoylation of Ser209 (Takada et al., 2006). This suggests that Porc could only be 
responsible for O-palmitoleoylation of Wnt, while another enzyme may catalyse the S-
palmitoylation of Cys77. Alternatively, Porc could carry out both acylations but with an 
absolute requirement for initial O-palmitoleoylation of Ser209. However, in this scenario it is 
hard to imagine how the same enzyme could show such distinct specificity for two very 
similar fatty acids but two different amino acid side-chains at the two sites, unless two 
separate active sites are present on the Porc protein. 
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GOAT has been shown to transfer medium-sized fatty acids, typically an octanoyl (C8:0 fatty 
acid) onto Ser3 of ghrelin, an appetite-stimulating peptide hormone (Gutierrez et al., 2008, 
Yang et al., 2008a). The conserved His of the MBOAT family is necessary for the function of 
GOAT and, although only the five N-terminal residues of ghrelin are sufficient for 
octanoylation by GOAT to occur, the activity of GOAT cannot be compensated by other 
members of the MBOAT family demonstrating the high specificity of this enzyme family 
(Yang et al., 2008b). 
Apart from homology to the MBOAT family, sequence analysis of Hhat reveals homology to 
glycerol and amino acid transporters in yeast (Perego et al., 1995, Holst et al., 2000). Hhat, 
Porc and GOAT presumably use acyl-coenzyme A (acyl-CoA) as substrate to acylate their 
targets. Acyl-CoAs are carried by acyl-CoA binding protein (ACBP) in the cytosol (Knudsen et 
al., 2000). Their presence in the ER lumen has been detected, although direct evidence for  
 
Figure 1.12 Phylogenetic tree and predicted topology of the MBOAT family of PATs.  
(A) Unrooted tree showing phylogenetic distances between human acyltransferases in the 
MBOAT protein superfamily. (B) Membrane topology of Hhat predicted by TOPCONS. 
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how acyl-CoAs are transported into ER is not available. The presence of a carnitine 
acyltransferase in cell derived microsomal membranes indicates the involvement of a 
transport system similar to the carnitine-acylcarnitine transporter system in the 
mitochondrion where β-oxidation occurs (Khaled et al., 1999, Washington et al., 2003, 
Gooding et al., 2004, Sierra et al., 2008). However, this evidence is circumstantial (Buglino 
and Resh, 2008). Alternatively, members of the MBOAT family, apart from catalysing 
acylation, may play a role in the recruitment of acyl-CoA to the ER lumen. 
All three PATs of the MBOAT protein family act on targets which have been implicated in 
various diseases. As previously discussed, both Hh and Wnt signalling have a role in cancer 
formation and, therefore, Hhat and Porc are potential therapeutic targets. As ghrelin is 
involved in appetite regulation, therapeutic targeting of GOAT has sparked interest for 
treatment of obesity and type II diabetes (Chang and Magee, 2009). 
1.2.3 Methods for detection of palmitoylation  
Methods to study palmitoylation aim at identifying palmitoylated proteins, performing 
enzymatic measurements on proteins that catalyse palmitoylation, and developing high-
throughput screens to identify selective palmitoylation inhibitors. The identification of 
palmitoylated proteins and enzymatic activity of PATs has traditionally been performed by 
qualitative or quantitative measurements of metabolic incorporation of radioactive 
palmitate ([3H]palmitate, [14C]palmitate or 125I-IC16 palmitate (16-[125I]iodohexadecanoic 
acid)) in live cells (Resh, 2006, Draper and Smith, 2009). Metabolic incorporation is achieved 
by adding labelled palmitate to the culture medium of growing cells. Cells are further lysed 
and the lysate is analysed by SDS-PAGE. Dried gels are then used to expose radio-sensitive 
film for detection of the radiolabel. Alternatively, the gels can be used for Western blotting 
to confirm the identity of the labelled protein. Using pulse-chase analysis followed by 
scintillation counting, the rate of palmitoylation or depalmitoylation can be determined 
(Resh, 2006). The disadvantages of this method include handling of radioactive material and 
potentially long film exposure times, which can vary between hours and weeks depending 
on the strength of the signal and the radioactive isotope used (Planey and Zacharias, 2009). 
A different approach to study palmitoylation of proteins called acyl-exchange chemistry was 
introduced by Drisdel and Green and utilises the unique properties of Cys which allow it to 
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be chemically modified in a variety of ways (Drisdel and Green, 2004). The method consists 
of three steps. First, cell lysates are treated with N-ethyl maleimide (NEM) to block all free 
Cys while not affecting palmitoyl-modified Cys residues which are protected. Second, 
palmitate linked to proteins by thioester bonds is removed by treatment with 
hydroxylamine, thus exposing palmitoylatable Cys residues. Third, the exposed Cys residues 
are modified with thiol-specific reagents carrying detection tags. Roth et al. utilised this 
approach to attach biotin to palmitoylated protein – a method called acyl-biotinyl exchange 
(ABE) – in order to identify the full palmitoylome in yeast by affinity purification of 
palmitoylated proteins using streptavidin beads followed by mass spectrometry (MS) for 
protein identification in complex samples (Roth et al., 2006). Although this procedure 
provides a powerful tool for identification of palmitoylated proteins, the method is prone to 
producing a high number of false positives due to difficulties with obtaining full blockage of 
unmodified Cys. Its use is further limited to proteins modified by a thioester linkage, 
restricting its use to S-acylation, and it cannot be used to identify the group removed from 
the modified Cys (Draper and Smith, 2009). 
Alternative methods to enrich and detect palmitoylated proteins have recently emerged 
utilising bioorthogonal ligation chemistry. This technique is based on labelling of cells in 
culture with bioorthogonal fatty acid analogues carrying an azide or an alkyne as a 
functional group positioned at the distal carbon (Martin and Cravatt, 2009, Heal et al., 2008, 
Kostiuk et al., 2009). After lysis, the labelled proteins are ligated to a reporter tag using 
Cu(I)-catalysed azide-alkyne cycloaddition (Tornoe et al., 2002, Rostovtsev et al., 2002), also 
known as click chemistry, or the Staudinger reaction (Saxon and Bertozzi, 2000), Figure 1.13. 
Reporter tags consist of a pair of ligating functional groups – an alkyne or an azide in Cu(I)-
catalysed azide-alkyne cycloaddition or a triarylphosphine ester in the Staudinger reaction, 
coupled via a linker to biotin or a fluorescent molecule for affinity purification or 
fluorescence detection. In collaboration with Dr. Ed Tate’s group (Department of Chemistry, 
Imperial College London), we recently reported a trifunctional reporter tag combing a 
ligating functional group with both biotin and a fluorescent reporter (Heal et al., 2011). After 
ligation, the protein can be affinity purified using streptavidin beads or analysed directly by 
SDS-PAGE followed by imaging of in-gel fluorescence. The major advantages of click 
chemistry over radiolabelling include increased sensitivity, the use of non-radioactive  
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Figure 1.13 Bioorthogonal ligation reactions used for detection of palmitoylated proteins. 
substances, detection variability, as well as shorter procedure times requiring only a few 
days of processing from cell lysis to end result (Hang et al., 2011). 
1.2.4 Palmitoylation inhibitors 
As members of both DHHC and MBOAT PATs are involved in the activity of intra- and 
intercellular signalling pathways implicated in a variety of diseases it has been of interest to 
find specific inhibitors of palmitoylation by blockade of PAT activity. Three general 
palmitoylation inhibitors have been widely used – 2-bromopalmitate (2-BP), tunicamycin 
and cerulenin (Figure 1.14). These are lipid-based compounds with broad substrate 
specificity affecting not only PATs but also a range of processes in fatty acid metabolism 
(Planey and Zacharias, 2010, Draper and Smith, 2009, Resh, 2006). 2-BP inhibits 
palmitoylation both in vivo and in vitro. By using purified DHHC protein-target pairs it has 
been demonstrated that it can act directly on PATs (Webb et al., 2000, Jennings et al., 2009). 
However, is also affects fatty acid synthesis and is poorly tolerated by cells causing cell 
death even after brief exposures to the compound at typical working concentrations (Resh, 
2006). Although it appears to inhibit DHHC proteins by irreversible binding (Jennings et al., 
2009), its mechanism of action remains unknown. Tunicamycin and cerulenin inhibit S-
palmitoylation in cells (Patterson and Skene, 1995, Lawrence et al., 1999), but similarly to 2-
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BP, they also act on the fatty acid synthesis pathway and the mechanism of their action is 
unknown. Tunicamycin is primarily known as an antibiotic able to inhibit N-glycosylation of 
proteins (Kuo and Lampen, 1974), thus limiting its uses as a specific therapeutic agent. A 
study of cerulenin analogues’ ability to inhibit S-palmitoylation of HRas showed that longer 
aliphatic chains helped increase the potency of the compound and that only chains shorter 
than 14 carbons were inhibiting fatty acid synthase (Lawrence et al., 1999). A palmitate 
analogue of cerulenin – compound 7e (Figure 1.14), showed highest potency in inhibition of 
HRas-dependent cancer cell growth without inhibiting fatty acid synthase. However, the 
highly reactive epoxycarboxamide moiety and the high hydrophobicity of the lipid tails 
rendered them inappropriate as therapeutic agents which prevented their continued 
development (Teglund and Toftgard, 2010). 
In a study aimed at identifying non-lipid-based S-palmitoylation inhibitors targeting DHHC 
PATs, cell- and peptide-based assays for high-throughput screening of a library of 
compounds were used. 32 confirmed hits were identified to act selectively towards different 
PAT types – type I acting on a Ras-derived farnesyl-dependent S-palmitoylation motif, and 
type II acting on a Src-derived myristoyl-dependent S-palmitoylation motif (Ducker et al., 
2006). These 32 compounds were further classified into five chemotypes after their 
chemical structure and their behaviour was represented by compounds I-V (Figure 1.14). 
Although, this initial study implied a certain substrate specificity for these compounds, a 
subsequent study on purified DHHC proteins and their targets could not recapitulate the 
substrate specificity demonstrated in the cell- and peptide-based assays (Jennings et al., 
2009). Instead, they found that Compound V, which Ducker at al. reported to be selective 
for myristoylated targets, was able to inhibit S-palmitoylation by both myristoylated and 
farnesylated targets in vitro, while compounds I-III had little or no effect on either target 
type (compound IV was not tested). Although the differences in results may reflect intrinsic 
limitations of the methods used, these findings also reflect the complex cross-reactive 
nature of DHHC proteins in vivo or inhibition of proteins involved in palmitoylation other 
than DHHC PATs. 
Thus far, specific inhibitors targeted against the MBOAT family of PATs have been reported 
for Porc (Chen et al., 2009a) and GOAT (Yang et al., 2008b, Barnett et al., 2010), but not 
Hhat. By screening a library of small-molecules, a group of compounds called IWPs were 
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Figure 1.14 Molecular structures of general and specific DHHC and MBOAT PAT inhibitors. 
1 Introduction 
62 
identified which selectively inhibited the activity of Porc in a cell-based assay. Compound 
IWP-2 (Figure 1.14) displayed high selectivity for Porc, either by direct binding to Porc or by 
modulation of a Porc regulator, and was ineffective against Hhat and GOAT (Chen et al., 
2009a). GOAT inhibition has been achieved in vitro using a modified octanoylated 
pentapeptide comprised of the residues surrounding the octanoylated Ser in GOAT itself 
(Yang et al., 2008b). Maximum potency was reached by substituting the C-terminus of the 
pentapeptide with an amide and replacing the octanoylated Ser with (S)-2,3-
diaminopropionic acid octanoylated at its distal amine (Figure 1.14). Using the same 
principle, Barnett et al. developed a peptide-based GOAT inhibitor called GO-CoA-Tat, by 
combining coenzyme A (CoA), an octanoylated ghrelin peptide (GO) and an HIV-1-derived 
peptide called Tat which enhances cell penetration (Barnett et al., 2010). The compound 
potently inhibits weight gain in wild type mice on a fatty diet but not in GOAT-/- mice. 
Together, the finding of specific inhibitors of Porc and GOAT holds promise that specific 
inhibition of Hhat in the Hh pathway may also be possible. 
1.3 Hypothesis and aims 
Hh signalling studies over the past decade have firmly established palmitoylation as an 
important modulator of Hh protein activity. In parallel, efforts in cancer biology have 
revealed a potential role of Shh and Ihh in a variety of cancers. As palmitoylation of all Hh 
proteins depends on Hhat, it is of interest to determine the potential of Hhat as a 
therapeutic target in cancers dependent on Hh signalling for growth. In this thesis, I 
hypothesise that Hhat is a viable pharmacological target in SCLC and NSCLC and aim to 
provide proof-of-principle for this hypothesis by performing Hhat KD in lung cancer cell lines 
and measuring its effect on cell growth and Shh signalling. Further, I aim to determine the 
membrane topology of Hhat. Topology mapping of TM regions in membrane proteins is an 
approach which with relatively simple molecular methods provides information about the 
localisation of conserved residues relative to the membrane. With these studies I aim to 
gain understanding of the architecture of Hhat towards future mechanistic studies which 
may aid in the search for a suitable inhibitor candidate against this enzyme. The 
experiments performed in this thesis are summarised below. 
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In a collaborative effort with Dr. Ed Tate, click chemistry was introduced as a means to study 
both palmitoylation and cholesteroylation of Shh. In Chapter 3, palmitoylation and 
cholesteroylation of Shh transiently overexpressed in HEK293A cells was implemented and 
optimised. Cell toxicity of a novel bioorthogonal cholesterol analogue was assessed as well 
as the impact of mevastatin (an inhibitor of cholesterol biosynthesis) on cholesteroylation of 
Shh in cells. 
In Chapter 4, a small panel of lung cancer cell lines expressing Shh pathway components 
was tested for dependence on autocrine Shh signalling by measuring cell proliferation after 
Shh pathway inhibitor treatment. A NSCLC cell line was further tested for its ability to induce 
a juxtacrine/paracrine Shh signal response in co-culture with C3H10T½ cells which are 
known to differentiate upon stimulation with Shh. This assay was finally used to measure 
the effect of Hhat KD by siRNA on Shh signalling as a model for Hhat inhibition in lung cancer 
cells.  
Finally, in Chapter 5, the topology of Hhat was studied by N-glycosylation mapping of Hhat. 
Truncated mutants of Hhat were created with an N-glycosylation site and a V5 epitope tag 
at their C-termini which were used for topology studies in HEK293A cells and in an in vitro 
translation system. As N-glycosylation occurs in the ER lumen, Hhat truncates with their C-
termini in the ER were N-glycosylated upon translation, while those with their C-termini in 
the cytosol were not. The C-terminal V5 epitope tag was further utilised to validate the 
results obtained using N-glycosylation mapping by performing immunofluorescence imaging 
of semi-permeabilised cells.  
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2 Materials and methods 
2.1 Chemicals and reagents 
All chemicals were purchased from Sigma-Aldrich, unless stated otherwise. 
Name Supplier 
4× NuPAGE LDS protein sample buffer Invitrogen 
Acetic acid Merck  
Acrylamide-bisacrylamide mix (37.5:1) Bio-Rad 
Agarose NBS Biologicals 
Alkyne-TAMRA-biotin capturing reagent Provided by E. Tate 
Alkynyl-palmitate (YnC15) Provided by E. Tate 
All Blue Precision Plus molecular size marker Bio-Rad 
Ampicillin Stratagene  
Azido-cholesterol Provided by E. Tate 
Azido-TAMRA-biotin capturing reagent Provided by E. Tate 
Bovine serum albumin (BSA) Invitrogen  
Canine pancreatic microsomes Promega 
Complete Mini EDTA-free protease inhibitor Roche 
Coomassie G-250 Blue Bio-Rad 
dNTP Promega  
ECL Plus Western blot reagent GE Healthcare 
Ethanol Merck  
Ethidium bromide Bio-rad  
Ethylenediaminetetraacetic acid (EDTA) Merck  
FuGENE HD transfection reagent Promega 
Full-range Rainbow molecular size marker GE Healthcare 
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Hyperladder I Bioline Reagents 
Hyperladder IV Bioline Reagents 
Isopropanol Merck  
Lipofectamine 2000 transfection reagent Invitrogen 
Luria-Bertani (LB) broth Sigma  
Metafectene SI transfection reagent Biontex 
Methanol Fisher Scientific 
Milk powder (Marvel) Waitrose 
N,N,N',N'-tetramethylethylenediamine (TEMED) Bio-Rad  
Phosphate buffered saline (PBS) Invitrogen 
Prolong Gold Antifade mounting reagent Invitrogen 
Protein G-coupled microbeads Miltenyi Biotec 
RNase-free water Invitrogen 
Shh-C24II R&D Systems 
Sodium dodecyl sulphate (SDS) Merck  
Sodium hydroxide Merck  
Tris(hydroxymethyl)methylamine (Tris base) Merck  
Triton X-100  BDH 
Trizol reagent Invitrogen  
X-tremeGENE 9 transfection reagent Roche 
 
2.1.1 Buffers and solutions 
Water was purified to a Life Science purity grade using an ELGA purifier.  
Name Composition 
ALP lysis buffer PBS pH 7.4, 0.1% (v/v) Triton-X100, Complete Mini EDTA-free 
protease inhibitor 
ALP reagent buffer 1 M diethanolamine buffer pH 9.8, 0.5 mM MgCl2 
Ampicillin 100 mg/ml in water 
Blocking solution 5% (w/v) milk and 0.25% (w/v) sodium azide in PBS-T 
Buffer G7  50 mM sodium phosphate pH 7.5 
Chloramphenicol   30 mg/ml in ethanol 
Click-chemistry lysis buffer PBS pH 7.4, 0.1% (w/v) SDS, 1% (v/v) Triton X-100, Complete Mini 
EDTA-free protease inhibitor 
Coomassie destaining solution 10% (v/v) acetic acid, 20% (v/v) methanol in water 
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Coomassie staining solution  0.25% (w/v) Coomassie G-250 blue, 10% (v/v) acetic acid, 
45% (v/v) methanol in water 
Cyclopamine 5 mM in DMSO 
Electrophoresis buffer 25 mM Tris pH 8.3, 192 mM glycine and 0.1% (w/v) SDS 
FACS sorting medium D-PBS, 1% FCS , 2 mM EDTA 
Fixative solution 4% PFA in PBS pH 7.2 
Gentamycin 50 mg/ml in water 
Glycoprotein denaturing buffer 0.5% SDS, 40 mM DTT 
IgG binding buffer 20 mM sodium phosphate pH 7.0 
IgG elution buffer 100 mM glycine pH 2.8 
IgG neutralising buffer 1 M Tris-HCl pH 9.0 
IP low-salt buffer 20 mM Tris-HCl pH 7.5 
IP lysis buffer 50 mM Tris-HCl pH 8.0, 150 mM NaCl and 1% Triton X-100 
Kanamycin 50 mg/ml in water 
LB agar 1.5% (w/v) agarose in LB broth 
LB broth Tryptone (pancreatic digest of casein) 10 g/L, yeast extract 5 g/L, 
NaCl 5 g/L in water 
Mevastatin 10 mM in DMSO 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 
pH 7.4 
PBS-T PBS, 0.05% (v/v) Tween-20 
PNGase F reaction buffer 50 mM sodium phosphate pH 7.5, 0.5% SDS, 1% NP-40, 40 mM 
DTT 
Separating gel 250 mM Tris pH 8.8, 10-15% (v/v) acrylamide-bisacrylamide mix 
(37.5:1), 0.2% (w/v) APS, 0.1% (w/v) SDS, 0.082% (v/v) TEMED 
Shh-C24II 50 µg/ml in PBS +0.1% (w/v) BSA 
Spectinomycin 100 mg/ml in water:DMSO 1:1 
Stacking gel 158 mM Tris pH 6.8, 4% (v/v) acrylamide-bisacrylamide mix 
(37.5:1), 0.3% (w/v) APS, 0.1% (w/v) SDS, 0.15% (v/v) TEMED 
TBE 89 mM Tris pH 8.0, 89 mM boric acid and 2 mM EDTA 
TE buffer 10 mM Tris pH 8.0 and 1 mM EDTA 
Transfer buffer 25 mM Tris pH 8.3, 192 mM glycine and 0.1% (v/v) SDS 
Transformation solution I 80 mM CaCl2 and 50 mM MgCl2 
Transformation solution II 75 mM CaCl2, 25% (v/v) glycerol 
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2.1.2 Enzymes and reagents 
Name Supplier 
DpnI NEB 
EcoRV NEB 
Gateway LR Clonase II enzyme mix Invitrogen 
GoTaq qPCR master mix Promega 
NotI NEB 
NsiI NEB 
Pfu Ultra DNA polymerase NEB 
Platinum Pfx DNA polymerase Invitrogen 
PNGase F NEB 
PstI NEB 
Shrimp alkaline phosphatase (SAP) Promega 
Taq DNA polymerase NEB 
 
2.1.3 Commercial kits 
Name Supplier 
Amplex Red cholesterol assay Invitrogen 
CyQuant Direct proliferation assay Invitrogen 
EndoFree Plasmid Maxi kit Qiagen 
GoScript reverse transcriptase kit Promega 
PCR purification kit Qiagen 
pENTR directional cloning kit Invitrogen 
Plasmid Midi kit Qiagen 
QIAprep Spin Miniprep kit Qiagen 
TnT Quick coupled transcription/translation system Promega 
 
2.2 Bacterial strains 
Bacterial strain Supplier 
DH5α Invitrogen 
OneShot ccdB Survival 2 T1 Gift from H. Ho, Imperial College London 
TOP10 Invitrogen 
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2.2.1 Plasmids 
Plasmid Selective marker Supplier 
pENTR223.1-Shh Spectinomycin (100 µg/ml) DNAFORM 
pcDNA-DEST40 Chloramphenicol (30 µg/ml) Invitrogen 
pcDNA-DEST40-Shh Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-Hhat Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-Hhat-12/13 Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-Hhat-11/12 Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-Hhat-9/10 Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-Hhat-8/9 Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-Hhat-7/8 Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-Hhat-6/7 Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-Hhat-5/6 Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-Hhat-4/5 Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-HA-Hhat- Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-NLT-HA-Hhat-4/5 Ampicillin (100 µg/ml) Made by B. Jovanovic 
pcDNA-DEST40-Hhat Ampicillin (100 µg/ml) Made by B. Jovanovic 
pCR4-TOPO-Hhat Ampicillin (100 µg/ml) Open Biosystems 
pENTR⁄D-TOPO-Hhat Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-Hhat-12/13 Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-Hhat-11/12 Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-Hhat-9/10 Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-Hhat-8/9 Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-Hhat-7/8 Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-Hhat-6/7 Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-Hhat-5/6 Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-Hhat-4/5 Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-HA-Hhat Kanamycin (50 µg/ml) Made by B. Jovanovic 
pENTR⁄D-TOPO-HA-Hhat-4/5 Kanamycin (50 µg/ml) Made by B. Jovanovic 
pmU6-Hhat-3 Ampicillin (100 µg/ml) Genecopoeia 
pmU6-Hhat-4 Ampicillin (100 µg/ml) Genecopoeia 
pmU6-Hhat-5 Ampicillin (100 µg/ml) Genecopoeia 
pmU6-Hhat-6 Ampicillin (100 µg/ml) Genecopoeia 
pmU6-control Ampicillin (100 µg/ml) Genecopoeia 
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2.3 Cell culture reagents and cell lines 
Media, foetal calf serum (FCS, batch no.: A10108-1898), Dulbecco’s PBS (D-PBS), sodium 
pyruvate (100 mM), and trypsin-EDTA (0.05% (w/v) and 0.02% (w/v)) for cell culture were 
purchased from PAA Laboratories. Multi-well plates and Petri dishes for tissue culture were 
purchased from Nunc. All cell lines were maintained at 37°C and 5% CO2 and handled in 
tissue culture incubators and biological safety cabinets from NuAire, UK.  
 
2.4 Equipment 
Name Manufacturer 
5415R cooled microcentrifuge Eppendorf 
5810 cooled tabletop centrifuge Eppendorf 
7500 Fast Real-Time PCR system Applied Biosystems 
AccuSpin Micro R microcentrifuge Fisher Scientific 
Axiovert 200 inverted microscope Carl Zeiss 
ChemiDoc XRS+ imager Bio-Rad 
CR4-12 tabletop centrifuge Jouan 
Ettan DIGE imager GE Healthcare 
FACSCalibur flow cytometer BD Biosciences 
GelAir gel dryer Bio-Rad 
Mini-gel system Bio-Rad 
ND-1000 spectrophotometer Nanodrop 
Optima TL ultracentrifuge Beckman 
PowerPac Basic power pack Bio-Rad 
Primus 96 Plus thermal cycler MWG 
Cell line Maintaining medium Supplier 
5E1 IMDM + 20% FCS DSHB, University of Iowa 
A549 DMEM + 10% FCS Gift from S. Ali, Imperial College London 
C3H10T½ DMEM + 10% FCS Gift from K. Grobe, Universität Münster 
H146 RPMI 1640 + 10% FCS ATCC 
H1618 RPMI 1640 + 10% FCS ATCC 
H209 RPMI 1640 + 10% FCS Gift from S. Ali, Imperial College London 
H82 RPMI 1640 + 10% FCS ATCC 
HEK293A DMEM + 10% FCS Gift from B. Leitinger, Imperial College London 
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SpectraMax M2e microplate reader Molecular Devices 
Sunrise microplate reader TECAN 
TE77x semi-dry transfer unit Hoefer 
Tissue culture incubator NuAire 
TLA-45 ultracentrifuge rotor Beckman 
 
2.5 Molecular biology methods 
2.5.1 DNA purification 
Cloning plasmids, PCR products and gel-excised DNA were purified using the QIAprep Spin 
Miniprep or Qiagen PCR purification kits according to the manufacturer’s instructions. 
Plasmids used for mammalian transfection were purified using EndoFree Plasmid Maxi or 
Plasmid Midi kits and eluted in sterile water. DNA concentration and purity were 
determined by measuring absorbance at 260 nm and 280 nm using a Nanodrop ND-1000 
spectrophotometer. Samples with A260/A280 ratios of >1.8-2.0 were considered free of 
contaminants. 
2.5.2 RNA extraction 
To extract RNA from cells in culture, cells were first washed twice with D-PBS. RNA was 
purified using Trizol reagent according to the manufacturers’ instructions and resuspended 
in RNase-free water. The RNA integrity was assessed by gel electrophoresis using a 1% (w/v) 
agarose gel (Section 2.5.5) where the presence of the ribosomal RNA subunits 28S and 18S 
at a density ratio of 2:1 indicated intact RNA. RNA concentration was further determined by 
measuring absorbance at 260 nm using a Nanodrop ND-1000 spectrophotometer. RNA was 
considered pure if its A260/A280 and A260/A230 ratios were >1.8.  
2.5.3 Phenol removal from extracted RNA 
Extracted RNA with low A260/A230 ratios may indicate phenol contamination originating 
from the Trizol reagent which can inhibit subsequent enzymatic reaction. To remove phenol, 
extracted RNA samples were diluted to 400 µl in RNase-free water. 400 µl of a 24:1 
chloroform: isoamyl-alcohol mixture were added and the sample was mixed vigorously for 
20 sec. Phase separation was achieved by centrifugation at 16,000×g for 10 min at 4°C. The 
upper aqueous phase was transferred into a new tube and the extraction was repeated. 
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1 ml of 120 mM sodium acetate in 96% ethanol was added to the aqueous phase and 
incubated on ice for 20 min. The precipitated RNA was collected by centrifugation at 
16,000×g for 10 min at 4°C. The pellet was air-dried and resuspended in 20 µl RNase-free 
water. RNA concentration was determined by measuring absorbance at 260 nm using a 
Nanodrop ND-1000 spectrophotometer. RNA was considered pure if its A260/A280 and 
A260/A230 ratios were >1.8. 
2.5.4 Polymerase chain reaction (PCR) 
Routine PCR was performed using Taq DNA polymerase. Typically, a 50 µl reaction was 
prepared as specified in Table 2.1. The thermal cycler was set for denaturation at 94°C for 5 
minutes, followed by 30 to 45 cycles of denaturation at 94°C for 45 sec, annealing at 50-
60°C for 30 sec and extension at 72°C for 1 min, followed by a final annealing step at 72°C 
for 10 min. 10-20 µl of PCR products were examined by agarose gel electrophoresis (Section 
2.5.5). For E.coli colony screening after cloning, a small amount of the colony picked from a 
freshly grown plate using a pipette tip was used as template and the amount of water in the 
reaction was adjusted accordingly. 
Table 2.1 Reaction set-up used for DNA amplification using Taq DNA polymerase. 
Component Volume (µl) 
10× Reaction buffer 5 
25 mM MgSO4 3 
10 mM dNTP 1 
10 µM Forward primer 1 
10 µM Reverse primer 1 
DNA or cDNA template 1-3 
Water 35.6-37.6 
Taq DNA polymerase 0.4 
Total 50 
 
2.5.5 Nucleic acid gel electrophoresis 
DNA and RNA were analysed by separation on 1-1.7% (w/v) agarose gel in TBE buffer 
supplemented with ethidium bromide (0.5 μg/ml). Gels were run at 100 mA constant 
current until sufficient separation was obtained. Bands were imaged after UV light 
illumination using a ChemiDoc XRS+ imager. Molecular size markers used were Hyperladder 
I and Hyperladder IV. 
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2.5.6 Preparation of chemo-competent cells 
Chemo-competent cells were regularly prepared from DH5α and OneShot ccdB Survival 2 T1 
cells. 3-5 colonies of freshly grown E.coli cells were inoculated in 6 ml LB medium for growth 
overnight at 37°C. 5 ml were used to inoculate 100 ml of LB broth. The cells were grown 
until the optical density at 600 nm (OD600) reached 0.6. The culture was cooled on ice and 
cells were collected by centrifugation (800×g, 4°C, 20 min). The supernatant was discarded 
and the cell pellet was resuspended in 20 ml ice-cold transformation solution I and 
incubated on ice for 15 minutes. The cells were pelleted, resuspended again with 10 ml ice-
cold transformation solution I and incubated on ice for 20 minutes. After a final 
centrifugation, cells were resuspended in pre-chilled transformation solution II, aliquoted 
into pre-chilled tubes, flash-frozen in dry ice and ethanol and stored at -80°C for future use. 
2.5.7 Transformation of bacteria 
50 µl of chemo-competent E.coli cells thawed on ice were mixed with 2-5 µl plasmid DNA 
(10-500 ng/µl) and incubated on ice for 15 minutes. The mixture was heat-shocked at 42°C 
for 45 seconds in a water bath and cooled on ice for 2 minutes. 200-1000 µl pre-heated LB 
medium were added to the cells and incubated at 37°C for 1 hour. Finally, 20-200 µl of the 
culture were spread on selective 10 cm LB-agar plates and incubated at 37°C overnight. 
2.5.8 Gateway cloning of mammalian expression vectors 
Expression vectors for mammalian expression of Shh, Hhat and Hhat truncates were 
constructed using the Gateway LR Clonase II enzyme mix through in vitro recombination 
between an entry vector and a destination vector. The destination vectors used were 
pcDNA-DEST40 (Invitrogen) and its derivative pcDNA-DEST40-NLT (Section 2.5.13.1). Entry 
vectors used were pENTR223.1-Shh and pENTR⁄D-TOPO into which Hhat and Hhat truncates 
had been cloned (Section 2.5.13), see Table 2.2. 150 ng each of an entry and a destination 
vector were mixed in TE buffer to a total volume of 4 µl. Recombination was performed by 
addition of 1 µl of the LR Clonase II enzyme mix and incubation for 1 h at room temperature. 
The reaction was stopped by addition of 0.5 µl of Proteinase K solution and incubation for 
10 min at 37°C. 2 µl were used to transform DH5α cells. Transformants were selected on LB 
agar with ampicillin (100 µg/ml) and further negatively selected using chloramphenicol 
(30 µg/ml). Colonies which were ampicillin resistant but chloramphenicol sensitive were 
2 Materials and methods 
74 
used for plasmid purification. All clones were confirmed by DNA sequencing (Section 
2.5.10). Hhat clones were also screened by PCR amplification and endonuclease digestion 
prior to sequencing. PCR screening was performed using Taq polymerase (Section 2.5.4) and 
primers M13(-20) F (GTAAAACGACGGCCAG) and M13 R (CAGGAAACAGCTATGAC) supplied with 
the Gateway LR Clonase II enzyme kit at an annealing temperature of 56°C. Plasmids from 
colonies showing correctly oriented gene inserts were purified and endonuclease digestion 
was performed (Section 2.5.9) using PstI which cuts at two sites inside Hhat at a distance of 
60 bp from each other and once outside, and analysed by DNA electrophoresis (Section 
2.5.5) using a 1% agarose gel. A correctly cut plasmid was finally confirmed by DNA 
sequencing.  
Table 2.2 Entry and destination vectors used for Gateway expression vector cloning. 
Entry vector Destination vector Resulting expression vector 
pENTR223.1-Shh pcDNA-DEST40 pcDNA-DEST40-Shh 
pENTR⁄D-TOPO-Hhat pcDNA-DEST40 pcDNA-DEST40-Hhat 
pENTR⁄D-TOPO-Hhat pcDNA-DEST40-NLT pcDNA-DEST40-NLT-Hhat 
pENTR⁄D-TOPO-Hhat-12/13 pcDNA-DEST40-NLT pcDNA-DEST40-NLT-Hhat-12/13 
pENTR⁄D-TOPO-Hhat-11/12 pcDNA-DEST40-NLT pcDNA-DEST40-NLT-Hhat-11/12 
pENTR⁄D-TOPO-Hhat-9/10 pcDNA-DEST40-NLT pcDNA-DEST40-NLT-Hhat-9/10 
pENTR⁄D-TOPO-Hhat-8/9 pcDNA-DEST40-NLT pcDNA-DEST40-NLT-Hhat-8/9 
pENTR⁄D-TOPO-Hhat-7/8 pcDNA-DEST40-NLT pcDNA-DEST40-NLT-Hhat-7/8 
pENTR⁄D-TOPO-Hhat-6/7 pcDNA-DEST40-NLT pcDNA-DEST40-NLT-Hhat-6/7 
pENTR⁄D-TOPO-Hhat-5/6 pcDNA-DEST40-NLT pcDNA-DEST40-NLT-Hhat-5/6 
pENTR⁄D-TOPO-Hhat-4/5 pcDNA-DEST40-NLT pcDNA-DEST40-NLT-Hhat-4/5 
pENTR⁄D-TOPO-HA-Hhat pcDNA-DEST40-NLT pcDNA-DEST40-NLT-HA-Hhat- 
pENTR⁄D-TOPO-HA-Hhat-4/5 pcDNA-DEST40-NLT pcDNA-DEST40-NLT-HA-Hhat-4/5 
 
2.5.9 Endonuclease digestion 
After mutagenesis or cloning and prior to further experiment or sequencing, plasmid sizes 
were determined by endonuclease digestion followed by gel analysis, typically using a 1% 
agarose gel. An endonuclease digestion reaction was typically set up by mixing 2µl 10× 
reaction buffer (NEB), 1 µg plasmid DNA, 0.5 µl of each endonuclease used (5-20 U/µl) and 
adding water to a total volume of 20 µl. Reactions were incubated and terminated according 
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to manufacturer’s instructions. NEB Double Digest Finder tool 
(http://www.neb.com/nebecomm/DoubleDigestCalculator.asp) was used to determine the 
compatibility of endonucleases used in double digestion. 
2.5.10 DNA sequencing 
All plasmids were confirmed by sequencing. Sequencing was performed by Beckman Coulter 
Genomics.  
2.5.11 mRNA analysis by RT-PCR  
2.5.11.1 Reverse transcription (RT) 
Reverse transcription of cell extracted RNA to cDNA was performed using the GoScript 
reverse transcriptase kit. Typically, 0.5 µg RNA were used as template in a 20 µl total 
reaction using random hexamers as primers. RNA was combined with 1 µl primers 
(0.5 µg/µl) and RNase-free water to a volume of 10 µl. The mix was heated at 70°C for 5 min 
and chilled at 4°C for 5 min. Separately, a GoScript reverse transcriptase master mix was 
prepared on ice by mixing 1.5 µl RNase-free water, 4 µl GoScript 5× reaction buffer, 2 µl 
MgCl2 (25 mM), 1 µl dNTP (10 mM), 0.5 µl recombinant RNasin ribonuclease inhibitor and 
1 µl GoScript reverse transcriptase per reaction. 10 µl of master mix were added to 10 µl of 
RNA and primer mix per reaction, and incubated in a thermal cycler for annealing at 25°C for 
5 min, followed by extension at 42°C for 1 hour and inactivation at 70°C for 15 min.  
2.5.11.2 Qualitative RT polymerase chain reaction (RT-PCR) 
To determine the presence of Hh pathway components in cancer cell lines, 0.5 µg of RNA 
extracted from exponentially growing cells was used to perform RT reactions as described in 
Section 2.5.11.1. Reactions without addition of GoScript reverse transcriptase (RT-) were 
used as negative controls. The resulting cDNA was diluted 2× in 20 µl RNase-free water prior 
to PCR analysis. All PCR primers apart from ActB span at least one intron eliminating the risk 
of false positives from DNA contamination (Table 2.3). PCR reaction was performed using 
Taq DNA polymerase as described in Section 2.5.4, with an annealing temperature of 60°C 
and 40-45 PCR cycles. 
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2.5.11.3 Quantitative RT-PCR (qRT-PCR) 
qRT-PCR was performed using GoTaq qPCR master mix. Prior to use, cDNA (prepared 
according to Section 2.5.11.1), was diluted 5× in water and a 2 µM solution of mixed 
forward and reverse primers was prepared. Primers used in the reactions are shown in 
Table 2.3. 10 µl of GoTaq qPCR master mix, 2 µl of pre-mixed primer pairs and 5 µl of water 
were combined per reaction and added to 3 µl diluted cDNA in 96-well thermal plates to a 
final reaction volume of 20 µl. All reactions were prepared in triplicate. The plates were 
sealed and run in an 7500 Fast Real-Time PCR System cycler according to Table 2.4 followed 
by a standard dissociation programme to obtain product melting curves. Data were analysed 
using the ΔΔCt method for determination of relative gene expression by normalisation to an 
internal control gene (GAPDH, RPLPO or ActB) and further to a control sample treated with 
non-targeting siRNA. 
Table 2.3 Primers used for qualitative and quantitative RT-PCR. 
Target Primer Size (bp) Reference 
Hhat 
Forward 
Reverse 
GAGCTGATGGCTCACCTGATG 
GAACATGGTGCTCACGCAG 
213 
Designed by B. 
Jovanovic 
Shh 
Forward 
Reverse 
CGCACGGGGACAGCTCGGAAGT 
CTGCGCGGCCCTCGTAGTGC 
477 
(Vestergaard et al., 
2006) 
Ptch1 
Forward 
Reverse 
GCCGTGCCCGTGGTCAT 
CCCATTGAGAACGCCGAGGAT 
264 
(Vestergaard et al., 
2006) 
Smo 
Forward 
Reverse 
GAAGTGCCCTTGGTTCGGACA 
CCGCCAGTCAGCCACGAAT 
192 
(Vestergaard et al., 
2006) 
Gli1 
Forward 
Reverse 
CAGGGAGTGCAGCCAATACAG 
GAGCGGCGGCTGACAGTATA 
313 
(Vestergaard et al., 
2006) 
GAPDH 
Forward 
Reverse 
ACGACCACTTTGTCAAGCTC 
GGTCTACATGGCAACTGTGA 
226 
(Kikuchi et al., 
2006) 
RPLP0 
Forward 
Reverse 
TCTACAACCCTGAAGTGCTTGATATC 
GCAGACAGACACTGGCAACATT 
90 
(Doucet et al., 
2007) 
ActB 
Forward 
Reverse 
CTGGAACGGTGAAGGTGACA 
AAGGGACTTCCTGTAACAATGCA 
139 
(Vandesompele et 
al., 2002) 
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Table 2.4 qRT-PCR cycling conditions for GoTaq qPCR master mix. 
Step Cycles Temperature Time 
Activation 1 95°C 5 min 
Denaturation 
40-45 
95°C 45 sec 
Annealing/extension 60°C 30 sec 
 
2.5.12 RNAi gene knock-down 
2.5.12.1 Optimisation of shRNA plasmid transfection in A549 cells 
To obtain Hhat KD, transfection of A549 cells with Hhat targeting shRNA plasmids was 
attempted. Individual plasmids targeting four different Hhat sequences and a non-targeting 
shRNA able to constitutively express mCherry alongside shRNA, were transformed into 
DH5α cells and purified using the EndoFree Plasmid Maxi kit. shRNA plasmids and the shRNA 
targeting sequences are summarised in Table 2.5. Vector pmU6-control was used to 
optimise transfection of A549 cells using transfection reagents Lipofectamine 2000, X-
tremeGENE 9, and FuGENE HD. 
Table 2.5 shRNA vectors and their target sequences for Hhat KD. 
shRNA vector Target sequence 
pmU6-Hhat-3 CGGCGATGACATTTGCATT 
pmU6-Hhat-4 CCTGTCCAACCTGGTATTT 
pmU6-Hhat-5 CTGGAGACTGTCTCTTGTT 
pmU6-Hhat-6 GGAATAGGATCTTCATACA 
pmU6-control TGGCTGCATGCTATGTTGA 
 
3×105 cells were seeded in 2 ml DMEM +10% FCS per well in 6-well plates and allowed to 
grow overnight. For transfection using Lipofectamine 2000, the medium was replaced with 
fresh medium followed by addition of the transfection mixture. The transfection mixture 
contained Lipofectamine 2000 and DNA at ratios 3 µl:1 µg, 2 µl:1 µg, or 1 µl:1 µg of 
Lipofectamine 2000 to DNA in 400 µl Opti-MEM medium (prepared according to 
manufacturer’s instructions) and was added to the cells in a dropwise fashion. Transfection 
medium was exchanged for fresh medium after 6 h. For transfection using X-tremeGENE 9, 
the transfection mixture was prepared using 6 µl:2 µg or 3 µl:1 µg transfection reagent to 
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DNA in 100 µl Opti-MEM medium. After 15 min of incubation at room temperature, the 
mixture was added dropwise to the cells. For transfection using FuGENE HD, the 
transfection mixture containing 6 µl FuGENE HD and 2 µg DNA in 200 µl Opti-MEM medium 
was prepared according to the manufacturer’s instructions. Medium was replaced with 
fresh medium followed by dropwise addition of the transfection mixture. All cells were 
allowed to express protein for 24 h prior to analysis. 
24 h after transfection, transfection efficiency for cells treated with Lipofectamine 2000 and 
X-tremeGENE 9 was measured using fluorescence-activated cell sorting (FACS) by detection 
of mCherry fluorescence. Cells were trypsinised, washed once in D-PBS and resuspended in 
FACS sorting medium at cell densities of about 5×105 cells/ml. FACS analysis was performed 
using a FACSCalibur flow cytometer (excitation at 540 nm). Transfection efficiency of 
FuGENE HD-treated cells was assayed by visually comparing cell fluorescence with cells 
transfected with Lipofectamine 2000. 
2.5.12.2 siRNA transfection 
To obtain Hhat KD, A549 or HEK293A-Shh cells were transfected with siRNA targeting Hhat 
mRNA (Table 2.6) using Metafectene SI as transfection reagent. siRNA stocks were diluted 
to 20 µM in 1×siRNA buffer. A standard non-targeting pool of four siRNAs was used as 
control (ON-TARGETplus Non-Targeting pool, D-001810-10-05, Dharmacon). 60 µl of 
1×Metafectene SI buffer, 4 µl Metafectene SI transfection reagent and 2 µl of siRNA (20 µM) 
were mixed per reaction, distributed in a 24-well plate and incubated for 15 minutes. 
Meanwhile, subconfluent cells were trypsinised and resuspended in DMEM + 10% FCS at a 
density of 8×104 cells/ ml. 0.5 ml of cell suspension (4×104 cells) was added per each well 
containing transfection reagent. Medium was exchanged after 24 h and cells were 
incubated for 2-4 days for analysis by qRT-PCR, proliferation assay or click chemistry. 
Table 2.6 Target sequences of siRNA oligos used for Hhat KD. 
siRNA oligo Target sequence 
1 AGGACAGUCUGGCCCGAUA 
2 CUUAGGAGGACUGGCGUUA 
3 GAAUUACGUAGUCGAAGAA 
4 AGACCUACGCCACGGACUA 
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2.5.12.3 Measurement of gene expression in cells treated with Hhat siRNA 
On Day 2, 3 and 4 of Hhat KD, cells were harvested and RNA was extracted. 0.25 µg RNA was 
used to make cDNA according to Section 2.5.11.1. qRT-PCR was used according to Section 
2.5.11.3 to determine Hhat expression in Hhat siRNA-treated samples relative to non-
targeting siRNA. GAPDH expression was used as an internal control.  
2.5.13 Molecular cloning of Hhat truncations 
2.5.13.1 Site-directed mutagenesis for expression plasmid cloning 
Site-directed mutagenesis in plasmids was performed according to the QuickChange II Site-
Directed mutagenesis protocol from Stratagene based on PCR amplification of a double-
stranded plasmid using a high fidelity polymerase, Pfu Ultra. The PCR reaction was prepared 
by mixing 5 µl 10× Pfu Ultra reaction buffer, 1.5 µl of dNTP (20 mM), 1.5 µl of each 
oligonucleotide primer (10 mM), 50 ng of plasmid template, and water to a final volume of 
50 µl. 2.5 U of Pfu Ultra were added prior to PCR cycling for 25 cycles (initial denaturation at 
95°C for 30 sec and 25 cycles of denaturation at 95°C for 20 sec, annealing at 55°C for 30 sec 
and extension at 68°C for 6 min). After cycling, 10 U of DpnI restriction enzyme were added 
to the reaction which was incubated at 37°C for 1 h to digest the methylated template 
plasmid. 5 µl of the digestion reaction were transformed into a suitable E.coli strain 
(OneShot ccdB Survival 2 T1 for mutagenesis of pcDNA-DEST40 or DH5α for mutagenesis of 
pcDNA-DEST-NTL-Hhat). Plasmid DNA from resulting colonies was amplified and analysed by 
endonuclease digestion (Section 2.5.9). Positive clones were sent for sequencing to confirm 
mutations. Oligonucleotides used for site-directed mutagenesis are shown in Table 2.7. 
Table 2.7 Oligonucleotides used for site-directed mutagenesis with mismatched 
nucleotides underlined. 
Oligonucleotide Sequence 
DEST40-NLT F GTACAAAGTGGTTAATCTAACGGGCCCGCGGTTCGAAGGTAAGC 
DEST40-NLT R GAACCGCGGGCCCGTTAGATTAACCACTTTGTACAAGAAAG 
Hhat-S182N F CTACTACACCAGCTTCAGCCTGGAGCTCTGCTGGCAGCAGC 
Hhat-S182N R CAGGCTGAAGCTGGTGTAGTAGAGGCAGCGAACGGTCAGCG 
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2.5.13.2 PCR amplification of gene inserts for TOPO-cloning 
PCR amplification of Hhat inserts for TOPO-cloning was performed using Platinum Pfx DNA 
polymerase and primers shown in Table 2.8. Reactions were set up by mixing 5 µl 10× 
Platinum Pfx reaction buffer, 1.5 µl dNTP (10 mM), 2 µl MgSO4 (50 mM), 1.5 µl of each 
primer (10 µM), 100 ng template DNA, 1 U Platinum Pfx DNA polymerase and water up to a 
total volume of 50 µl. The reactions were run in a thermal cycler using a programme with 25 
cycles (initial denaturation at 94°C for 5 min, cycling at 95°C for 15 sec, 58°C for 30 sec and 
68°C for 1 min 30 sec, final extension at 68°C for 5 min). PCR products were separated from 
template plasmid by electrophoresis on a 1% agarose gel (Section 2.5.5) and purified from 
the gel excisions using Qiagen PCR purification kit and dissolved in sterile water. 
Table 2.8 PCR primers for amplification of inserts for TOPO-cloning. 
Insert Primers Size (bp) 
Hhat-FL Forward 
Reverse 
CACCATGCTGCCCCGATGG 
GTCCGTGGCGTAGGTCTG 
1483 
Hhat-12/13 Forward 
Reverse 
CACCATGCTGCCCCGATGG 
TTTCCCAACCTCATTGCCCCC 
1366 
Hhat-11/12 Forward 
Reverse 
CACCATGCTGCCCCGATGG 
AGTCTCCACCAGCCTCCG 
1228 
Hhat-9/10 Forward 
Reverse 
CACCATGCTGCCCCGATGG 
CCTGATTAAGAAATTATGCAGTCCAACATC 
1048 
Hhat-8/9 Forward 
Reverse 
CACCATGCTGCCCCGATGG 
ATCCAGGCGCATGAGCAGAG 
947 
Hhat-7/8 Forward 
Reverse 
CACCATGCTGCCCCGATGG 
GCTGCTGTAGATGGCATGCATG 
823 
Hhat-6/7 Forward 
Reverse 
CACCATGCTGCCCCGATGG 
TTTGATGAACTCCGAGAAGCTGAGG 
685 
Hhat-5/6 Forward 
Reverse 
CACCATGCTGCCCCGATGG 
CTGCCAGCAGAGCTCCAG 
574 
Hhat-4/5 Forward 
Reverse 
CACCATGCTGCCCCGATGG 
CTTGTACCACCTTCTCTTAACTTC 
487 
HA-Hhat-FL Forward 
 
Reverse 
CACCATGTACCCCTACGACGTGCCCGACTACGCCC
TGCCCCGATGGGAACTG 
GTCCGTGGCGTAGGTCTG 
1516 
HA-Hhat-4/5 Forward 
 
Reverse 
CACCATGTACCCCTACGACGTGCCCGACTACGCCC
TGCCCCGATGGGAACTG 
CTTGTACCACCTTCTCTTAACTTC 
520 
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2.5.13.3 TOPO cloning  
Entry vectors used in Gateway cloning were made by topoisomerase cloning of PCR inserts 
into vector pENTR⁄D-TOPO using the pENTR directional TOPO cloning kit. The inserts and the 
vector were mixed at a molar ratio of 1:1, using 0.5 µl vector (15-20 ng/µl) and 0.5 µl salt 
solution (1.2 M NaCl, 60 mM MgCl2) in a total reaction volume of 3 µl. Reactions were 
incubated at room temperature overnight and used to transform DH5α cells. Transformants 
were selected on LB agar with kanamycin (50 µg/ml). All resulting colonies were transferred 
onto master plates and screened by PCR using Taq DNA polymerase as described in 
Section 2.5.4. PCR was run for 35 cycles at an annealing temperature of 56°C using primers 
Hhat F (CACCATGCTGCCCCGATGG) and T7 F (TAATACGACTCACTATAGGG) which amplify 
across the 5’-boundary identifying correctly oriented gene inserts. Positive clones were 
further analysed by endonuclease digestion using NotI and EcoRV (Section 2.5.9). Positive 
clones were used for Gateway cloning (Section 2.5.8). 
2.6 Protein analysis 
2.6.1 Lysis of mammalian cells 
Cells were rinsed twice with ice-cold PBS and incubated with an appropriate amount of 
suitable lysis buffer for 10 minutes. After incubation, cells were scraped off the surface with 
the flat end of a P1000 tip and sheared by passing the lysate multiple times though a 0.5 
mm syringe. Insoluble material was removed from the lysate by centrifugation at 16,000×g 
for 10 min at 4°C. The supernatant was used directly or stored for future experiments at  
-80°C. 
2.6.2 Protein content assay 
Total protein content in cell lysates was determined using the DC protein assay. Samples 
were prepared in triplicates in 96-well microtiter plates according to the supplier’s 
instructions. A standard curve of bovine serum albumin (BSA) dissolved in sample lysis 
buffer (0-1.5 mg/ml) was used for all measurements. Absorbance was measured at 700 nm 
using a Sunrise microplate spectrophotometer. 
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2.6.3 Protein separation by SDS-PAGE 
Proteins were separated according to their size by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE). Polyacrylamide gels were made of 4% stacking gel and 10-
15% separating gel using a mini gel system from Bio-Rad. All protein samples except for 
Hhat analysis were prepared with 1×NuPage LDS sample buffer supplemented with 50 mM 
DTT and incubated at 95°C for 5 minutes prior to loading. Samples for analysis of Hhat were 
incubated with 1×NuPage LDS sample buffer at room temperature for 1 h to avoid Hhat 
protein aggregation resulting from the highly hydrophobic nature of membrane proteins. 
Typically, 10 µg of protein was loaded per well for analysis of overexpressed Shh and Hhat. 
5 µl of molecular size markers All Blue Precision Plus or Full-range Rainbow were used. 
Separation was run in electrophoresis buffer at 200 V for 60 min using PowerPac Basic as 
power source. 
2.6.4 Coomassie Blue gel staining 
To visualise protein bands after SDS-PAGE using Coomassie Blue, gels were soaked in 
Coomassie staining solution and slowly brought to boiling temperature using a microwave 
oven. After 15 min of gentle agitation on a horizontal shaker, Coomassie solution was 
removed and the gel was rinsed in water. Coomassie destaining solution was added and the 
gel was again heated and gently agitated at room temperature for 15 min. The procedure 
was repeated until the background was clear. A paper tissue was added during destaining to 
soak up the unbound Coomassie stain and speed up destaining. Finally, the gel was dried 
between two soaked cellophane sheets using a heated GelAir drier. 
2.6.5 Western blotting 
Proteins separated by SDS-PAGE were transferred from gel onto methanol-activated PVDF 
membranes (Millipore) using a TE77X semi-dry transfer unit. Transfer was run for 1.5 h at 
1 mA/cm2 in transfer buffer. After transfer, membranes were blocked for 1 h at room 
temperature or overnight at 4°C in blocking solution and subsequently incubated with the 
primary antibody diluted in blocking solution. After primary incubation, the membranes 
were washed 4×5 min in PBS-T and incubated with the secondary antibody in PBS-T. After 
secondary incubation, the membrane was washed 5×5 min in PBS-T. Bands were detected 
using the ECL Plus Western blotting reagent imaged at 530/40 nm and 0.15 sec exposure 
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using Ettan DIGE imager. Details of primary and secondary antibodies used are shown in 
Table 2.9. All antibodies were incubated for 1 h at room temperature apart from Ab-90 
which was incubated overnight at 4°C. 
Table 2.9 List of antibodies used in Western blotting.  
Name Antigen Type Dilution Supplier 
Primary antibodies 
Ab-90 Hhat Rabbit IgG 1:3,000 Made by Magee group 
Anti-tubulin 
(ab7291) 
α-tubulin Mouse IgG1 1:10,000 Abcam 
Anti-V5 
(R960-25) 
V5 epitope Mouse IgG2a 1:10,000 Invitrogen 
H-160  
(sc-9024) 
Shh-N Rabbit IgG 1:500 Santa Cruz Biotechnology 
Secondary antibodies 
GAM-HRP 
(#1080-05) 
Mouse IgG2a Goat-anti-mouse 1:20,000 Southern Biotech 
GAR-HRP 
(#4050-05) 
Rabbit IgG H+L Goat-anti-rabbit 1:20,000 Southern Biotech 
 
2.6.6 Protein immunoprecipitation (IP) 
Cell lysate or recombinant Shh (Shh-C24II) diluted in IP lysis buffer was used to 
immunoprecipitate Shh using Protein G-coupled microbeads on magnetic columns. 0.5 ml of 
cell lysate or protein solution were incubated rotating with 1 µg of anti-Shh-N antibody 
MAb-5E1 and 50 µl Protein G-coupled microbeads for 1 h at 4°C. Samples were loaded on 
magnetic columns pre-equilibrated with 200 µl of IP buffer, washed with IP lysis buffer 
4×200 µl and 1×100 µl IP low-salt buffer (20 mM Tris pH 7.5). The protein captured on 
columns was denatured for 5 min by addition of 20 µl 1×NuPage LDS sample buffer pre-
heated to 95°C. The denatured protein was eluted by addition of 50 µl of pre-heated sample 
buffer. Samples were analysed by SDS-PAGE and Western blotting. 
2.6.7 Bioorthogonal labelling (click chemistry) 
2.6.7.1 Transfection of cells for bioorthogonal labelling 
For transfection of HEK293A cells with pcDNA-DEST40-Shh used in click-chemistry labelling 
experiments 8×106 cells were seeded in 6-well plates in 1 ml DMEM +10% FCS. 24 h later, 
the medium was replaced with fresh medium followed by addition of the transfection 
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mixture. The transfection mixture contained 5 µl Lipofectamine, 2 µg DNA in 200 µl Opti-
MEM medium and was prepared according to manufacturer’s instructions. 
2.6.7.2 Bioorthogonal palmitate analogue labelling for click chemistry 
To label overexpressed Shh with the palmitate analogue YnC15 (see Figure 3.1 for 
structure), cells were transfected with the pcDNA-DEST-Shh expression vector in 6-well 
plates according to Section 2.6.7.1 and incubated for 24 h prior to changing medium to 
labelling medium (DMEM + 5% FCS, 1 mM sodium pyruvate and 0, 25, 50 or 100 µM YnC15. 
After 16 hours, cells were lysed in 100 µl click chemistry lysis buffer. Cell lysate was used in a 
click reaction (Section 2.6.7.5). This protocol was further optimised by changing to labelling 
medium immediately before transfection and lysing the cells after 24 hours of labelling. The 
latter protocol with 50 µM YnC15 was used for all subsequent labelling experiments. 
2.6.7.3 Bioorthogonal cholesterol labelling for click chemistry 
To label Shh with the cholesterol analogue azido-cholesterol (see Figure 3.1 for structure), 
cells were transfected with expression vector pcDNA-DEST-Shh in 6-well plates according to 
Section 2.6.7.1. After 6 hours, the medium was exchanged for low-serum medium 
containing mevastatin (DMEM, 1% FCS, 10 µM mevastatin). After additional 2 hours, 
medium was exchanged again for labelling medium (DMEM + 1% FCS, 10 µM mevastatin, 0, 
40 or 100 µM azido-cholesterol). After 16 hours in labelling medium cells were lysed in 
100 µl click chemistry lysis buffer. The cell lysate was used in a click reaction according to 
Section 2.6.7.5. 
2.6.7.4 Dual bioorthogonal labelling 
To simultaneously label cells with YnC15 and azido-cholesterol, 1×106 HEK293A cells were 
seeded in 5 ml DMEM +10% FCS in 6 cm-plates. Cells were transfected with the pcDNA-
DEST-Shh expression vector in 5 ml medium supplemented with 5 µM mevastatin and 1 mM 
sodium pyruvate after scaling up the transfection reagent volumes in Section 2.6.7.1 by 
×2.5. After 4 hours of transfection, the medium was exchanged for labelling medium 
(DMEM + 1% FCS, 50 µM YnC15, 50 µM azido-cholesterol, 5 µM mevastatin, 1 mM sodium 
pyruvate). Cells were lysed in 200 µl of click reaction lysis buffer after 20 h of labelling.  
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2.6.7.5 The click chemistry reaction 
Click chemistry was performed to add a detectable tag onto Shh labelled with YnC15 and/or 
azido-cholesterol. Protein concentration for the cell lysates was determined (Section 2.6.2) 
and reagents were prepared in the following sequence. 0.5 µl of 10 mM azido- or alkyne-
TAMRA-biotin capturing reagent was premixed with 1.25 µl 40 mM CuSO4 and 1 µl 50 mM 
TCEP. The mixture was incubated at room temperature for 2 minutes to allow TCEP to 
reduce CuSO2 to Cu(I). Following copper reduction, 0.5 µl 10 mM TBTA and 50 µg protein 
were added to the mix and the reaction volume was adjusted to 50 µl with click chemistry 
lysis buffer. The reaction was run for 1 h at room temperature and stopped by addition of 
-20°C methanol. The protein was precipitated at -80°C overnight. Precipitate was collected 
by centrifugation at 16,000×g for 20 min at 4°C, washed twice with 300 µl -20°C methanol 
and air-dried for 10 min. Precipitated protein was finally solubilised in 50 µl 1×NuPage LDS 
sample buffer supplemented with 50 mM DTT and 10 µl were loaded on an 15% SDS-PAGE 
gel for analysis. Fluorescently tagged protein was detected by fluorescence gel imaging 
using the Cy3 channel (excitation at 540/25 nm, emission at 595/25 nm) of Ettan DIGE 
imager and by further Western blotting against Shh using the anti-Shh antibody H-160. 
2.6.7.6 Palmitate analogue labelling of cells treated with Hhat siRNA 
To label cells with the palmitate analogue YnC15 after Hhat siRNA KD, HEK293A-Shh cells 
were treated with Hhat siRNA for three days (Section 2.5.12.2). On Day 3, the medium was 
exchanged for YnC15 labelling medium (Section 2.6.7.2) and cells were incubated for 16 h. 
After lysis in click-reaction buffer, click reaction was performed as described in Section 
2.6.7.5. Cells treated with a standard pool of four non-targeting siRNAs were used as a 
control. 
2.6.8 Purification of anti-Shh monoclonal antibody (MAb)-5E1 
2.6.8.1 Antibody expression in mouse hybridoma cell culture 
5E1 hybridoma cells were cultured in IMDM supplemented with 20% FCS and gentamycin 
(50 µg/ml). Cells were expanded to 200 ml and grown at high density for five days without 
changing the medium. Supernatant containing MAb-5E1 antibodies was pre-cleared by 
removing cells by centrifugation at 300×g for 5 min at room temperature. The supernatant 
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was centrifuged again at 3000xg for 20 min at 4°C to remove cell debris. The supernatant 
was used directly for IgG purification or stored at -80°C for later use. 
2.6.8.2 IgG purification 
To purify IgG, either MAb-5E1 from 5E1 hybridoma culture medium or FCS-IgG from fresh 
culture medium (IMDM +20% FCS), about 200 ml of sample was used per batch. Prior to 
affinity chromatography samples were concentrated to about 25 ml by centrifugation 
(2,500×g, 8°C) using 15 ml filter columns with 30,000 kDa molecular weight cut-off 
(Amicon). Buffer was then exchanged for IgG binding buffer (20 mM sodium phosphate pH 
7.0) by further centrifugation using the same column. Concentrated samples were filtered 
though a 0.45 µm syringe filter (Sartorius) and the volume was adjusted to 5 ml.  
10 ml chromatography columns (Bio-Rad) were filled with 1 ml protein G-Sepharose 4 Fast 
Flow and equilibrated with 5×1 ml binding buffer. Concentrated samples were applied to 
the resin and allowed to flow through by gravity. Flow-though was collected for later 
analysis. Columns were washed with 6×1 ml binding buffer and all wash fractions were 
collected. Finally, protein was eluted with 3×1 ml IgG elution buffer and neutralised directly 
by collection in 1.5 ml tubes containing 1 ml IgG neutralising buffer. Collected samples and 
elution fractions were analysed by SDS-PAGE using a 12% gel and subsequently stained with 
Coomassie blue (Section 2.6.4). Protein-containing elution fractions were pooled and 
concentrated using 15 ml filter columns as described above and buffer was exchanged for 
PBS. Final protein concentration was determined by measuring absorbance at 280 nm using 
a NanoDrop ND-1000 spectrophotometer. 
2.6.9 N-glycosylation analysis of Hhat truncates 
2.6.9.1 In vitro transcription and translation (TnT) 
In vitro protein expression of Hhat truncations was performed using the TnT Quick Coupled 
Transcription/Translation System based on rabbit reticulocyte lysate with canine pancreatic 
microsomes. 40 µl TnT master mix, 1 µg plasmid template, 1 µl methionine (1 mM), and 3.6 
µl canine pancreatic microsomes were mixed on ice. Volume was adjusted to 50 µl with 
RNase-free water and reactions were incubated at 30°C for 1.5 h.  
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2.6.9.2 HEK293A transfection for N-glycosylation analysis 
HEK293A cells were transfected with plasmids encoding Hhat truncates using FuGENE HD 
transfection reagent. 8×105 cells were seeded in 4 ml DMEM +10% FCS in 3 cm plates. 24 h 
later, the medium was replaced with fresh medium followed by dropwise addition of the 
transfection mixture. The transfection mixture contained 6 µg DNA and 18 µl FuGENE HD, in 
200 µl Opti-MEM medium and was prepared according to the manufacturer’s instructions. 
Cells were allowed to express protein for 18 h prior to lysis. 
2.6.9.3 Removal of protein N-glycosylation by treatment with PNGase F  
Proteins glycosylated in vitro or in vivo were treated with the endoglycosidase PNGase F to 
remove all N-glycosylation (high mannose, hybrid and complex oligosaccharides). After in 
vitro protein transcription and translation (Section 2.6.9.1), in order to purify microsomal 
membranes, the TnT reaction was diluted to 500 µl in PBS and carefully layered on top of 
100 µl of 5% (w/v) sucrose in 1.5 ml tubes for ultracentrifugation (Beckman). The samples 
were centrifuged at 100,000×g for 45 min at 4°C in an Optima TL ultracentrifuge using a TLA-
25 rotor to pellet the membranes. Supernatant was discarded, membrane pellet was 
resuspended in 10 µl of glycoprotein denaturing buffer supplied with PNGase F and heated 
at 100°C for 10 min. The samples were split in two, PNGase F reactions were prepared 
according to the reaction set-up in Table 2.10 and incubated at 37°C for 1 h (buffer G7 was 
provided with PNGase F). The reactions were stopped by addition of 6.7 µl 4× NuPage LDS 
sample buffer and analysed by Western blotting against the V5 epitope using anti-V5 
antibody (Section 2.6.5). 
Table 2.10 Reaction set-up for removal of N-glycosylation from proteins using PNGase F. 
Component PNGase F treated Mock treated 
10% NP-40 2 µl 2 µl 
Buffer G7 2 µl 2 µl 
Protein sample 5 µl 5 µl 
H2O 10 µl 11 µl 
PNGase F (500 U/µl) 1 µl 0 µl 
Total 20 µl 20 µl 
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Proteins expressed in vivo (Section 2.6.9.2) were lysed in 200 µl PNGase F reaction buffer 
according to Section 2.6.1. 20 µl of cell lysate were treated with 1 µl PNGase F and 
incubated at 37°C for 1 h. Mock-treated lysate was used as a control. The reactions were 
stopped by addition of 6.7 µl 4×SB and analysed by Western blotting against the V5 epitope 
using anti-V5 antibody (Section 2.6.5). 
2.7 Cell culture assays 
2.7.1 Cholesterol content assays 
Cholesterol content was determined using the fluorescence-based Amplex Red cholesterol 
assay kit. 1×Amplex Red reaction buffer and standard curve were prepared according to the 
manufacturer’s instructions. 50 µl of cholesterol containing sample were mixed with 50 µl of 
Amplex Red reaction buffer per well in solid black 96-well plates (Corning) in a total reaction 
of 100 µl. After 30 min of incubation at 37°C, fluorescence was determined by excitation at 
530-560 nm and emission at 585 nm using a SpectraMax M2e microplate reader. 
Measurements were performed in duplicate and samples were normalised to a cholesterol 
standard curve of 0-8 µg/ml cholesterol provided with the kit. Amplex reaction buffer 
without cholesterol served as a negative control.  
2.7.1.1 Determination of cholesterol content in cells 
6×105 HEK293A cells were seeded per 3 cm-plate in 5 ml DMEM +10% FCS. 24 h after 
seeding, medium was exchanged for DMEM supplemented with 1 or 10% FCS and 1, 2.5, 5 
or 5 µM mevastatin or with DMSO only as a vehicle control. 24 and 48 h after mevastatin 
addition, cells were trypsinised and suspended in 2 ml DMEM +1% FCS. Cells were counted 
and 1.8×106 were pelleted by centrifugation (300×g, 5 min) and lysed by addition of 200 µl 
1×Amplex Red reaction buffer. Cells were further sheared by passing 10 times through a 
0.5 mm syringe. Insoluble material was removed by centrifugation at 16,000×g for 10 min at 
4°C. 50 µl of supernatant were used for analysis of cholesterol content as described above.  
2.7.1.2 Determination of cholesterol content in serum 
Cholesterol content in FCS was determined by measuring cholesterol concentration of 
DMEM medium supplemented with 0, 1, 5 or 10 % FCS diluted 10× in 1×Amplex Red 
reaction buffer. 50 µl of diluted sample were used for analysis of cholesterol content as 
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described above. FCS cholesterol content was determined in µg/ml using a cholesterol 
standard curve. 
2.7.2 Cell proliferation 
2.7.2.1 Proliferation assay 
To measure cell proliferation in culture CyQuant Direct cell proliferation assay was used. A 
2× stock solution of the detection reagent was prepared at a concentration of 0.1% (v/v) of 
CyQuant Direct nucleic acid stain and 0.5% (v/v) of CyQuant Direct background suppressor I 
in culture medium without FCS. Cells were grown in clear-bottomed 96-well plates with 
black walls for fluorescent imaging (Corning) in 100 µl of medium. At the day of analysis, 100 
µl of detection reagent were added per culture well and the plate was incubated at 37°C. 
After 1 h of incubation, fluorescence was measured using the Cy2 channel (excitation at 
480/30 nm, emission at 530/40, 0.02 sec exposure) of the Ettan DIGE imager. The 
fluorescence intensity was integrated over each well using Ettan DIGE imager software 
ImageQuant TL. Background from wells containing medium only was subtracted before 
analysis.  
2.7.2.2 Cell growth curve measurements 
Cell growth of cell lines A549, H209 and H82 was measured over 1-6 days using the CyQuant 
direct cell proliferation assay (Section 2.7.2.1). Subconfluent A549 cells were trypsinised and 
resuspended in DMEM +3% FCS. Cells were counted using a haemocytometer and a 10,000 
cells/ml stock suspension in DMEM +3% FCS was prepared. 1000 cells were seeded per well 
by distributing 100 µl of the stock solution per well of a 96-well plate (clear-bottomed with 
black walls for fluorescent imaging). Prior to seeding of H209 and H82 cell lines, growing 
cells were transferred to 15 ml tubes and incubated at 37°C for at least 30 min to gently 
collect them by gravity. The medium was taken off and replaced with RPMI 1640 +3% FCS. 
Cell density was further determined by calibration against a standard curve of 0-46,000 
cells/ml of A549 cells. 16,000 cells of H209 and H82, were seeded per well in 100 µl 
RPMI 1640 +3% FCS by preparing a 160,000 cells/ml stock suspension of cells and 
distributing 100 µl per well of a 96-well plate. Cell content was measured in triplicates each 
day from Day 0 to Day 8 at the longest, or until cells stopped growing exponentially.  
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2.7.2.3 Cell growth measurement after inhibitor treatment 
To measure growth of A549, H209 and H82 cells treated with inhibitors MAb-5E1 and 
cyclopamine, cells were seeded in triplicate as described in Section 2.7.2.2. Just prior to 
seeding, cell stocks were supplemented with inhibitors, MAb-5E1 at concentrations 0, 5, 10 
or 20 µg/ml diluted in D-PBS +0.1% BSA, or cyclopamine at concentrations 0, 1, 2.5, 5 or 10 
µM diluted in DMSO. A549 and H82 cells were assayed after 4 days in culture and H209 cells 
after 5 days (Section 2.7.2.1).  
2.7.2.4 Cell growth measurement after Shh-C24II treatment 
To measure growth of A549 cells treated with recombinant Shh-C24II, cells were seeded as 
described in Section 2.7.2.2. Recombinant Shh-C24II was added to cell stocks just prior to 
seeding at concentrations 0, 0.5, 1 or 2 µg/ml diluted in D-PBS +0.1% BSA. Cells were 
assayed in triplicate after 4 days in culture (Section 2.7.2.1). 
2.7.2.5 Cell growth measurement of cells overexpressing Shh 
In order to test the effect of overexpressed Shh on A549 cell growth, cells were transfected 
with increasing amounts of pcDNA-DEST40-Shh expression vector and used for cell growth 
measurements. 2×105 cells were seeded in 2 ml DMEM +10% FCS in a 6-well plate. 24 h 
later, the medium was replaced with fresh medium followed by addition of the transfection 
mixture prepared according to the manufacturer’s instructions containing 6 µl FuGENE HD 
reagent and 0, 0.5, 1 or 2 µg DNA in 100 µl Opti-MEM medium. After 24 h of expression, 
cells were trypsinised and resuspended in DMEM +3% FCS. Cells were further counted and 
seeded as described in Section 2.7.2.2. Proliferation assay was performed on Day 4 
according to Section 2.7.2.1. 
2.7.3 C3H10T½ cell differentiation 
2.7.3.1 Alkaline phosphatase (ALP) activity measurement 
ALP catalyses hydrolysis of p-nitrophenyl phosphate to p-nitrophenol, a chromogenic 
product which absorbs light at 405 nm. ALP substrate solution was prepared by dissolving a 
tablet of 5 mg p-nitrophenyl phosphate in 5 ml ALP reagent buffer. To measure ALP activity 
in cell lysates, 50 µl of sample prepared in ALP lysis buffer were mixed with 200 µl of ALP 
substrate solution in a 96-well plate and the reaction was incubated at room temperature 
for 1-2 h. The reaction was stopped by addition of 50 µl 3 M NaOH. The absorbance was 
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measured at 405 nm using a Sunrise microplate reader. All samples were normalised to a 
standard curve of shrimp alkaline phosphatase (SAP) diluted in ALP lysis buffer at 
concentrations of 0, 0.5, 1, 2, 4 and 8 mU (U as defined by the supplier).  
2.7.3.2 C3H10T½ cell stimulation using Shh-C24II 
1×105 of C3H10T½ cells were seeded per well in a 6-well plate in DMEM +10% FCS. The 
medium was exchanged the next day for 1.5 ml DMEM +3% FCS supplemented with 0.5, 1 or 
2 µg/ml Shh-C24II. Shh-C24II was prepared by solubilisation from lyophilised sample to a 
stock concentration of 50 µg/ml in D-PBS with 0.1% BSA. Control cells were treated with D-
PBS with 0.1% BSA only. Cells were incubated at 37°C for five days prior to lysis and ALP 
activity measurement (Section 2.7.3.1). 
2.7.3.3 C3H10T½ cell differentiation in co-culture 
To achieve differentiation of C3H10T½ cells in co-culture with other cell types, A549, 
HEK293A or HEK293A-Shh cells were typically mixed at a 1:2 ratio to C3H10T½ and 3,200 
cells were seeded per well in 96-well plates. The cells were allowed to grow for 5 days. On 
Day 5 cells were carefully washed on ice with ice-cold PBS, 50 µl of ALP lysis buffer was 
added per well and the plate was gently shaken on ice for 10 min in order to lyse the cells. 
ALP activity was measured directly in the cell culture plate as described in Section 2.7.3.1. 
For co-culture experiments performed in 6-well plates, 1×105 cells were seeded per well in 
1.5 ml medium (typical ratio 1:2 of cells of interest to C3H10T½) and incubated for 5 days. 
To measure ALP activity on Day 5, cells were lysed in 0.25 ml ice-cold 0.25 ml ALP lysis buffer 
according to the cell lysis protocol in Section 2.6.1. 50 µl of lysate of each sample were 
transferred to a 96-well plate for ALP activity measurements according to Section 2.7.3.1. 
2.7.3.4 Time-line measurement of C3H10T½ cell differentiation in co-culture 
A549 cells were co-cultured with C3H10T½ cells at a 1:1 ratio for 2-6 days. Cells were seeded 
in 96-well plates in DMEM +3% FCS at densities according to Table 2.11 and lysed in ALP 
lysis buffer each day 2-6 days after seeding. ALP activity was normalised to a standard curve 
of SAP (Section 2.7.3.1). 
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Table 2.11 Total cell numbers at seeding for time-line measurements of C3H10T½ cell 
differentiation. 
Days in co-culture Cells per well 
2 14,800 
3 8,700 
4 5,100 
5 3,000 
6 1,760 
 
2.7.3.5 Inhibition of C3H10T½ cell differentiation in co-culture 
To inhibit C3H10T½ differentiation in co-culture using Hh pathway inhibitors, cells were 
seeded at a ratio of 1:2 (cells of interest:C3H10T½) in DMEM +3% FCS. Specific experimental 
conditions are summarised in Table 2.12. Medium was supplemented with 20 µg/ml MAb-
5E1 or 5 µM cyclopamine at seeding. In experiments performed in 6-well plates, both 
inhibitors were newly added on Day 2 and Day 4 without changing the medium. Samples for 
analysis were prepared as described in Section 2.7.3.3 and ALP activity was measured 
according to Section 2.7.3.1. 
Table 2.12 Experimental conditions used for inhibition of C3H10T½ differentiation in co-
culture. 
Experiment Plate format Cells at seeding 
Inhibitor 
supplementation 
Days in co-culture 
1 96-well 3,200 No 5 
2 6-well 100,000 Yes 5 
3 96-well 14,800 No 2 
 
2.7.3.6 Co-culture of cells treated with Hhat siRNA 
After two days of treatment with Hhat or non-targeting siRNA (Section 2.5.12.2), A549 or 
HEK293A-Shh cells were trypsinised and used for co-culture with C3H10T½ cells in DMEM 
+3% FCS. Cells were mixed with C3H10T½ cells at a ratio of 1:2 and 14,800 cells were seeded 
per well in a 96-well plate. After two days of culture, medium was removed and the cells 
were lysed in 50 µl of ice-cold ALP lysis buffer by gentle shaking on a horizontal shaker on 
ice for 10 min. ALP activity was further determined as described in Section 2.7.3.1.  
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2.8 Cell microscopy  
2.8.1 Pre-treatment of coverslips for cell adhesion 
Coverslips (⌀22 mm) used for imaging of adhesive cells were pre-treated with acetone to 
achieve better cell adhesion in culture. Coverslips were gently mixed in acetone for 1 h, then 
washed thoroughly in ethanol to remove all traces of solvent, dried individually on lint-free 
tissue at room temperature and autoclaved in a tightly sealed container prior to use. 
2.8.2 Cell culture for immunostaining 
Pre-treated coverslips were placed at the bottom of empty wells of a 24-well plate. 6×104 
HEK293A cells were seeded per well in 0.5 ml of DMEM +10% FCS. Cells were allowed to 
adhere for 48 h prior to immunostaining.  
2.8.3 Cell transfection for immunostaining 
6×104 HEK293A cells were seeded per well in 24-well plates onto pre-treated coverslips in 
0.5 ml DMEM +10% FCS. 24 h after seeding, medium was exchanged for 0.5 ml of fresh 
DMEM +10% FCS. 0.8 µg DNA and 2.4 µl FuGENE HD transfection reagent were premixed in 
40 µl Opti-MEM per reaction and incubated for 15 minutes at room temperature. The mix 
was added to the cells in a dropwise fashion. Cells were allowed to express protein for 24 h 
prior to immunostaining (Section 2.8.5). 
2.8.4  Preparation of fixative solution  
4% paraformaldehyde (PFA) used to fix cells for imaging was prepared by dissolving 1 g of 
PFA in 25 ml of PBS. First, the mixture was heated at 65°C for 5 minutes. After cooling down, 
400 µl of 1 M NaOH were added and the mixture was heated again at 65°C for 10 minutes 
until the PFA had completely dissolved. Finally, approximately 250 µl of 1 M HCl were added 
to adjust the pH to 7.2. pH was determined using pH test strips (pH 6.0-7.7). 
2.8.5 Fluorescence immunostaining 
Cells grown on coverslips were washed once with 1 ml PBS and fixed by addition of 0.5 ml 
fixative solution for 10 min. Fixative solution was removed by washing 3× with 1 ml PBS. For 
full permeabilisation, cells were treated with 0.5 ml of 0.2% (v/v) Triton X-100 in PBS for 5 
minutes at room temperature. For semi-permeabilisation (permeabilisation of plasma 
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membrane only), cells were treated with 0.5 ml of 0.00005, 0.0001, 0.0002, 0.0004 or 
0.0008% (w/v) digitonin in PBS for 10 minutes on ice. Permeabilising detergent was 
removed by rinsing once and incubating 2×5 minutes in PBS. Next, 0.5 ml 5% (w/v) BSA in 
PBS was added for 30 minutes at room temperature to block cells for immunostaining. The 
blocking solution was replaced with primary antibodies diluted in 5% BSA in PBS (Table 2.13) 
and cells were incubated for 1 hour at room temperature. The primary antibody was 
washed off by carefully dipping coverslips 10× in PBS and incubation on a 100 µl drop of PBS 
for 5 minutes. Next, the cells were incubated with secondary antibodies and/or 
fluorescently-conjugated phalloidin in 5% (w/v) BSA in PBS for 30 minutes (Table 2.13). Cells 
were again washed as previously described but with an additional incubation on a drop of 
PBS for 5 minutes. Lastly, the cells were desalted by dipping 10× into water and air-drying 
for 5 to 10 minutes. Coverslips were mounted onto glass slides using 10 µl Prolong Gold 
Antifade reagent. 
Table 2.13 Antibody and fluorescent conjugates used in immunostaining of fixed cells. 
 
2.8.6 Fluorescence imaging  
Fluorescently stained fixed cells were imaged using a Zeiss Axiovert 200 inverted microscope 
with a 10× objective (EC Plan-Neofluar 10x 0.30 M27), or a 63× oil-immersion objective 
(Plan-Apochromat 63x 1.40 Oil Ph3 M27). For detection of Alexa Fluor 488, filter GFP-3035B 
Name Antigen Type Dilution Supplier 
Primary antibodies 
Anti-V5 Antibody V5 epitope MAb, mouse IgG2a 1:200 Invitrogen 
Calnexin pAb Calnexin-C pAb, rabbit 1:100 
Enzo Life 
Sciences 
Calnexin (AF18) Antibody Calnexin-N MAb, mouse IgG1 1:50 Santa Cruz 
Secondary antibodies 
Alexa Fluor® 488 Rabbit IgG (H+L) Goat 1:200 Invitrogen 
Alexa Fluor® 555 Mouse IgG2a Goat 1:200 Invitrogen 
Alexa Fluor® 638 Mouse IgG1 Goat 1:200 Invitrogen 
Fluorescent conjugates 
Alexa Fluor® 488 phalloidin F-actin  1:40 Invitrogen 
Alexa Fluor® 568 phalloidin F-actin  1:40 Invitrogen 
2 Materials and methods 
95 
was used (Semrock; excitation 472/30 nm, emission 520/35 nm), for Alexa Fluor 555 and 
568, filter CY3-4040B (Semrock; excitation 531/40 nm, emission 593/40 nm), and for Alexa 
Fluor 638, filter cube 41008 Cy5 (Chroma; excitation 640/20 nm, emission 680/30 nm). A 
xenon arc lamp was used as a light source and images were collected using a 1 mega pixel 
resolution ImagEM EM-CCD camera (Hamamatsu). The microscope was operated using 
Simple-PCI acquisition software (C-Imaging) and images were post-processed and analysed 
using ImageJ image analysis software. 
2.9 Statistical analysis 
Statistical analysis was performed using Graphpad Prism software. Statistical significance in 
figures is stated as asterisks representing P values where * is P<0.05, ** P<0.01, and *** 
P<0.001. P>0.05 is not considered significant. Only significant differences are stated in the 
figures. 
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3 Click chemistry for detection of lipid modifications 
of Shh 
3.1 Introduction 
Hh proteins go through extensive post-translational processing during intracellular transport 
for secretion. The mature protein consists of the N-terminal domain Shh-N with a palmitoyl 
attached to an N-terminal Cys residue and a cholesterol at its C-terminus. Traditionally, 
acylation of proteins has been detected by metabolic labelling of living cells with a 
radiolabelled fatty acid (typically 3H or 14C), which are analysed by SDS-PAGE followed by 
autoradiography (Resh, 2006). Apart from involving handling of radioactive substances, this 
process is typically time consuming and may take a few days up to several weeks. In the past 
few years, a new method for studying post-translational modifications of proteins based on 
metabolic cell labelling with alkynyl or azido tags, known as bioorthogonal ligation or “click 
chemistry”, has emerged. The method evades the use of radioactive reagents and is 
considerably faster, reducing the time of analysis to one or two days.  
Click chemistry is a method based on protein tagging with bioorthogonal tags in vivo to 
detect post-translational modifications of proteins. Bioorthogonal tags are post-translational 
modification analogues with azido or alkynyl functional groups, which are not found 
naturally in living cells. After metabolic incorporation cells are lysed for analysis and 
analogues are ligated to a secondary reporter tag using Cu(I)-catalysed Huisgen 
cycloaddition (Figure 3.1 A).  
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Figure 3.1 The click reaction for studies of Shh lipidations and its components. 
(A) Shh metabolically labelled with a palmitate analogue is ligated to a reporter tag using an 
azide-alkyne cycloaddition reaction catalysed by Cu(I) – “click chemistry”. Cu(I) is obtained by 
reduction of Cu2+ by the reducing agent TCEP. TBTA chelates Cu(I) into its catalytic form. 
(B) Structures of palmitate and cholesterol analogues used for labelling of Shh. (C) Structures 
of the alkyne and azido detection tags. Fluorescent TAMRA is indicated in red, biotin in blue, 
alkynyl and azido groups in green. All click chemistry reagents were provided by Ed Tate, 
Imperial College London. 
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Synthesis of acyl analogues for palmitoylation and myristoylation of proteins as well as 
working click chemistry protocols have been reported in the past (Charron et al., 2009, Heal 
et al., 2008). In collaboration with Ed Tate at the Department of Chemistry at Imperial 
College London, we have reported a novel azido-cholesterol analogue for labelling proteins 
(Heal et al., 2011), see structures in Figure 3.1 B. The reporter tag can be designed in a 
variety of ways depending on the choice of detection. We have made use of trifunctional 
reporter tags illustrated in Figure 3.1 C containing an alkynyl or a azido group for click 
chemistry, a TAMRA fluorescent moiety for detection of in-gel fluorescence, and biotin for 
affinity pull-down using streptavidin beads (Heal et al., 2011).  
In this chapter, I present the implementation of click chemistry based on fluorescence 
imaging of SDS-PAGE gels and Western blotting as a tool to study post-translational 
modifications of Shh in cell culture. Also, the evaluation of the first bioorthogonal tag for 
cholesteroylation of proteins using Shh as model is shown. 
3.2 Results 
3.2.1 Shh expression vector cloning 
In order to obtain a mammalian expression vector of human Shh, the Shh cDNA was cloned 
into the pcDNA-DEST40 destination vector by Gateway recombination based cloning. 
Gateway recombination requires an entry vector carrying the gene of interest (GOI) flanked 
by directional recombination sites, attL1 and attL2. These sites are designed to recombine 
with attR1 and attR2 sites in the destination vector pcDNA-DEST40, respectively, to create 
attB1 and attB2 sites producing a directional expression clone of Shh – pcDNA-DEST40-Shh – 
as confirmed by sequencing. The commercially available entry vector pENTR223.1-Shh was 
used to clone Shh. The expression cassette of pcDNA-DEST40-Shh provides a C-terminal tag 
consisting of a V5 epitope and a His6 tag which may be used for detection of the 
autocatalytic Shh-C domain by immunoblotting using anti-V5 or anti-His6 antibodies. Also, a 
neomycin resistance gene allows for selection of stable cell lines (see plasmid map in Figure 
3.2 A). Cell lysates of HEK293A cells transiently transfected with pcDNA-DEST40-Shh vector 
analysed by Western blotting against Shh and the V5 epitope 24 h after transfection, show 
that full-length Shh (Shh-FL) is detected at about 45 kDa, Shh-C at about 30 kDa and Shh-N  
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Figure 3.2 Plasmid map and expression profile of the mammalian vector pcDNA-DEST40-Shh. 
(A) Plasmid components of pcDNA-DEST-Shh. (B) Transient expression profile in HEK293A cells 
shows that Shh is largely autoprocessed into Shh-N as detected by anti-Shh antibody H-160. 
Shh-C domain is detected using the anti-V5 antibody. Shh-FL is detectable both by H-160 and 
anti-V5 antibody. 
between 20 and 25 kDa (Figure 3.2). Shh is predominantly autocleaved into Shh-N and Shh-
C and the relative abundance of the processed forms of Shh shows that Shh-N is more 
abundant in the cells than Shh-C indicating degradation or loss of Shh-C by secretion. 
3.2.2 Detection of Shh palmitoylation using click chemistry 
Bioorthogonal labelling of cells with alkynyl palmitate, YnC15, was tested on HEK293A cells 
transiently transfected with pcDNA-DEST40-Shh. Prior to labelling, cells were treated with 
1 mM pyruvate in DMEM medium containing 5% (v/v) FCS to inhibit β-oxidation and to 
decrease levels of fatty acids from the serum. No cytotoxic effects on the cell morphology 
were observed up to the highest tested concentration of 100 µM of YnC15.  
After click reaction, palmitoylation of Shh was detected both by in gel-fluorescence scanning 
of TAMRA and Western blotting against Shh. Due to high palmitoylation background, tagged 
Shh-N was only weakly visible in the fluorescence scan over the background (Figure 3.3, left 
panel). On the other hand, Western blotting revealed that tagged Shh-N (Shh-N-YnC15) 
migrated slower than untagged Shh-N which resulted in their separation in 15% gels (Figure 
3.3, right panel) allowing labelling efficiency to be quantified by densitometry 
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measurements of Shh-N and Shh-N-YnC15 bands. In initial experiments, cells were 
transfected and allowed to express Shh for 24 h prior to changing medium to labelling 
medium. Cells were then incubated for additional 16 hours before lysis. This approach 
resulted in a maximum Shh-N labelling efficiency of 28% at 100 µM (Figure 3.3 A, right 
panel). When labelling medium was added at the start of the transfection and cells were 
harvested after 24 h of Shh expression, the labelling efficiency improved to ~50% or more 
without any added cytotoxic effects (Figure 3.3 B, right panel). Therefore, the latter labelling 
protocol was used in further YnC15-labelling experiments. 
For Shh-FL, palmitoylation could be seen neither by in-gel fluorescence nor by shift in gel 
migration. As the precursor is expected to be palmitoylated (Abe et al., 2008), the difficulty 
in identifying palmitoylated Shh-FL is likely to be due to high palmitoylation background in 
the total cell lysate in the TAMRA scan and to poor band resolution at the molecular size of 
unprocessed Shh using Western blotting. Immunoprecipitation of Shh prior to click reaction, 
or alternatively, pull-down of YnC15-modified proteins on streptavidin beads after click 
reaction and Western blotting against Shh should allow us to see if Shh-FL is palmitoylated. 
 
Figure 3.3 In vivo labelling of Shh with the click chemistry palmitate analogue YnC15. 
(A) Click reaction performed on cell lysates labelled with YnC15 for 16 h, 24 h post 
transfection. The left panel shows fluorescence of all proteins in whole cell lysate modified by 
YnC15. Right panel shows an anti-Shh Western blot using anti-Shh antibody H-160 
demonstrating the band shift of Shh-N induced by the fluorescent detection tag (Shh-N*). (B) 
Click reaction performed on cell lysates co-transfectionally labelled with YnC15 for 24 h results 
in label incorporation in about 50% of Shh-N. 
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3.2.3 Detection of Shh cholesteroylation by click chemistry 
To detect cholesteroylated Shh-N, HEK293A cells transiently transfected to express Shh 
were fed with 0, 40 or 100 mM azido-cholesterol in medium containing 1% FCS and 10 µM 
mevastatin. Mevastatin is a drug used to inhibit de novo synthesis of cholesterol precursors 
(Endo, 1992). It acts by inhibiting 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) 
reductase in the mevalonate pathway, the rate-limiting enzyme in cholesterol biosynthesis 
which converts HMG-CoA to mevalonate. Mevastatin treatment was therefore included in 
the protocol to reduce endogenous cholesterol levels in the cells and thus help increase 
azido-cholesterol labelling of Shh. The cells were incubated in labelling medium for 16 h 
prior to lysis. Considerable cytotoxicity was observed resulting in cell rounding, detaching 
from the dish and sometimes cell death.  
To identify the cause of the cytotoxic effect, cells were treated separately with mevastatin 
and azido-cholesterol. Serum starved cells grown at 1% FCS for 24 h were treated with 0, 5, 
10 or 20 µM mevastatin for additional 24 h. While DMSO treatment had no obvious effect 
on cell morphology and adhesion after 24 h of treatment, mevastatin-treated cells were 
loosely attached already after 4 h at 20 µM. At 5 µM, cells were indistinguishable from the 
vehicle control during the first 6 h of observation. However, all tested concentrations 
resulted in cell rounding, detachment and partial cell death after 24 h of treatment.  
The cytotoxic effect of azido-cholesterol was evident even at low analogue concentrations 
and was further enhanced when cells were simultaneously transfected. Nevertheless, to 
analyse azido-cholesterol incorporation into Shh, cells were treated both with the analogue 
and 10 µM mevastatin at 1% FCS and were collected by mild centrifugation prior to lysis.  
A gel fluorescence scan of azido-cholesterol treated cells after click chemistry showed 
multiple protein bands being labelled above background, where two were highly 
predominant (Figure 3.4, left panel). One of these is tagged Shh-N (Shh-N*) at ~22 kDa. 
Although the fluorescence signal of cholesteroylated Shh-N was much more prominent than 
with alkynyl palmitate labelling, only about 15% of Shh-N was labelled with the analogue as 
detected by band mobility shift in an anti-Shh Western blot (Figure 3.4, right panel). The 
shifted bands corresponded well in size to the fluorescent bands at ~23 kDa confirming that 
they represent analogue-tagged clicked Shh and that despite the toxic effects of the azido-
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cholesterol, the label was capable of entering the cell and acting as an autoprocessing 
substrate of Shh.  
In addition, the fluorescence scan revealed several other protein bands labelled with azido-
cholesterol above background (marked with red arrows in Figure 3.4). The most prominent 
of these is a band at ~35 kDa. The possible presence of proteins other than Hh proteins 
covalently modified by cholesterol has been suggested in the past (Porter et al., 1996), 
however, the development of a click chemistry cholesterol analogue is the first step towards 
identifying these proteins. 
 
Figure 3.4 HEK293A cells transiently expressing Shh labelled in vivo with azido-cholesterol. 
Cell lysates were used in a click reaction to attach a fluorescent detection tag (TAMRA) onto 
azido-cholesterol. The left panel shows whole lysate fluorescence where tagged Shh-N (Shh-
N*) is highly visible at ~22 kDa. Red arrows indicate protein bands other than Shh-N labelled 
with azido-cholesterol over background. The right panel shows a Western blot against Shh 
using antibody H-160 showing the labelling efficiency demonstrated by the band shift induced 
by the fluorescent reporter tag.  
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3.2.4 Inhibition of de novo cholesterol synthesis by mevastatin has no 
influence on Shh processing 
Mevastatin partially contributed to cell toxicity at low FCS levels in azido-cholesterol 
labelling experiments. To determine if mevastatin could be excluded from the labelling 
protocol, its effect on cell cholesterol content of cells treated with mevastatin was 
determined using the Amplex Red cholesterol assay. After 24 h of treatment with 0, 1, 2.5 or 
5 µM mevastatin in 10% FCS, cells were lysed and cholesterol content was measured. No 
difference in whole cell cholesterol content compared to the control was observed (Figure 
3.5 A). Further, extending the treatment to 48 h at 1% FCS did not have any significant effect 
(Figure 3.5 A), suggesting either that FCS contains enough cholesterol to compensate for the 
inhibition of the mevalonate pathway or that the turnover of cholesterol in cells is too slow 
to have an effect on the pools of cholesterol present in the cell membranes. The cholesterol 
content of the FCS batch used in the lab was determined using the Amplex Red cholesterol 
assay to be 250 µM, resulting in a cholesterol concentration of 2.5 µM in medium 
supplemented with 1% FCS. As this was tens of times lower than the concentration of the 
added analogue, it suggests that the poor labelling efficiency using azido-cholesterol was 
likely to be due to poor substrate recognition by the autoprocessing domain of Shh rather 
than to substrate competition. 
Finally, to ascertain the effect of mevastatin directly on the processing of Shh, HEK293A cells 
transiently transfected with Shh were treated with mevastatin and the ratio of processed to 
unprocessed Shh was compared. Treatment resulted in no significant change of the Shh-FL 
to Shh-N ratio under tested conditions (Figure 3.5 B). These experiments suggested that 
mevastatin would not have any significant effect on azido-cholesterol labelling of Shh or any 
other protein and was therefore excluded from future labelling protocols. 
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Figure 3.5 The effect of mevastatin on cellular cholesterol content and Shh processing. 
(A) Cholesterol content in HEK293A cells treated with mevastatin determined using the 
Amplex Red cholesterol assay (N=1 in duplicate, mean±SD). (B) Western blot of Shh processing 
in HEK293A cells after mevastatin treatment. The percentage of Shh-N out of total Shh is 
shown below. There are no pronounced differences in Shh processing at different mevastatin 
concentrations compared to the control. 
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3.2.5 Dual labelling of Shh 
To test if it is possible to dually label Shh both with alkynyl-palmitate and azido-cholesterol 
in order to detect both modifications simultaneously, HEK293A cells transiently transfected 
to express Shh were simultaneously fed with alkynyl-palmitate and azido-cholesterol (Heal 
et al., 2011). Cell lysates were allowed to in turn react with an azido-TAMRA reporter tag to 
label alkynyl-palmitoyl, and an alkynyl-fluorescein reporter to label azido-cholesterol (click 
reactions and imaging were performed by Dr. William Heal). Protein was precipitated and 
washed in methanol between reactions to remove excess reporter tags. Dual labelling was 
achieved without any cross reactivity of reporter tags as demonstrated by singly labelled 
samples (Figure 3.6). 
While alkynyl-palmitate labelling was consistent, there were difficulties in obtaining 
reproducible azido-cholesterol labelling, partially due to poorer Shh incorporation of azido-
cholesterol and partially due to the lower fluorescent signal of the fluorescein label 
compared to TAMRA. 
 
Figure 3.6 In-gel fluorescence of Shh dually labelled with YnC15 and azido-cholesterol using 
click chemistry. 
The YnC15 modification is captured using the azido-biotin-TAMRA reporter tag. The azido-
cholesteroyl is captured sequentially using the alkynyl-fluorescein reporter tag. Click chemistry 
and imaging were performed by Dr. William Heal. 
YnC15 (100 µM) − − + +
Azido-cholesterol (50 µM) − + − +
TAMRA channel
Fluorescein channel
Overlay
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3.3 Discussion and future work 
Detection of palmitoylated Shh from lysates of cells fed with alkynyl-palmitate using click 
chemistry was achieved without difficulty. Consequently, this means that the alkynyl-
palmitate was readily taken up by cells and converted to alkynyl-palmitoyl-CoA used by Hhat 
to acylate Hh proteins. Detection of palmitoylated Shh by in-gel fluorescence was hampered 
by high fluorescence background from other palmitoylated proteins present in whole cell 
lysate. However, due to the relatively small size of Shh-N, it was possible to detect 
palmitoylated Shh-N by a migration shift in 15% SDS-PAGE gels. The shift also allowed direct 
quantification of the label incorporation efficiency. Addition of the YnC15 analogue to cells 
in culture did not cause any cytotoxicity at tested concentrations and resulted in a highly 
reproducible incorporation where about 50% of Shh-N was labelled when the analogue was 
added co-transfectionally. Although labelling efficiency was satisfactory for studying 
overexpressed Shh, further optimisation of experimental conditions (concentrations of FCS 
and pyruvate and time of label addition) may result in even better labelling efficiency. 
Cell labelling with azido-cholesterol caused considerable cytotoxicity in the form of cell 
rounding, detachment and in some cases cell death, ultimately resulting in poor labelling 
reproducibility. As cellular cholesterol resides in and is a key component of cell membranes 
(especially the plasma membrane), azido-cholesterol is likely to do the same. However, the 
differences in the hydrophobic tail between cholesterol and the highly polar analogue may 
be the cause for the poor ability of analogue-treated cells to attach to the culture dish. 
Another cause for cytotoxicity may be dissociation of the azido group from the analogue 
causing cell toxicity. However, this is unlikely as no degradation of the compound was 
observed by HPLC analysis after months of storage at -20°C (analysis performed by Dr. 
William Heal). 
Cholesterol is an abundant constituent of cell membranes and is able to freely diffuse and 
move across lipid bilayers (van Meer and de Kroon, 2011). Mevastatin treatment was shown 
not to affect whole cell cholesterol content or Shh autoprocessing. As mevastatin only 
reduces de novo production of cholesterol, it may be possible that the turnover of 
membranous cholesterol in cells is too slow to be altered by mevastatin during 48 h of 
treatment. This is consistent with reports where only acute cholesterol deprivation using a 
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combination of a cholesterol synthesis pathway inhibitor and cyclodextrin – which extracts 
cholesterol from the cell membrane – was able to reduce Shh processing, but not 
cholesterol synthesis pathway inhibition on its own (Cooper et al., 1998, Guy, 2000). It is 
also unlikely that sterol-depleted medium will have an impact on cholesterol labelling as the 
concentrations of the cholesterol analogue are in large excess to the cholesterol levels of 
medium supplemented with 1% FCS. The poor labelling effect of azido-cholesterol appears 
rather to be a combined effect of its toxicity and poor substrate binding by the 
autoprocessing domain of Shh. The latter is supported by the recent development of an 
alkynyl-cholesterol analogue by Paulina Ciepla in the Magee/Tate laboratories which does 
not exhibit any cytotoxicity and is incorporated at near 100% in Shh-N in HEK293A cells 
stably transfected with Shh (unpublished data).  
A number of protein bands were tagged by azido-cholesterol in addition to Shh, suggesting 
that proteins other than Hh may be modified by cholesterol. These results have prompted 
the development of the above mentioned alkynyl-cholesterol analogue which is currently 
being employed in identification of novel cholesteroylated proteins in cells in the 
Magee/Tate laboratories. Apart from discovering other cholesteroylated proteins, 
development of this tag will enable biochemical studies of the Shh autoprocessing with the 
aim to block Hh processing for therapeutic use in cancer. 
Dual labelling of Shh was used to demonstrate that proteins tagged simultaneously with an 
alkynyl and an azido tag can be detected in the same sample by use of sequential click 
chemistry. Applied click reaction conditions successfully avoided the possibility of an 
intermolecular click reaction resulting in the two protein modifications reacting with one 
another through an intramolecular reaction. Further, due to the high concentrations of 
capturing reagents used in the click reaction, proteins did not appear to multimerise by 
linking click reactions. Although the azido-cholesterol tag is not ideal for use in living cells, 
this work represents one of the first examples of dual labelling of proteins with an azido and 
an alkynyl tag (Heal et al., 2011). 
Early on, it was observed that Shh-N consistently appeared on Western blots as two distinct 
bands when run on high density gels. While the percentage of processed Shh was about 60% 
both after 24 h and 48 h of expression, the lower band of Shh-N was initially predominant 
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after 24 h, while after 48 h both bands were equally strong (demonstrated in Figure 3.5 B). 
As hydrophobic moieties bind SDS better than hydrophilic and thereby may cause proteins 
to migrate faster on SDS-PAGE gels, the two Shh-N bands may reflect the pools of 
palmitoylated Shh-N (pShhN) and unpalmitoylated Shh-N. This idea is supported by the 
observation that YnC15-labelled Shh-N was represented only by one band on the gel. The 
release of multimeric Shh from the cell surface has been associated with metalloprotease 
cleavage of the palmitoylated N-terminus and the cholesteroylated C-terminus 
demonstrated by the presence of a medium derived Shh migrating faster that any cell 
associated Shh (Dierker et al., 2009, Ohlig et al., 2011). In the light of this, the increase of 
the upper band in Shh blots over time may reflect accumulation of palmitoylated Shh-N in 
the signal-producing cell due to saturation of the metalloprotease cleavage and the signal 
packaging machinery during Shh overexpression.  
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4 The role of Hhat in Shh signalling in lung 
cancer cell lines 
4.1 Introduction 
Studies of the Hh signalling pathway in lung cancer have shown that Shh is overexpressed in 
a subset of both SCLC and NSCLC cell lines and primary tumours (Watkins et al., 2003, Yuan 
et al., 2007, Yauch et al., 2008, Chi et al., 2006). Studies using cancer cell lines have typically 
been performed by Shh pathway inhibition in isolated cell lines in vitro, in cancer cell lines 
co-cultured with Shh-responsive cells or in xenograft transplants of cancer cell lines into 
nude mice (Watkins et al., 2003, Yuan et al., 2007, Yauch et al., 2008). While the former 
represents an experimental model for autocrine Hh dependence of cancer cells, the latter 
two represent juxtacrine/paracrine signalling models. The aim of this chapter is to provide 
proof-of-principle that Hhat is a viable pharmaceutical target in cancer by performing RNAi 
KD of Hhat in lung cancer cell lines and studying the effect of Hhat depletion on cell growth 
and cell signalling in: 1. an autocrine signalling cell culture system consisting of isolated lung 
cancer cell lines and 2. a juxtacrine/paracrine signalling cell culture system where lung 
cancer cell lines are co-cultured with Shh-responsive cells. Here, a small panel of lung cancer 
cell lines including NSCLC cell line A549 and SCLC cell lines H146, H1618, H209 and H82 
reported in the studies above to over-express Hh pathway components were assessed for 
their dependence on Hh signalling for growth and signal transduction and hence their 
suitability for studying the effect of Hhat KD. Growth of H146 and H1618 was previously 
shown to be inhibited by cyclopamine treatment both in vitro and in xenografts in nude 
mice, while H82 could be inhibited in vitro (Watkins et al., 2003). H209 has been reported to 
lack SuFu and to respond to SuFu overexpression by reducing its growth (Chi et al., 2006). 
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A549 has been reported not to be dependent on Shh for growth (Watkins et al., 2003, Yuan 
et al., 2007, Chi et al., 2006) and would thus serve as a control for off-target effects. 
4.2 Results 
4.2.1 Growth rates of lung cancer cell lines in serum-depleted media 
While A549 is an adherent cell line which grows in monolayers, H146, H1618, H208 and H82 
cells grow as suspended cell aggregates and are highly dependent on cell-cell contacts for 
survival (Figure 4.1). All cell lines were successfully initiated and expanded. However, cell 
line H1618, which grows in cyst-like structures reminiscent of lung alveoli (not shown), was 
difficult to maintain at a constant growth rate. Similarly, H146 which grows in aggregates 
had a doubling time exceeding one week which was highly impractical for growth rate 
measurements. Both these cell lines were therefore excluded from the study. A549, H209 
and H82, on the other hand, grew well. 
To reduce the impact of growth factors from the serum on inhibition studies using Hh 
pathway inhibitors and during Hhat KD, the growth rates of the studied cell lines at 
decreasing FCS concentrations were determined (Figure 4.2 A). Growth was measured each 
day up to 8 days by cell quantification using the CyQuant proliferation assay based on 
fluorescent labelling of DNA. A549 cells were seeded at a density of 1000 cells/well in a 96-
well plate and growth measurements were performed each day up to 7 days. The cells  
 
Figure 4.1 Cell morphologies of lung cancer cell lines A549 (NSCLC) and H209 (SCLC). 
A549 cells are adherent, while H209 cells grow in cell aggregates. H82 is similar in morphology 
to H209 (not shown). Both H209 and H82 are dependent on cell-cell contacts. 
A549 H209
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Figure 4.2 Growth measurements of lung cancer cell lines in serum-depleted media. 
(A) Growth curves of A549, H209 and H82. Samples were normalised to measurements on Day 
0 to account for differences in cell seeding between experiments (N=3 in triplicate, 
mean±SEM). (B) Doubling times in days calculated by fitting exponential growth curves to data 
obtained in A. (C) Cell doubling times normalised to growth at 8% FCS shows that all three cells 
lines appear to become drastically inhibited in growth at serum concentrations below 3% FCS. 
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grew exponentially up to 5 days in culture when they reached confluency resulting in a 
decreased growth rate. As H209 and H82 cells grow in aggregates, the cell density at 
seeding could not be determined by haemocytometer counting. Instead, prior to each 
experiment, cell densities of aggregate cell suspensions were determined using the CyQuant 
proliferation assay and comparing the signal to a standard curve of a known density of 
serially diluted A549 cells. 16,000 cells of H209 and H82 each were seeded per well in a 96-
well plate to achieve a consistent cell number for seeding between experiments.  
The growth rate of A549 was most sensitive to variations in FCS concentration, although no 
evident cell death was observed even at 1% FCS after 5 days in culture. H209 and H82 
appeared less sensitive to variations in FCS; however, H82 showed exponential growth only 
for 4 days, cells thereafter started to die, probably due to nutrient depletion. H209 had the 
lowest growth rate growing exponentially for 6 days and then starting to decline. Doubling 
times were determined by fitting an exponential growth curve to obtained growth data 
which showed that all three cell lines were only mildly affected by a decrease in serum 
concentration down to 3% FCS. Below 3% FCS, A549 and H82 responded by dramatically 
increasing their doubling time (Figure 4.2 B). H209 showed least sensitivity to FCS depletion, 
but had a severe increase in doubling time at 1% FCS. As a result, 3% FCS was used in all 
following experiments to provide the cells with the minimum amount of growth factors 
necessary for healthy growth, but at the same time allowing growth rate dynamics in both 
directions.  
4.2.2 Expression of Hh pathway components in lung cancer cell lines 
Prior to performing Shh pathway inhibition studies, it was important to confirm that A549, 
H209 and H82 cells express Shh pathway components. To do this, RT-PCR amplification of 
Hhat, Shh, Ptch1, Smo and Gli1 mRNA was performed. Figure 4.3 demonstrates a typical 
result obtained after Taq polymerase PCR amplification of cDNA produced with (RT+) or 
without (RT-) reverse transcriptase treatment of 0.5 µg of extracted RNA. Experiments were 
repeated at least three times. All RT- samples were consistently negative, while RT+ samples 
were all positive apart from one case of Gli1 which appeared negative for H209. 
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Figure 4.3 RT-PCR of Shh pathway components in selected lung cancer cell lines. 
0.5 µg of RNA extracted from cell lines A549, H209 and H82 was reverse transcribed and cDNA 
was amplified using Taq polymerase PCR amplification to determine the presence of Hhat, Shh, 
Ptch1, Smo and Gli1 transcripts. RT reactions were performed with (RT+) or without (RT-) 
reverse transcriptase. Experiments were repeated at least three times. 
4.2.3 Purification of the Shh blocking antibody MAb-5E1 
The Shh binding monoclonal antibody MAb-5E1 raised against the N-terminus of rat Shh 
(Ericson et al., 1996) has been reported to bind all three Hh ligands, Shh, Ihh and Dhh 
(Bosanac et al., 2009) and its activity has been reported using the rat, chick, mouse and 
human Shh. It binds Shh at its zinc-containing pseudo-active site which prevents it from 
binding its receptor Ptch (Maun et al., 2010). In order to use it as a Shh inhibitor in cell 
culture, I purified it from hybridoma cell culture supernatant and tested its activity by use in 
immunoprecipitation of recombinant Shh (Shh-C24II) from lysis buffer. As 5E1 hybridoma 
cells are only able to grow in serum-rich medium (IMDM +20% FCS), to assess the effect of 
IgG present in FCS, control IgG from fresh growth medium was purified in parallel to MAb-
5E1. Purification results show that about 40% of total heavy chain (HC) IgG in a MAb-5E1 
preparation (quantified by band intensity measurement in a Coomassie stained gel) is  
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Figure 4.4 Purification and activity validation of MAb-5E1. 
(A) Coomassie-stained SDS-PAGE gel showing IgG purified from fresh medium (left lane) and 
5E1 hybridoma culture medium (right lane) after 4 days of culturing. Samples were reduced by 
addition of DTT to the protein sample buffer. HC represents the IgG heavy chains and LC 
represents the IgG light chains. 4 µg of purified IgG were loaded per lane. (B) Western blotting 
of Shh-C24II immunoprecipitated with FCS-IgG or MAb-5E1 using anti-Shh antibody H-160 
shows that MAb-5E1 but not FCS-Ig is able to immunoprecipitate Shh-C24II, confirming that 
the produced MAb-5E1 actively binds Shh. 
unspecific FCS-IgG HC (Figure 4.4 A, right lane). However, while MAb-5E1 is able to bind 
Shh-C24II during immunoprecipitation from lysis buffer, FCS-IgG is not (Figure 4.4 B). 
4.2.4 The effect of Shh pathway inhibition on growth of lung cancer 
cell lines 
MAb-5E1 and the Smo antagonist cyclopamine, were used to assess the effect of the Shh 
pathway on cell growth of cell lines A549, H209 and H82 in a dose-dependent manner. 
Tomatidine, an inactive structural analogue of cyclopamine (Cooper et al., 1998), was used 
as an off-target control for cyclopamine. Structures of both compounds are shown in Figure 
4.5. Growth of A549 and H82 cells was measured using the CyQuant proliferation assay after 
4 days in culture, growth of H209 was measured after 5 days.  
Treatment with MAb-5E1 resulted in no change of growth of H209 and H82. Unexpectedly, 
A549 showed an apparent, yet not significant, dose-dependent increase in growth (upper 
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left panel in Figure 4.6 A). To test if the way MAb-5E1 was prepared was responsible for this 
trend, A549 cells were treated with FCS-IgG only and compared to MAb-5E1-treated cells. 
The results showed an increase in growth comparable to MAb-5E1 treatment (Figure 4.6 A, 
lower left panel) suggesting that the effect is caused by growth factors co-purified with 
MAb-5E1 from the FCS-rich hybridoma culture medium. When this positive off-target effect 
is normalised and subtracted from the growth rate of A549, the slight dose-dependent 
increase in growth is lost and no effect compared to the vehicle control is observed (Figure 
4.6 A, lower right panel). 
Treatment with cyclopamine, on the other hand, resulted in a significant decrease in the 
growth of A549 and H82, while growth of H209 did not change significantly (Figure 4.6 B, 
right panel). This puzzling result was not in agreement with the results obtained after A549 
and H82 treatment with MAb-5E1. While the results of the MAb-5E1 treatment suggest that 
none of the cell lines are dependent on Shh for their growth, cyclopamine treatment, on the 
other hand, suggests that growth of A549 and H82, but not H209 is Shh-dependent.  
Meanwhile, cell treatment with tomatidine had a large negative effect on the viability of all 
three cell lines resulting in a significant dose-dependent reduction in growth when 
concentrations up to 2 µM were used (Figure 4.6 B, right panel). All cell lines have shown 
marked sensitivity to tomatidine treatment which indicates that under conditions used in 
these experiments, these cell lines may be sensitive to cyclopamine through an off-target 
effect, presumably similar to the effect of tomatidine itself, and not through direct blockade 
of the Shh pathway. Tomatidine concentrations higher than 2 µM were not tested. 
 
 
Figure 4.5 Structures of the Smo antagonist cyclopamine and its inactive analogue tomatidine. 
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Figure 4.6 Growth dose-response curves of lung cancer cell lines treated with Hh pathway 
inhibitors normalised to vehicle controls. 
(A) A549, H209 and H82 cells treated with MAb-5E1 did not show any reduction in growth. 
MAb-5E1 gave rise to an apparent increase in growth of A549, which was also caused by 
unspecific FCS-IgG (lower left panel) and is likely to be caused by growth factors co-purified 
with MAb-5E1 during antibody purification. Growth curve of MAb-5E1-treated A549 cells 
corrected for FCS-IgG treatment shows no effect after treatment (lower right panel). 
(B) Cyclopamine inhibits growth in A549 and H82, but not in H209 (left panel). Tomatidine 
treatment reduces growth in all cell lines. All measurements have been normalised to vehicle 
controls (N=3 in triplicate, mean ±SEM, paired t-test compared to vehicle control). 
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4.2.5 Expression analysis of Shh target genes in A549 cells treated with 
Shh inhibitors  
The inconsistency between the responses to MAb-5E1 and cyclopamine treatment in cell 
lines A549 and H82 raised doubts regarding the target specificity of cyclopamine. 
Tomatidine also had a negative effect on growth which in some cases was even higher than 
that of cyclopamine, further suggesting that the affected cell lines were sensitive to these 
compounds through an Hh-independent mechanism. In addition, at cyclopamine 
concentration of 10 µM and higher it was noticed that small crystals, presumably of 
precipitated cyclopamine, formed in the cell medium during the course of the experiments. 
It is also possible that the difference in the inhibitor response depends on an Hh pathway 
activating mutation downstream of Shh, but upstream of Smo, e.g. in the receptor Ptch1. 
Therefore, to verify if MAb-5E1 and cyclopamine had a similar effect on target gene 
expression of the Shh signalling pathway, the relative expression of target genes Ptch1 and 
Gli1 after 24 and 48 h of inhibitor treatment was determined using qRT-PCR. An online 
applet for determination of the best normalisation factor based on the calculation of the 
geometric mean, GeNorm (Vandesompele et al., 2002) was used to calculate the best single 
normalisation gene out of three which were tested – GAPDH, RPLPO and ACTB. GAPDH was 
found to be the best normalisation gene based on 27 measured samples and hence all qPCR 
data were normalised to GAPDH gene expression. 
After 24 h, Ptch1 expression was unchanged after either MAb-5E1 or cyclopamine 
treatment (Figure 4.7 A, left panel). After 48 h, it was reduced by about 30% for both 
inhibitors without any significant difference between MAb-5E1- and cyclopamine-treated 
cells (Figure 4.7 A, right panel). Expression of Gli1 appeared slightly reduced already after 
24 h (Figure 4.7 B, left panel). The reduction was at about the same level after 48 h of 
treatment. Cyclopamine appeared to give a slightly higher reduction in Gli1 expression than 
MAb-5E1; however, having performed the experiments only twice, no significant difference 
between the two inhibitors was detected (Figure 4.7 B, right panel).The results clearly show 
that 20 µg/ml of MAb-5E1 is indeed able to reduce the Shh pathway activity to the same or 
almost the same extent as 5 µM cyclopamine. The overall reduction in Shh pathway activity 
is relatively weak reaching at best 35% ±5.6 (P=0.0245) in Gli1 expression after 48 h of 
cyclopamine treatment. It can be concluded that the discrepancy between MAb-5E1 and 
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cyclopamine treatment seen in growth inhibition is likely to be due to an off-target effect of 
cyclopamine and not due to true reduction in growth upon Shh pathway inhibition. As a 
result, none of the tested lung cancer cell lines were suitable for studying the effect of Hhat 
KD on autocrine Hh signalling by measuring cell growth. 
 
 
Figure 4.7 Shh pathway target gene expression in A549 cells after inhibitor treatment 
measured by qRT-PCR. 
 (A) Relative mRNA expression of Ptch1 compared to untreated cells. (B) Relative mRNA 
expression of Gli1 compared to untreated cells. Cells were treated with MAb-5E1 (20 µg/ml) or 
cyclopamine (5 µM) for 24 or 48 hours (N=2 in duplicate, mean±SEM, unpaired t-test).  
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4.2.6 Shh pathway stimulation does not induce growth in A549 cells 
Although Hh pathway inhibitors are not able to reduce growth of A549 cells, as the pathway 
components are expressed in these cells, there is a possibility that A549 cells would respond 
to an increase of the Shh ligand by increasing their growth rate. Therefore, A549 cells were 
treated with 0.5-2.0 µg/ml recombinant Shh, Shh-C24II. However, after four days in culture, 
no increase in A549 growth was detected (Figure 4.8 A).  
Shh-C24II consists of the Shh-N domain without the cholesterol modification where the N-
terminal Cys, the site of palmitoylation, has been replaced with two Ile residues (II), creating 
a hydrophobic N-terminus that partially mimics palmitoylation. As fully processed 
multimeric Shh is known to be a far more potent signalling molecule than the monomeric 
Shh-C24II, to confirm to results obtained, A549 cells were transfected with increasing 
amounts of the Shh expression vector pcDNA-DEST-Shh. Western blotting with the anti-Shh 
antibody H-160 one day after transfection showed that Shh was highly expressed when  
 
Figure 4.8 Stimulation of A549 cells with recombinant or transfected Shh does not increase cell 
growth. 
(A) A549 cells treated with Shh-C24II for four days show no significant difference in growth. 
(B) A549 cells transfected with Shh vector pcDNA-DEST40-Shh show no dose-dependent 
increase in growth due to dosed Shh stimulation (left panel, N=2 in triplicate, mean ±SEM, 
unpaired t-test). pcDNA-DEST40-LacZ was used as a transfection control. A Western blot 
showing the level of Shh expression in differentially transfected cells (right panel). 
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cells were transfected using 2 µg DNA and 6 µl FuGENE HD transfection reagent, but was 
barely or not at all detected when cells were transfected using 1 or 0.5 µg DNA and 6 µl 
FuGENE HD (Figure 4.8 B, right panel). Expression of Shh resulted in slightly lower growth 
than control cells and cells transfected with the control vector pcDNA-DEST40-LacZ (Figure 
4.8 B, left panel), presumably due to differences in plasmid composition. Nonetheless, no 
difference between cells expressing increasing amounts of Shh was observed. Combined 
with growth inhibition studies, these findings confirm that A549 cells, although they express 
Shh pathway components, do not respond to Shh by altering their growth and are therefore 
not suitable as models for studying the effect of Hhat KD on lung cancer cell proliferation. 
4.2.7 A549 cells induce Shh-dependent response in C3H10T½ cells 
Although the tested panel of lung cancer cell lines did not depend on autocrine Shh 
signalling for their growth, the Shh expressed by these cell lines may still play a role in 
cancer progression in a reverse paracrine fashion within the tumour microenvironment by 
stimulating the surrounding stromal cells with Shh which in turn are able to provide them 
with other growth promoting factors (see Section 1.1.4.1). To test if Shh produced by A549 
cells is able to induce a Hh response in surrounding cells in a juxtacrine/paracrine fashion, 
A549 cells were co-cultured with C3H10T½, a mouse osteoblast progenitor cell line which 
responds to Shh stimulation by differentiating into osteoblast (Nakamura et al., 1997, Pathi 
et al., 2001). The differentiation is marked by induced production of ALP which can easily be 
measured by colorimetric means. In previous studies of Shh signalling using C3H10T½ cells, 
typically, these cells have either been treated with purified Hh protein, with conditioned 
medium from Shh-producing cells, or in co-culture. The advantage of a co-culture system 
over the use of conditioned medium is that it takes into account both paracrine and 
juxtacrine signalling, both of which may be important in Hh signalling in the tumour 
microenvironment. 
Initially, the A549 to C3H10T½ cell ratio was optimised to obtain the maximum signal by co-
culturing A549 and C3H10T½ cells (Figure 4.9 A). The cultures were seeded at a high density 
in a 96-well plate resulting in full confluency after a few days of incubation, allowing 
extensive cell-cell contacts between the two cell types. The cells were allowed to grow for 5 
days to achieve high-level differentiation. At ratios 1:1, 1:2 and 1:3 (A549:C3H10T½) the ALP 
signal is proportional to the number of C3H10T½ cells indicating maximum differentiation 
4 The role of Hhat in Shh signalling in lung cancer cell lines 
123 
rate. The linear response was lost at lower proportions of C3H10T½ confirming that ALP 
induction only occurs in C3H10T½ and not in A549 cells. The maximum signal was obtained 
at the A549:C3H10T½ ratio of 1:2. A549 cells on their own did not express any significant 
levels of ALP, as individually cultured A549 showed ALP activity comparable to 
undifferentiated C3H10T½. 
Attempts to induce a response in C3H10T½ cells only by addition of Shh-C24II, gave 
inconsistent results depending on the “state” of Shh-C24II used. 1 µg/ml Shh-C24II newly 
prepared from lyophilised sample gave rise to a response similar to the maximum response 
of A549:C3H10T½ co-culture (data not shown). After freezing or cold storage, Shh-C24II lost 
parts of its activity resulting in only about a third of the response initially seen. Despite 
difficulties in obtaining consistent measurements, it was evident that C3H10T½ responded 
to Shh-C24II by induction of ALP as has been seen in the literature (Nakamura et al., 1997, 
Spinella-Jaegle et al., 2001, Yuasa et al., 2002). 
The induction of ALP response in C3H10T½ cells by A549 cells was inhibited by Shh pathway 
inhibitors MAb-5E1 (20 µg/ml) and cyclopamine (5 µM) confirming that the ALP response in 
C3H10T½ cells was largely due to Shh produced by A549. Cells were seeded at a 1:2 
(A549:C3H10T½) ratio in 96-well plates, inhibitors were added on Day 0 and cells were 
incubated for 5 days without any further treatment. The C3H10T½ response was reduced by 
about 27% for both MAb-5E1- and cyclopamine-treated cells, confirming that MAb-5E1 is 
active (Figure 4.9 B, left panel). The response of inhibitor-treated cells was further 
decreased if the experiment was performed in 6-well plates which allowed for convenient 
inhibitor supplementation. By adding inhibitors every other day and assaying the C3H10T½ 
response after 5 days in co-culture, the response after inhibitor treatment was further 
reduced by 44% ±14 (P=0.0961) with MAb-5E1 and by 61% ± 6.4 (P=0.0110) with 
cyclopamine (Figure 4.9 B, right panel).  
The 6-well assay required more processing as well as significantly larger quantities of 
inhibitors than an assay performed in 96-well plates. The disadvantage with the latter was 
its small culture volume (200 µl) which was impractical for supplementation of the culture 
medium with inhibitors during incubation. The possibility to entirely replace medium with 
fresh inhibitors added every other day was not tested. The ALP induction in C3H10T½ cells 
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Figure 4.9 A549 cells are able to induce Shh-dependent differentiation of C3H10T½ cells in co-
culture as measured by induction of ALP. 
(A) ALP response in individually grown cell lines or in co-culture at different cell ratios after 5 
days in culture. ALP activity is normalised to a standard curve of SAP (mU). (B) ALP response in 
co-culture of A549:C3H10T½ at ratio 1:2 was partially inhibited by Shh pathway inhibitors 
MAb-5E1 (20 µg/ml) and cyclopamine (5 µM). Cell medium in the experiment performed in 6-
well format was supplemented with inhibitors every other day. (N=3, means ± SEM, paired t 
test). (C) ALP response in A549:C3H10T½ co-culture at 1:1 ration measured after 2-6 days 
(N=1, mean±SD). ALP activity is normalised to a standard curve of SAP (mU). (D) ALP response 
in co-culture of A549:C3H10T½ cells at ratio 1:2 measured after 2 days was comparable to ALP 
response in 6-well format supplemented with inhibitors every other day in B (N=3, means ± 
SEM, paired t test).  
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has been reported to reach its maximum after 5-6 days in culture (Nakamura et al., 1997, 
Spinella-Jaegle et al., 2001, Yuasa et al., 2002). To test if the ALP signal would be sufficient 
after only two days, a time-course experiment was conducted. A549 and C3H10T½ cells 
were grown in co-culture at a 1:1 ratio for 2-6 days. To achieve comparable data, different 
amounts of cells were seeded with the aim to reach the same cell density on the final day. 
Calculations for cell seeding were based on the doubling time of A549 at 3% FCS. C3H10T½ 
cells were by experience judged to have a similar doubling time to A549 cells. Obtained ALP 
activity was normalised to a standard curve of SAP (expressed in mU as defined by the 
manufacturer). During Day 2-4, ALP induction appears to be linear. On Day 4-6 it starts to 
level off (Figure 4.2 C). As the level of background ALP activity from individual cultures on 
Day 2 was close to zero (data not shown) it was concluded that 2 days of co-culture were 
sufficient to detect differentiation. Indeed, inhibitor treatment of A549:C3H10T½ cells co-
cultured over 2 days in 96-well plates gave comparable reduction in ALP response to cells 
grown for 5 days in 6-well plates supplemented with inhibitors every other day (Figure 
4.9 D). In conclusion, the most time and resource efficient way to assay C3H10T½ cell 
differentiation in co-culture was over two days in 96-well format. 
4.2.8 siRNA KD of Hhat in A549 cells reduces the Shh signalling 
response in C3H10T½ cells in co-culture 
After having established a Shh-responsive cell system by co-culturing A549 and C3H10T½ 
cells, the effect of Hhat KD in A549 cells on C3H10T½ cells was tested. Firstly, KD of Hhat in 
A549 cells had to be established. Two ways of knocking down Hhat expression were tested, 
shRNA- and siRNA-mediated KD. siRNA transfection was performed and optimised by Dr. 
Antonio Konitsiotis. shRNA KD was attempted by transfection of A549 cells with shRNA-
expressing vectors psi-mU6 targeting Hhat under the control of the U6 promoter with 
simultaneous constitutive expression of mCherry under a CMV promoter (Figure 4.10). Four 
shRNA plasmids targeting different regions of Hhat were purchased together with a non-
targeting control plasmid. Transfection efficiency was determined by FACS analysis of psi-
mU6-control-transfected A549 cells using co-expression of mCherry as fluorescent marker. 
The best transfection result was obtained using Lipofectamine 2000 transfection reagent 
resulting in mCherry expression in 30% of A549 cells, while only 10% of cells were 
transfected using X-tremeGENE 9 (data not shown). Transfection using FuGENE HD was also 
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tested, but resulted in poorer transfection than Lipofectamine 2000 (determined by visually 
comparing mCherry expression under a fluorescence microscope). Due to the poor 
transfection efficiency of plasmids into A549, the use of shRNA to knock-down Hhat was 
abandoned in favour of siRNA treatment.  
Initially, a pool of four siRNA oligos targeting different sequences of Hhat was used to 
optimise Hhat KD efficiency in A549 cells using Lipofectamine 2000, FuGENE HD, or 
Metafectene SI transfection reagents. Metafectene SI transfection resulted in about 60% KD 
of Hhat mRNA when assayed by qRT-PCR normalised to GAPDH expression (performed by 
 
Figure 4.10 RNA silencing methods used to achieve Hhat KD in A549 cells. 
(A) shRNA plasmid map carrying two expression cassettes, one with mCherry under control of 
the constitutive CMV promoter and one with Hhat-targeting shRNA under control of the U6 
promoter. (B) shRNA folding after expression results in a hairpin loop which is processed to a 
double-stranded RNA able to interfere with Hhat mRNA and target it for degradation. 
(C) Structure of siRNA oligos used for transfection to directly silence Hhat expression. 
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Dr. Antonio Konitsiotis). Next, all four siRNAs were tested individually using Metafectene SI 
transfection reagent to find the most efficient oligo against Hhat. An oligo targeting 
sequence 5’-AGGACAGUCUGGCCCGAUA-3’ of Hhat was found to have the greatest effect, 
typically resulting in Hhat mRNA reduction by about 60% 2-4 days after siRNA transfection 
(Figure 4.11 A, data pooled from experiments performed by Dr. Antonio Konitsiotis and 
Biljana Jovanovic). The large error bar on Day 2 is a result of one outlier measurement. Due 
to the lack of a suitable antibody, I was unable to confirm Hhat KD by Western blotting. As 
the half-life of Hhat protein is unknown, this level of mRNA KD may be an underestimate of 
the effect at the protein level. 
After Hhat KD was established, A549 cells treated with Hhat siRNA were co-cultured with 
C3H10T½ cells to test the effect of Hhat KD on Shh signalling. After two days of siRNA 
treatment, cells were trypsinised and seeded in co-culture with C3H10T½ cells, ratio 1:2 
(A549:C3H10T½), and incubated for additional two days. The response of C3H10T½ cells by 
ALP production was reduced by 37% ±10 (P=0.04) compared to treatment with a non-
targeting pool of siRNAs, showing that Hhat KD indeed leads to a reduction in paracrine Shh 
signalling by cancer cells.  
 
Figure 4.11 Hhat KD in A549 cells leads to reduction of Shh signal response in C3H10T½ cells. 
(A) qRT-PCR analysis of Hhat gene expression 2-4 after siRNA transfection (N=6 for Day 2 and 
Day 3, N=2 for Day 4 in duplicate, means±SEM, paired t-test, data pooled from Dr. Antonio 
Konitsiotis and Biljana Jovanovic). (B) ALP induction in A549:C3H10T½ cell co-culture (1:2 ratio) 
shows a significant reduction in Hhat KD samples. (N=4 in triplicate, mean±SEM, paired t-test). 
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4.2.9 HEK293A and HEK293A-Shh in co-culture with C3H10T½ 
Hh proteins are expressed at very low levels and attempts to detect Shh from cells or 
medium by Western blotting or immunoprecipitation in cell lines A549, H209 and H82 were 
unsuccessful. Therefore, in order to be able to conveniently study lipidation of Shh in vivo, a 
stable clone of HEK239A cells expressing plasmid pcDNA-DEST40-Shh, HEK293A-Shh, was 
created in the lab (performed by Naoko Matsumoto and Paulina Ciepla). Out of 16 stable 
clones, a Western blot of Shh expression patterns of clones 11-16 are shown below (Figure 
4.12 A). Clone 16 selected for further studies showed high expression of processed Shh, was 
morphologically indistinguishable from HEK293A wt and had a comparable growth rate. 
Click chemistry experiments further confirmed that autoprocessed Shh-N also was 
efficiently palmitoylated (Figure 4.12 B).  
HEK293A-Shh cells were further tested for their ability to produce functional Shh by 
inducing differentiation of C3H10T½ cells. HEK293A or HEK293A-Shh cells were co-cultured 
with C3H10T½ cells at different cell ratios for five days. Although pure HEK293A cells 
displayed higher levels of background ALP activity than pure C3H10T½ cells, in co-culture,  
 
Figure 4.12 Screen and functional test of stable HEK293A-Shh clones. 
(A) Shh expression patterns of HEK293A-Shh clones derived from colonies 11-16. (B) SDS-PAGE 
in-gel fluorescence and Western blot of HEK293A-Shh clone 16. Click reactions were 
performed on lysates of HEK293A-Shh or wild type fed with either YnC15 or palmitate. 
Reactions were either analysed directly or after biotin-capture on streptavidin beads. Sample C 
represents click reaction only; S, capture supernatant and B, protein captured on beads. Clone 
selection was performed by Naoko Matsumoto and Paulina Ciepla. YnC15 labelling 
experiments were performed by Naoko Matsumoto. 
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they were not able to induce a response in C3H10T½ cells. This was demonstrated by a 
decreasing ALP activity as HEK293A cells were diluted with C3H10T½ cells in co-culture 
(Figure 4.13 A). On the other hand, HEK293A-Shh cells were able to induce a response in 
C3H10T½ cells which resulted in considerably higher ALP production compared to HEK293A 
wild type cells (Figure 4.13 B). The signal response at low HEK293A-Shh:C3H10T½ cell ratios 
positively correlated to the number of C3H10T½ cells and was highest at a ratio of 1:2 
(HEK293A-Shh:C3H10T½) where it starts to level off, which indicates that the induction of 
ALP only occurs in C3H10T½ cells and not in HEK293A-Shh cells. This is supported by the 
facts that wild type HEK293A cells were not able to induce an ALP response in C3H10T½ cells 
and that the ALP induction was reduced by treatment with Shh pathway inhibitors (Figure 
4.2 C). Also, HEK293A-Shh cells gave rise to at least a 10 times stronger ALP induction in co-
culture when compared to A549 cells, reflecting the higher levels of expressed Shh. 
 
 
Figure 4.13 ALP induction in C3H10T½ cells after 5 days of co-culture with HEK293A or 
HEK293A-Shh cells. 
(A) HEK293A wild type cells do not express any detectable Shh and fail to induce an ALP 
response. ALP activity is normalised to a standard curve of SAP (mU). (B) HEK293A-Shh cells 
stably express Shh and are able to induce an ALP response in C3H10T½ cells. ALP activity is 
normalised to a standard curve of SAP (mU). (C) ALP response in co-culture of HEK293A-
Shh:C3H10T½ cells at ratio 1:2 measured after 2 days in co-culture was partially inhibited by 
Shh pathway inhibitors MAb-5E1 (20 µg/ml) and cyclopamine (5 µM). The background activity 
of C3H10T½ cells was subtracted from the measurements (N=3 in triplicate, means±SEM, 
paired t-test to untreated sample). 
4 The role of Hhat in Shh signalling in lung cancer cell lines 
130 
4.2.10 siRNA knock-down of Hhat in stable HEK293A-Shh cells 
reduces Shh signalling and the amount of intracellular Shh 
Interestingly, although HEK293A cells do not express enough endogenous Shh to be able to 
induce C3H10T½ differentiation, they express Hhat which is able to palmitoylate exogenous 
Shh and which can further be modulated by Hhat siRNA (Figure 4.14 A). Hhat siRNA 
treatment of HEK293A-Shh cells assayed on Day 2, 3 and 4 showed a decrease in Hhat 
mRNA. Expression on Day 2 was significantly reduced by 46% ±0.14 (P=0.032). KD on Day 3 
and 4 appears much less effective; however, the large error in the measurements on Day 3 
is due to a single outlier (N=6, data pooled from Dr. Antonio Konitsiotis and Biljana 
Jovanovic). Measurements on Day 4 were repeated only twice.  
HEK293A-Shh cells treated with non-targeting or Hhat siRNA co-cultured with C3H10T½ cells 
(ratio 1:2) for 2 days during Day 2-4 of KD, resulted in a C3H10T½ response decreased by 
32% ±10 (P=0.052), almost reaching significance (Figure 4.14 B). This represents a slightly 
smaller reduction compared to Hhat KD in A549 cells which possibly can be attributed to 
less efficient Hhat KD in HEK293A-Shh cells.  
The level of intracellular (ic) Shh in HEK293A-Shh cells was analysed by Western blotting 
(Figure 4.14 C). An attempt to detect the palmitoylation status of Shh (ic) was made by 
feeding HEK293A-Shh cells treated with non-targeting or Hhat siRNAs with YnC15 for 24 h 
on Day 3 of KD. Cell lysates were used in a click reaction to attach a TAMRA-biotin-tag to 
analogue-modified Shh. Unfortunately, due to technical difficulties (fluorescence scanner 
was temporary unavailable) it was not possible to obtain a fluorescence image of modified 
Shh. Further, although the experiment was repeated twice giving a similar result in overall 
band intensity, the band shift characteristic of YnC15-modified Shh after anti-Shh blotting 
could not be resolved due to gel overloading. Due to time constraints the Western blot 
analysis could not be repeated. Nonetheless, it was evident that Hhat KD results in a 
reduction of intracellular Shh consistent with the role of Shh palmitoylation in the cell as a 
membrane anchor for the protein. 
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Figure 4.14 Hhat KD in HEK293A-Shh cells leads to a reduction in Shh signal response in 
C3H10T½ cells in co-culture. 
(A) qRT-PCR analysis of Hhat gene expression 2-4 days after siRNA transfection (N=5 in 
duplicates for Day 2 and Day 3, N=2 in duplicates for Day 4, means±SEM, paired t-test, data 
pooled from Dr. Antonio Konitsiotis and Biljana Jovanovic). (B) ALP induction in HEK293A-
Shh:C3H10T½ co-culture (1:2 ratio) shows a nearly significant reduction in Hhat KD samples 
(N=4 in triplicates, mean±SEM, paired t-test). (C) Western blot (anti-Shh antibody H-160) of 
HEK293A-Shh cells treated with Hhat siRNA for 3 days shows a decrease in ic Shh after Hhat KD 
(N=2). 
4.3 Discussion and future work 
4.3.1 Autocrine Shh signalling in lung cancer cell lines 
The first step towards studying the role of Hhat in Shh signalling in lung cancer cell lines was 
to find lines which expressed Hh pathway components and depended on autocrine Shh 
signalling for their growth. While all tested cell lines expressed Hh pathway components, 
none of them reduced their growth upon MAb-5E1 treatment, while A549 and H82 did so 
after treatment with cyclopamine. Tomatidine, an inactive analogue of cyclopamine, also 
resulted in a reduction of growth suggesting that cyclopamine-induced growth reduction 
was an off-target effect not mediated by the Hh signalling pathway. The largest difference 
between treatments with MAb-5E1 and cyclopamine was found in A549 cells. As MAb-5E1 is 
able to bind all three Hh analogues, it is unlikely that the difference in response in A549 cells 
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is due to overexpression of Dhh or Ihh and not Shh. Further, MAb-5E1 was found to be 
active both by binding Shh-C24II in IP experiments and by inhibiting C3H10T½ cell 
differentiation, thus eliminating inactivity as a source of disparity between inhibitors. In a 
study of a large panel of both SCLC and NSCLC cell lines, Yauch et al. showed that 
cyclopamine inhibited growth in a variety of cancer cell lines without any correlation to Gli1 
expression indicating off-target activity of cyclopamine (Yauch et al., 2008). Here, qRT-PCR 
experiments showed that expression levels of target genes Ptch1 and Gli1 were only mildly 
affected and were almost identical after both cyclopamine and MAb-5E1 treatments, 
supporting the findings of Yauch et el. that cyclopamine-inhibited growth is an off-target 
effect in A549 cells. The low levels of target gene suppression in qRT-PCR measurements of 
A549 cells also shows that the autocrine signalling loop of Hh signalling in A549 cells is 
nearly irresponsive to Hh pathway modulation. Inhibitor treatment of A549 cells in co-
culture with C3H10T½ cells results in a much greater reduction in response suggesting that 
the small effect of autocrine signal inhibition is not due to low inhibitor concentrations but 
is an inherent property of these cells. Possibly, a mechanism downstream of Smo, but 
upstream of Gli1, may instead be responsible for Gli1 expression in the cells. In their studies 
of SCLC and NSCLC, Yauch et al. showed that cancer cells which have a high Gli1 expression 
but do not respond to Hh inhibitors by growth reduction become sensitive to inhibitors if 
expression of Gli1 is knocked down by siRNA (Yauch et al., 2008). This suggests that Gli1 in 
these cell lines may be regulated by a non-canonical pathway and may represent a problem 
for use of Hhat inhibition in lung cancer. Alternatively, the role of the Hh pathway in A549 
cells is not autocrine, but a relic of paracrine signalling to the surrounding stroma in the 
primary tumour they were derived from.  
Co-culture experiments of A549 cells with the Shh-responsive cell line C3H10T½ showed 
that supplementation of inhibitors at least every other day greatly increased inhibition of 
the Hh signalling. As both MAb-5E1 and cyclopamine act stoichiometrically to their 
molecular targets, the need to replenish inhibitors is likely to be due to inhibitor depletion. 
Also, while antibodies should be quite stable in cell medium, cyclopamine is a sterol and 
may be metabolised by the cells further reducing its concentration in the medium. Growth 
inhibition and stimulation experiments of isolated cell lines were performed for 4-6 days 
without any reagent supplementation which may have resulted in an overall 
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underestimation of their effect. However, A549 also failed to respond to stimulation by 
transient expression of Shh.  
Collectively, these studies show that although they express Shh and other pathway 
components, none of the tested lung cancer cell lines are dependent on autocrine Shh 
signalling for their growth. I therefore suggest that Hh signalling present in lung cancer is 
not responsible for maintenance of a potential lung CSC pool which is able to independently 
drive cancer growth by creating autocrine signalling loops. Instead, the Hh pathway is more 
likely to play a role in paracrine signalling to other cells within the tumour 
microenvironment. 
4.3.2 Juxtacrine/paracrine Shh signalling in lung cancer cell lines 
Co-culture experiments using C3H10T½ cells demonstrate the ability of A549 and HEK293A-
Shh cells to signal in a juxtacrine and/or paracrine fashion to neighbouring cells. Shh needs 
to be dually lipidated to be membrane anchored, as a single modification has been shown 
not to be sufficient (Zeng, 2001). Providing that Shh expression is not affected by Hhat KD, 
reduction of intracellular Shh-N in HEK293A-Shh cells clearly shows that palmitoylation is 
indeed necessary for membrane anchoring of Shh-N. Juxtacrine signalling is defined as 
signalling between ligand and receptor on the surface of adjacent cells. Paracrine signalling 
refers to secreted Shh ligands found in the extracellular space which are able to travel 
several cell diameters away from the signalling cell. In cell culture, these signalling 
molecules are thought to be present freely in the medium. To differentiate the contribution 
of paracrine from juxtacrine Hh signalling, medium conditioned by cells expressing Shh 
could be used to stimulate C3H10T½ cells. HEK293A-Shh cells would be ideal for this type of 
experiment as medium conditioned by wild type HEK293A cells could be used as a control. 
The role of Shh palmitoylation in paracrine signalling could thereby be elucidated if cells 
were treated with Hhat siRNA prior to medium conditioning. 
Hhat KD measurements using qRT-PCR showed a general KD of Hhat by 20-60%. As the half-
life of Hhat protein is not known, these figures may represent an underestimate of proteins 
KD in the cells. To gain more certainty regarding the level of Hhat KD, it would be useful to 
determine Hhat protein levels by Western blotting. Two commercially available anti-Hhat 
antibodies as well as one raised in our lab were tested for Western blotting on cells 
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overexpressing Hhat-V5 (Section 5.2.2). However, none of them was able to reproducibly 
detect Hhat and therefore qRT-PCR was used. Nonetheless, the reduction of intracellular 
Shh after Hhat KD correlated well with the reduction in Shh signal response in C3H10T½ cells 
as well as Hhat KD measured by qRT-PCR. These results confirm that Hhat inhibition would 
have an antagonising effect on Hh signalling in a juxtacrine/paracrine signalling system.  
It is noteworthy that although A549 cells express considerably less Shh than HEK293A-Shh 
cells, they are nevertheless able to induce differentiation in C3H10T½ cells, reflecting the 
high potency of Hh ligands. Therefore, it is possible that Shh expressed on the surface of 
tumour cells in vivo is also potent enough to induce a signalling response in the surrounding 
tumour microenvironment. Lung cancer studies have shown that Gli1 expression is usually 
more common in primary tumours than in cancer cell lines, suggesting that Hh pathway 
activity is even higher in vivo and that isolated cells do not require Hh signalling resulting in 
its down-regulation (Vestergaard et al., 2006, Yuan et al., 2007). The effect of Hh signalling 
originating from lung cancer cells on surrounding stromal cells has not yet been studied. 
Studies of PDAC cell lines and mice models, however, have shown that PDAC cell lines are 
dependent on Shh signalling for growth and Matrigel invasion (unpublished data from Dr. 
Shu-Chun Chang; Nagai et al., 2008) and that paracrine Shh signalling is able to induce a Gli1 
response in the PDAC-surrounding stroma (Olive et al., 2009). This tumour type therefore 
represents a better model to study the role of Shh inhibition on cancer progression than 
lung cancer. If inhibition of Hhat would have clinical benefits in PDAC, it is nonetheless 
important to assess the role of paracrine Shh signalling in the tumour microenvironment of 
SCLC or NSCLC and other Shh-expressing cancers with poor prognosis in vivo. 
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5 Membrane topology of human Hhat 
5.1 Introduction  
Solving molecular structures of multi-spanning membrane proteins at near atomic 
resolution is a very cumbersome task. Out of 79,697 protein structures available in the RCSB 
Protein Data Bank in March 2012 (http://www.pdb.org), only 615 are of membrane 
proteins. Out of these, only 322 structures are of unique proteins 
(http://blanco.biomol.uci.edu/mpstruc/listAll/list). Techniques for determining protein 
structures include electron crystallography, x-ray crystallography and solution NMR. While 
all are restricted by poor recombinant expression of membrane proteins, they vary in their 
other limitations. Electron and x-ray crystallography suffer from difficulties of producing 
ordered crystals and x-ray crystallography and NMR are restricted by the need of purified 
and detergent solubilised membrane proteins. NMR is further hampered by difficulties of 
resolving resonance peaks from larger membrane proteins (Bill et al., 2011, Ubarretxena-
Belandia and Stokes, 2010, Kielec et al., 2010). Given the difficulties associated with 
structure determination of membrane proteins, topology mapping is often employed to 
extract structure/function information about the protein of interest.  
Hhat is a multi-spanning membrane protein localised in the secretory pathway (Buglino and 
Resh, 2008) belonging to the MBOAT protein superfamily. There is no molecular structure 
available for Hhat or any other member of the MBOAT family. However, on the basis of 
homology, an highly conserved His residue, H379 in human Hhat, has been identified and 
suggested as being involved in the catalytic site of MBOATs (Hofmann, 2000). Since then, 
several studies have demonstrated that this His is required for full enzymatic activity of 
various members of the MBOAT protein family. Hhat, in contrast, does not absolutely 
require this His, although its activity is reduced by 50% when H379 is mutated to Ala 
(Buglino and Resh, 2010). Information about protein structures of drug targets have in the 
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past proved useful when designing inhibitor screens for drug discovery. In the light of Hhat 
as a viable target in anti-cancer treatment and the lack of its molecular structure, 
understanding its topology is an informative alternative to learn about its mechanism of 
action. By determining the topology and combining the information with bioinformatics 
analysis and existent biochemical data, a picture of the mechanism of the protein can start 
to be constructed. In this chapter, the first experimentally determined membrane topology 
of Hhat is presented. These findings are put into context of what is known about the role of 
conserved residues within Hhat and their role in catalysis. Finally, the topologies of Hhat and 
other members of the MBOAT protein superfamily are compared and the relevance of these 
findings for the protein family as a whole is discussed. 
5.1.1 Sequence-based prediction of membrane protein topology 
Designing membrane topology experiments depends on reliable computational prediction 
of TM regions in proteins. α-helices are the most commonly found structural features 
making up TM regions of all organisms (Krogh et al., 2001). β-barrels, on the other hand, 
have only been found in the outer membrane of gram-negative bacteria (Galdiero et al., 
2007). A membrane-spanning α-helix is characterised by a highly hydrophobic sequence of 
about 20 aas with the capability to form a helical secondary structure. The chemical 
environment across a lipid bilayer changes dramatically from hydrophilic head groups to a 
hydrophobic lipid core and back to hydrophilic head groups. The outer surface of a TM α-
helix is composed of side chains which mirror these changing surroundings in order to be 
accommodated by the membrane (von Heijne, 2006). Physical data reflecting 
hydrophobicity are commonly used on their own or in combination with pattern recognition 
algorithms based on Hidden Markov Models (HMMs) or artificial neural networks (ANNs) to 
predict TM regions (Krogh et al., 1994, Rost et al., 1996, Viklund and Elofsson, 2008).  
Because membrane proteins are always synthesised and inserted into the membrane from 
the cytosol, all membrane proteins of one kind are assumed to have the same orientation 
within the membrane. Apart from the discovery of hydrophobic aa patterns in TM regions, it 
has been found that positively charged aas are asymmetrically distributed between loops on 
opposite sides of the membrane, being more abundant in cytoplasmic than luminal loops 
(von Heijne and Gavel, 1988). This rule is known as the positive-inside rule and is generally 
used in prediction algorithms to predict loop localisation of TM proteins and to exclude 
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weak TM regions, thus producing a complete membrane topology including TM regions and 
orientation of the protein (von Heijne, 1992). 
5.1.2 Experimental methods for determining membrane protein 
topology 
Experimental procedures for determining topology of membrane proteins have usually been 
based on mapping the localisation of chemically modifiable or otherwise detectable sites 
within the protein. Typically, glycosylation sites, affinity epitopes, Cys residues, or 
proteolytic cleavage sites have been used. All these methods are based on sequence 
modification of the studied protein. Regardless of the method used, inconveniently 
positioned endogenous modifiable sites need to be removed while new sites need to be 
added to regions of interest within the protein. The sites can either be added internally into 
loops between predicted TM regions, or at the C-terminus of protein truncates ending in 
predicted loop regions. One should bear in mind that any sequence modification of the 
native protein may result in altered topology compared to the native protein. Therefore, to 
obtain high fidelity results, topology studies should be conducting using several different 
approaches. Here, I will describe two procedures for topology analysis used in this chapter, 
N-glycosylation and epitope mapping. 
N-glycosylation is a post-translational modification of proteins which occurs in the ER 
lumen. Membrane proteins carrying an N-glycosylation site on their luminal side are 
recognised by oligosaccharyltransferase which transfers a glycan onto the Asn residue of the 
N-glycosylation site (Schwarz and Aebi, 2011). The site, also known as a sequon, consists of 
Asn-X-Thr (NXT) or Asn-X-Ser (NXS), where X can be any aa but Pro (Marshall, 1974). For N-
glycosylation mapping, any inconveniently positioned endogenous glycosylation sites in the 
membrane protein need to be removed by mutagenesis. New N-glycosylation sites are 
systematically introduced into loops of interest either internally or C-terminally by creating 
protein truncates. By expressing the protein, either in vitro in the presence of microsomal 
membranes or in cell culture, luminal N-glycosylation sites become modified. These glycans 
are large in size (3-4 kDa) and their covalent attachment to the protein can be detected by a 
shift in molecular weight on an SDS-PAGE gel. To confirm that shifted bands are indeed 
glycosylated, a part of the samples can be treated with PNGase, an endoglycosidase which  
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Figure 5.1 Work-flow for N-glycosylation mapping of membrane protein topology. 
The N-glycosylation site becomes modified only if it resides in the ER lumen. 
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cleaves all types of N-glycosylation between the innermost sugar moiety and Arg. This 
treatment removes the shift in molecular weight of glycosylated proteins. A detailed 
schematic for the experimental workflow used in this chapter is shown in Figure 5.1.  
Epitope mapping is a method which complements N-glycosylation mapping by visualising 
cytosolic epitopes of membrane proteins. This is achieved by immunofluorescence imaging 
of semi-permeabilised cells, i.e. cells in which the plasma membrane has been 
permeabilised but the internal membranes are kept intact. Semi-permeabilisation is possible 
because of differences in the lipid compositions of the plasma and the ER membranes. 
While treating cells with Triton X-100 will fully permeabilise them, digitonin is used to 
selectively permeabilise only the plasma membrane (Plutner et al., 1992, Wilson et al., 1995, 
see Figure 5.2 for structures), thus exposing only the cytosolic epitopes of membrane 
proteins to staining antibodies. A detailed schematic for the experimental workflow of 
epitope tagging used in this chapter is shown in Figure 5.3. 
 
 
Figure 5.2 Chemical structures of Triton X-100 and digitonin. 
Triton X-100 is used to fully permeabilise cells, while digitonin is used to selectively 
permeabilise the plasma membrane. Critical micelle concentration (CMC) states the 
concentration above which the compound forms micelles.  
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Figure 5.3 Work-flow for epitope mapping of membrane protein topology using 
immunofluorescence imaging. 
White dots in the bottom frames represent individual cells stained with V5 localised to the ER. 
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5.2 Results 
5.2.1 Predicted membrane topology of Hhat 
In this study, seven prediction tools were used to predict the topology of Hhat; HMMTOP 
2.0 (Tusnády and Simon, 2001), PredictProtein (Rost and Liu, 2003), SOSUI (Hirokawa et al., 
1998), TopPred (Claros and von Heijne, 1994), TMHMM 2.0 (Krogh et al., 2001), Tmpred 
(Hofmann and Stoffel, 1993) and TOPCONS (Bernsel et al., 2009). The combined results 
show that Hhat is predicted to have 8-12 TM regions in 13 different segments of the protein 
(Figure 5.4). Predictions by SOSUI and TopPred are based on hydrophobicity data only.  
 
Figure 5.4 Membrane topology prediction for human Hhat. 
(A) A summary of membrane topology predictions of Hhat suggests that it consists of 8-12 TM 
regions. The MBOAT family domain is highlighted in orange and the position of the conserved 
H379 is in green. (B) Hydrophobicity profile of Hhat as calculated by TopPred topology 
prediction tool. Regions with hydrophobicity values above the upper cut-off 1.0 (red line) are 
predicted as certain TM regions, regions above the lower cut-off 0.6 (green line) are 
considered as putative TM regions. Tmpred bases its prediction solely on physical 
hydrophobicity data. 
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Therefore, they lack information about the orientation of the protein. All other prediction 
tools use the positive-inside rule to determine the overall topology and thus exclude weakly 
predicted TMs. Further, analysis of Hhat by signal peptide prediction tool SignalP 4.0 
(Petersen et al., 2011) predicts that the signal peptide is retained as a TM region in the 
mature protein. 
5.2.2 Molecular cloning of Hhat 
To create an expression vector of Hhat for both mammalian and in vitro expression, cDNA 
encoding human Hhat was cloned into the pcDNA -DEST40 vector using Gateway cloning 
previously described for cloning of Shh (see Section 3.2.1). Apart from a CMV promoter 
regulating mammalian protein expression, pcDNA -DEST40 also contains a T7 promoter for 
protein expression in in vitro transcription/translation systems. First, to produce an entry 
vector carrying Hhat, human Hhat cDNA (accession number: BC117130) was amplified by 
PCR from the commercially available plasmid pCR4-TOPO-Hhat. Primers used for 
amplification were designed to add a CACC nucleotide sequence at the 5’ end of the coding 
sequence to allow TOPO cloning of Hhat into the Gateway entry vector pENTR⁄D-TOPO. 
After obtaining a correct pENTR/D-TOPO-Hhat clone, the entry vector was recombined with 
the destination vector pcDNA-DEST40 creating pcDNA-DEST40-Hhat using the Gateway LR 
clonase enzyme kit (Figure 5.5 A, left panel). In addition, to be able to determine the 
localisation of the Hhat N-terminus, an Hhat construct containing an N-terminal HA-epitope 
tag was also cloned into pcDNA-DEST40 creating vector pcDNA-DEST40-HA-Hhat (Figure 
5.5 A, right panel). Insertion and correct orientation of gene inserts both in pENTR⁄D-TOPO 
and pcDNA-DEST40 vectors were confirmed using PCR screening across the gene boundaries 
and endonuclease digestion cutting inside and outside the gene inserts. pENTR⁄D-TOPO 
clones were screened using the forward amplification primer for Hhat and a T7 promoter 
primer targeting a complementary T7 promoter sequence downstream of Hhat. After 
purifying plasmids with correctly inserted genes, endonucleases NotI and EcoRV were used 
to cut inside and outside the Hhat gene, respectively. Positive clones were then used for 
Gateway cloning. pcDNA-DEST40 clones were screened using M13(-20) F and M13 R primers 
provided with the Gateway LR clonase enzyme kit and endonuclease PstI was used to cut at 
three sites positioned both inside and outside of Hhat. 
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Figure 5.5 Plasmid maps of pcDNA-DEST-Hhat and pcDNA-DEST-HA-Hhat and expression 
profile of C-terminally tagged Hhat transiently expressed in HEK293A cells. 
(A) Human Hhat cloned into the mammalian expression vector pcDNA-DEST40 without and 
with an N-terminal HA-tag. Both vectors provide Hhat with a C-terminal V5-His6 tag. (B) 
Western blot using anti-V5 antibody of HEK293A cells transiently transfected with pcDNA-
DEST-Hhat (left panel) shows that Hhat-V5 is expressed as a single band at about 50 kDa. 
Parallel transient expression of Shh-V5 detected both by anti-V5 antibody and anti-Shh 
antibody H-160 confirms the specificity of the anti-V5 antibody (middle panel). Blotting using 
anti-Hhat antibody Ab90 shows an unspecific band around 32 kDa, but fails to detect both 
endogenous Hhat and transiently expressed Hhat-V5-His6 (right panel). 
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The cloned cDNA sequence of Hhat is known to differ by two nucleotides from the human 
genomic Hhat sequence, a G to C change in position 567 resulting in a silent mutation, and a 
G to A change in position 576, resulting in a Ser to Asn mutation in position 182 of the 
protein. Prior to proceeding with making mutants of Hhat for topology analysis, the Ser to 
Asn mutation was corrected back to Ser by site-directed mutagenesis. All subsequent Hhat 
truncates were made using the corrected vector pcDNA -DEST40-Hhat as template. 
Expression of Hhat was detected by Western blotting using an anti-V5 antibody at about 
50 kDa (Figure 5.5 B, left panel). The expected size of Hhat is 57 kDa. The protein migrates 
differently in the gel probably due to its hydrophobic nature allowing it to bind more SDS 
than globular proteins used as molecular weight standards (Rath et al., 2009). An anti-Hhat 
antibody raised in our lab, Ab90, which previously had been found to recognise endogenous 
Hhat (Dr. Shu-Chun Chang, personal communication), was tested against Hhat-V5. For 
unknown reasons, it failed to recognise both endogenous Hhat and Hhat-V5, binding only an 
unspecific band at about 32 kDa (Figure 5.5 B, right panel). Two commercially available anti-
Hhat antibodies from Abcam and Abgent were also thoroughly tested in our lab by Dr. 
Antonio Konitsiotis. However, after extensive optimisation attempts, none of them could 
detect Hhat-V5. The search for a working anti-Hhat antibody continues. 
5.2.3 Molecular cloning of Hhat truncations 
The strategy used for determination of Hhat topology was based on creating Hhat 
truncations ending in loop regions between predicted TM segments 4-13 with a C-terminal 
tag consisting of an N-glycosylation site and a V5 epitope (Figure 5.6). This tag allows the 
same constructs to be used both for N-glycosylation and epitope mapping methods. The C-
terminal tag of pcDNA-DEST40 contains a 20 amino acid long spacer between the Hhat 
coding region and the V5 epitope. In this region, an N-glycosylation site was introduced by 
mutating the region encoding Asp-Leu-Gly located 12 aa residues downstream of the gene 
boundary to a sequence encoding Asn-Leu-Thr (NLT). In order for N-glycosylation to occur 
efficiently, the site requires a minimum of 14-15 aa flanking it on both sides (Nilsson and 
von Heijne, 1993). The introduced N-glycosylation site was flanked upstream by 12 aa within 
the spacing region requiring at least two additional aas in the C-terminal loop of the Hhat 
truncate inserts.  
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Sequence analysis of Hhat shows that the protein does not have any N-glycosylation sites of 
its own, conveniently allowing me to proceed with cloning without first removing 
endogenous N-glycosylation sites and thus not having to further compromise the primary 
sequence of the protein. As the first four loop regions were predicted to have the same 
topology by all used prediction tools, the experimental topology analysis was focused on 
loops between TM segments 4 through 13. Gene inserts for each truncation clone were 
made by PCR amplification using the corrected pcDNA-DEST40-Hhat plasmid as template 
and primers which included a CACC nucleotide sequence at the 5’ end. This addition served 
to facilitate TOPO cloning of the inserts into the Gateway entry vector pENTR⁄D-TOPO which 
was then used to insert the truncated genes into the destination vector pcDNA-DEST40-NLT 
by recombination (as described in Section 5.2.2). Insertion and correct orientation of the 
inserts both in pENTR⁄D-TOPO and pcDNA-DEST40-NLT were confirmed using PCR screening 
across the gene boundary and double endonuclease digestion cutting inside and outside the 
gene insert. The resulting expression vectors were further sequenced. Predicted TM regions 
of all truncation constructs ended at least three residues away from the C-terminal tag to 
satisfy the need of 14-15 aa flanking the NLT site. As the putative loop between TM10 and 
TM11 consists of a single amino acid, due to the short length, no truncation in that region 
was introduced. 
 
Figure 5.6 Schematic representation of Hhat truncation clones. 
The predicted TM regions in each truncation are outlined in white boxes, N-glycosylation site 
in yellow, V5 epitope in green and His6 tag in blue. Hhat-FL represents full-length Hhat.  
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5.2.4 Subcellular localisation of Hhat 
Protein sequence analysis shows that Hhat does not contain an ER retention sequence 
(KDEL), which is a signal for retrieval of proteins from the Golgi back to the ER. Hhat has 
previously been reported to co-localise both with ER and Golgi markers, but not with the 
plasma membrane (Buglino and Resh, 2008). Unpublished data from our group by Shu-Chun 
Chang confirms that Hhat co-localises well with the ER marker protein disulphide isomerase 
(PDI), but not with the Golgi marker GM130. To confirm that the newly cloned Hhat-V5 is 
localised in the ER and thus can be N-glycosylated, co-staining of the ER marker calnexin and 
Hhat-V5 was performed in cells transiently transfected with pcDNA-DEST40-NLT-Hhat. As 
expected, anti-V5 staining was obtained in transfected cells, but not in untransfected 
control cells and Hhat-V5 co-localised well with the ER membrane protein calnexin (Figure 
5.7). The Pearson’s correlation coefficient calculated over nine image frames was 
0.606±0.115 (mean±SD) representing good correlation (+1 – perfect co-localisation; 0 – 
random distribution; -1 – perfect exclusion). However, some discrepancies in the intensity 
and pattern of the signal were obvious. This may possibly be due to sub-fractionation of the 
two proteins within the ER. 
 
 
Figure 5.7 Co-localisation of Hhat-V5 with the ER marker calnexin-N in HEK293A cells.  
The cell in the lower right corner expresses Hhat-V5, whereas the cell in the upper left corner 
does not and thus serves as a negative control for staining of the V5 epitope. 
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5.2.5 N-glycosylation analysis of Hhat truncates 
For N-glycosylation mapping of Hhat topology, Hhat truncates were initially expressed in 
vitro in rabbit reticulocyte lysate in the presence of dog pancreatic microsomal membranes. 
Membrane proteins expressed in vitro become inserted into microsomal membranes where 
N-glycosylation and other post-translational modification of proteins can take place 
(Schwarz and Aebi, 2011). The foremost advantage of using an in vitro expression system 
compared to cell culture is the short expression time. While protein expression in vitro takes 
only a few hours, protein production by transfection of cells typically takes two days. Hhat-
FL and truncates Hhat-4/5, Hhat-8/9 and Hhat-12/13 were analysed by expression in 
microsomal membranes in vitro (Figure 5.8 A). However, due to detection problems, the 
remaining truncates Hhat-5/6, Hhat-6/7, Hhat-7/8 and Hhat-9/10, were analysed after 
transient transfection in HEK293A cells (Figure 5.8 B). The results showed at least partial 
glycosylation of truncates Hhat- 4/5, Hhat-6/7, Hhat-7/8, Hhat-9/10 and Hhat-12/13, 
suggesting that their C-termini are localised in the ER lumen. Hhat-5/6, Hhat-8/9 and Hhat-
FL, on the other hand, were not glycosylated, suggesting that their C-termini are cytosolic. 
Due to time constraints, I failed to obtain a clear result with truncate Hhat-11/12. 
Fortunately, after performing expression in HEK293A cells and N-glycosylation analysis, Dr. 
Antonio Konitsiotis was able to show that Hhat-11/12 was glycosylated indicating a luminal 
localisation of loop 11/12.  
In order to find out the fate of the signal peptide, truncates Hhat-4/5 and HA-Hhat-4/5 were 
expressed in vitro and their molecular sizes were compared. Hhat-4/5 appeared smaller 
than HA-Hhat-4/5 for both glycosylated and deglycosylated proteins, as would be expected 
if the N-terminal tag was still present due to a retained signal peptide. On the other hand, if 
the signal peptide was cleaved, the two proteins should have identical mobility. The 
presence of the N-terminal tag in the mature protein indicated that the signal peptide is 
retained confirming the prediction by SignalP 4.0 (Figure 5.8 C). However, attempts to 
immunoblot these samples with two different monoclonal anti-HA antibodies available in 
the lab failed. This may be due to poor antibodies, or the HA-tag sequence being 
compromised after translation. However, Dr Antonio Konitsiotis has subsequently been able 
to detect expression of HA-Hhat in HEK293A cells both by Western blotting and 
immunofluorescence imaging using an anti-HA antibody (data not shown). 
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Figure 5.8 N-glycosylation analysis of Hhat truncates. 
Protein expression was performed in (A) microsomal membranes or (B) in living cells (analysis 
of Hhat-11/12 was performed by Dr. Antonio Konitsiotis). (C) A size comparison between N-
terminally tagged HA-Hhat-4/5 and Hhat-4/5 suggests that the N-terminus is not cleaved after 
translation and therefore the signal peptide is likely to be retained in the mature protein. 
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5.2.6 Optimisation of HEK293A cell permeabilisation for epitope 
mapping by immunofluorescence imaging 
Epitope mapping by immunofluorescence in fixed cells requires cells to be semi-
permeabilised. Here, optimisation of conditions for achieving semi-permeabilisation is 
shown. Using two different antibodies against calnexin (anti-calnexin-C, targeting its luminal 
C-domain, and anti-calnexin-N, targeting its cytosolic N-terminal tail) I optimised the 
concentration of digitonin needed to achieve semi-permeabilisation in HEK293A cells. 
Typically, 0.2% (v/v) Triton X-100 is used to fully permeabilise cells while digitonin is used at 
concentrations of 0.00005-0.0008% (w/v) to semi-permeabilise cells (Lin et al., 1999, Guo et 
al., 2005, McFie et al., 2010). To find the appropriate working concentration of digitonin for 
HEK293A cells, this concentration range was tested by simultaneous staining for actin, 
calnexin-C and calnexin-N (Figure 5.9). 
Cells treated with PBS only or with 0.00005% digitonin did not show any ER staining at all. At 
digitonin concentrations of 0.0001% and higher, staining of calnexin-C was achieved, but not 
of calnexin-N. This showed that the plasma membrane was permeabilised, but not the ER. 
Calnexin-N was only visible in cells permeabilised with 0.2% Triton X-100. In this experiment, 
I was not able to reach the concentration of digitonin necessary to fully permeabilise the 
cells.  
Interestingly, in PBS only, although neither cytosolic nor luminal calnexin epitopes were 
visible, actin was fully stained. The same result was obtained when phalloidin used to stain 
F-actin was substituted with anti-tubulin antibodies (data not shown). It appeared that cell 
fixation with paraformaldehyde permeabilised the cell membrane. Reducing the 
paraformaldehyde concentration from 4% to 3% along with the fixation time from 20 to 10 
minutes did not have any noticeable effect. In summary, cell fixation appears to 
permeabilise HEK293A cells to a degree that makes staining of highly abundant proteins 
such as actin and tubulin possible, but not enough to obtain sufficient staining of low 
abundance of ER- residing proteins such as calnexin. This idea is supported by the fact that 
calnexin is not visible at 0.00005% digitonin, but appears as the concentration is increased. 
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Figure 5.9 Optimisation of semi-permeabilisation of HEK293A cells using digitonin. 
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5.2.7 Immunofluorescence imaging of Hhat truncates in semi-
permeabilised HEK293A cells 
HEK293A cells seeded on coverslips were transiently transfected to express Hhat-FL or Hhat 
truncates. After 24 h of expression cells were fixed, treated with 0.2% Triton X-100 or 
0.0004% digitonin and stained with a mix of anti-V5 and anti-calnexin-N antibodies. Actin 
staining with phalloidin was used to outline the cells. Representative images of each 
truncate are shown in Figure 5.10. 
Hhat-FL expressed well and a comparable number of cells were stained in both digitonin- 
and Triton X-100-treated cells. Hhat-12/13, Hhat-11/12, Hhat-9/10, Hhat-8/9 and Hhat-7/8 
expressed at successively lower levels. All except Hhat-7/9 were stained in digitonin-treated 
cells; however, the staining appeared lower than after Triton X-100 treatment. Expression 
levels of Hhat 6/7, Hhat-5/6, and Hhat-4/5 were too low to be reliably detected under these 
conditions. 
Statistical analysis of V5-stained areas expressed as a percentage of total cell area was used 
to calculate the differences between digitonin- and Triton X-100-treated cells (Figure 
5.11 A). Stained areas, rather than staining intensity, was used for quantification as it was 
noticed that digitonin-treatment generally resulted in lower staining intensities than Triton-
X100, most likely due to reduced penetration of antibodies in digitonin-treated cells 
compared to Triton X-100. Analysis of Hhat-FL shows that no significant difference between 
digitonin and Triton X-100-treated cells could be detected. On the other hand, Hhat-12/13 
and Hhat-11/12 show a significant difference in staining between digitonin- and Triton X-
100-treated cells (PHhat-12/13=0.0002; PHhat-11/12=0.0003). Also Hhat-9/10 shows a smaller but 
significant difference in staining (PHhat-9/10=0.0457). Neither Hhat-7/8 nor Hhat-8/9 show any 
statistically significant difference between the two permeabilisation conditions, although 
high variance and low signal levels make any conclusions difficult to make. The 
quantification also clearly illustrates the expression levels of Hhat truncates represented by 
staining of Triton X-100-treated cells, where longer truncates appear to be better expressed. 
This is likely to be due to poorer stability of truncates with fewer TM regions. 
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Figure 5.10 Immunostaining of the V5 epitope of Hhat truncates transiently expressed in 
HEK293A using anti-V5 antibody. The inserted magnified merged colour image represents a 
40×40 µm area of the frame. 
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If significantly less than 50% of transfected cells were visible in digitonin-treated samples, 
the V5 tag was considered to be luminal. Hhat-11/12 and Hhat-12/13, but not Hhat-9/10 
have less than 50% V5 visible in digitonin-treated cells, suggesting that these truncates are 
likely to have their C-termini inside the ER lumen protected from staining in semi-
permeabilised cells (Figure 5.11 B). These results should, however, be considered with 
caution as the used cut-off value does not have any experimental support. Further, the 
experiment has only been performed once and would need to be repeated for any 
conclusions to be made.  
 
Figure 5.11 Quantification of V5 staining in cells transiently expressing Hhat truncates. 
(A) V5 staining is expressed as a percentage of V5-stained area to total cell area as measured 
by actin staining (N=1, mean ± SD of three image frames per sample, unpaired t-test). 
(B) Percentage of V5-stained cell area detectable in digitonin-treated samples. 
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5.2.8 Summary of Hhat topology experiments 
The combined results for Hhat topology obtained from N-glycosylation and V5-epitope 
mapping of Hhat truncates are summarised in Table 5.1. To obtain a topology model for 
Hhat given the experimental data, the topology prediction server TOPCONS was used. 
TOPCONS has a feature which allows restrictions to be applied to residues or sections of 
known orientation which form a basis for the topology prediction of the remainder of the 
protein. Restrictions defining loop localisations as in Table 5.1 result in the topology 
model A presented in Figure 5.12. In contrast to predictions based on the positive-inside 
rule, N-glycosylation results of Hhat-4/5 suggest the N-terminus of Hhat to be luminal. On 
the other hand, localisation of the C-terminus has with high confidence been determined to 
be cytosolic. As TM regions 7 and 12 are predicted to be highly hydrophobic but do not span 
the membrane, there is a possibility that they are imbedded in the membrane to protect 
their hydrophobic residues from the aqueous solution (model B, Figure 5.12). In summary, 
this model shows that Hhat consists of 11 TM regions and that the conserved His residue, 
H379, resides in TM10 close to the cytosolic side of the protein. However, to characterise 
TM regions 10 and 11 in more detail, it may be necessary to create additional Hhat mutants 
targeting loop 10. 
Table 5.1 Summary of the orientation of the C-termini of Hhat truncates.  
Truncate Loop 
C-terminal orientation 
N-glycosylation Cell imaging Consensus 
Hhat-4/5 4 Luminal - Luminal 
Hhat-5/6 5 Cytosolic - Cytosolic 
Hhat-6/7 6 Luminal - Luminal 
Hhat-7/8 7 Luminal ? Luminal 
Hhat-8/9 8 Cytosolic ? Cytosolic 
Hhat-9/10 9 Luminal ? Luminal 
Hhat-11/12 11 Luminal Luminal Luminal 
Hhat-12/13 12 Luminal Luminal Luminal 
Hhat-FL C-terminus Cytosolic Cytosolic Cytosolic 
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Figure 5.12 Suggested membrane topology models based on experimental topology analysis 
and restricted topology prediction by TOPCONS. 
TM regions 10 and 11 are predicted to span the membrane resulting in His379 positioned 
inside TM10 close to the cytosolic membrane interface. In model A, TM7 and TM12 are 
suggested to make up loop regions. In models B, TM7 and TM12 are suggested to associate 
with the membrane. Loops with verified orientation are depicted in bold lines. 
5.2.9 Localisation of conserved residues in the topology model of Hhat 
To elucidate which residues in Hhat may be important for the catalytic function of the 
enzyme, a multiple sequence alignment using the T-COFFEE server (Di Tommaso et al., 
2011) was performed with Hhat proteins from nine species spanning the entire animal 
kingdom (Figure 5.13). Highly conserved residues are mostly located in the MBOAT region 
and are particularly concentrated in a portion which makes up TM regions 8-11. By locating 
these conserved residues in the proposed topology model B, patterns start to emerge 
(Figure 5.14). In addition, residues of known function based on available literature 
(Chamoun et al., 2001, Buglino and Resh, 2008) have been highlighted in the model. 26 
residues in model A and 28 in model B out of 32 fully conserved residues are located within, 
or in close proximity (1-2 aa) of a TM region. While most of them are hydrophobic, five are 
positively and two are negatively charged. It is not uncommon for charged residues to 
reside inside a TM region, as they may be involved in interactions with neighbouring TM 
helices. Although this may be the role for these charged residues in Hhat, it is possible they 
instead are involved in substrate binding of the negatively charged co-substrate palmitoyl-
CoA (Figure 5.15). The proposed catalytic site, H379, resides inside TM region 10 close to 
the cytosolic side of the membrane. Hence, H379 does not appear to be able to interact 
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Figure 5.13 Multiple sequence alignment of Hhat orthologues from nine species spanning the animal kingdom using the T-COFFEE server. 
Conserved residues are highlighted in blue shaded by percentage identity, fully conserved residues are marked with red asterisks, MBOAT domain of 
human Hhat is framed in yellow. Residues marked with green asterisks are considered to be fully conserved as B. taurus Hhat sequence is truncated. 
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Figure 5.14 Hhat topology model B in detail outlining conserved and catalytically important residues. 
Residues conserved across the animal superkingdom identified by multiple sequence analysis are outlined in purple. Highlighted residues of known 
function were derived from available literature (Chamoun et al., 2001, Buglino and Resh, 2008).  
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Figure 5.15 Molecular structure of palmitoyl-CoA. 
At physiological pH the three phosphate groups of CoA are partially deprotonated making 
palmitoyl-CoA a negatively charged amphiphilic molecule. 
directly with Hh during catalysis as it is positioned closer to the cytosolic side of the protein. 
This is further supported by a report that substitution of H379 by Ala reduces catalytic 
activity of Hhat only by 50% (Buglino and Resh, 2010).There are 14 Cys residues in Hhat, of 
which only one (C324) is highly conserved. In the topology model, it is positioned in the 
same area of TM9 as H379 in TM10, suggesting that by proximity interaction between them 
could be possible. As a Cys residue in DHHC PATs is responsible for catalytic activity, it is 
possible that C324 has a similar function in Hhat.  
5.3 Discussion and future work 
5.3.1 Method evaluation 
Depending on the studied protein, approaches used to map topology often involve 
interfering with the native protein sequence. It is usually necessary either to create N-
terminally modified protein truncates, or to introduce internal epitope tags in the full-length 
protein. Although removal of endogenous N-glycosylation sites in Hhat was not necessary, 
this study is based on the assumption that protein truncation does not interfere with the 
native folding of the protein. As neighbouring TM helices imbedded in the membrane often 
interact with each other to form a stable structure in the lipid bilayer, this assumption may 
in some cases prove wrong and some truncates may either be misfolded, resulting in poor 
expression efficiencies, or form dual topologies, ultimately leading to mistakes when 
interpreting the results. In N-glycosylation experiments, only half or less than half of 
truncates Hhat-4/5, Hhat-9/10 and Hhat-12/13 were glycosylated. As truncated Hhat are 
recombinant proteins, due to suboptimal placement of N-glycosylation sites possibly 
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resulting in steric hindrance, N-glycosylation is not expected to reach 100% efficiency. 
Nonetheless, partial N-glycosylation underlines the necessity of confirming the results by 
other means, for example by epitope mapping. In particularly, the localisation of loop 4 is in 
direct contrast to topology predictions in which the positive-inside rule dictates that loops 
with more positive residues are located in the cytosol. Loops 2 and 4 are rich in positively 
charged residues and are therefore expected to reside on the cytosolic side (Figure 5.16 A). 
Although Hhat may be an exception to the positive-inside rule (other exceptions include 
adenovirus protein E3-6.7K (Moise et al., 2004) and chloroplastic outer membrane protein 
 
Figure 5.16 Alternative Hhat topology with cytosolic N-terminus and TMs 1-4 complying to the 
positive-inside rule.  
(A) Topology of TM regions 1-4 of Hhat based on the positive-inside rule showing the N-
terminus and loop 4 in the cytosol. The truncation site in Hhat-4/5 is positioned upstream of 
two Arg residues possibly redirecting the orientation of TM4 from cytosolic to luminal. 
(B) Alternative Hhat topology which follows the positive-inside rule depicting TM5 as a 
cytosolic loop. This model is supported by recent evidence that the N-terminus of HA-Hhat-FL 
resides in the cytosol (experiment performed by Dr. Antonio Konitsiotis). 
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OEP14 (Li and Chen, 1996)), a close look at the sequence of Hhat-4/5 reveals that the 
truncate was created by introducing the C-terminal tag just upstream of two Arg residues. 
This loss of two positively charged aas may have disturbed the topology of TM4 which at 
least partially ended up in the ER lumen. Alternatively, the lack of subsequent TM regions 
may be destabilising Hhat-4/5 allowing it to adopt two topologies (personal communication 
with Gunnar von Heije). Preliminary epitope mapping studies of HA-Hhat-FL stably 
expressed in HEK293A cells recently performed by Dr. Antonio Konitsiotis, showed that the 
N-terminus of Hhat is located on the cytosolic side of the ER. These results contradict the N-
glycosylation results of Hhat-4/5 and necessitate the need to re-examine the localisation of 
loop 4, e.g. by remaking clone Hhat-4/5 to include all positively charged residues in the loop, 
inserting internal epitopes or N-glycosylation sites into loop 4 of wild-type Hhat, 
alternatively, performing Cys mapping with PEG-maleimide in the region (described below). 
If loop 4 would then prove to be cytosolic as it is predicted to be, the topology of Hhat 
would include 10 TM regions (TM5 would make up a cytosolic loop region as it is only 
weakly hydrophobic compared to TMs 1-4, see Figure 5.4) and would thus follow the 
positive-inside rule (Model C in Figure 5.16 B). 
Both Western blotting and imaging of Hhat truncates overexpressed in HEK293A cells in 
epitope mapping experiments demonstrated that ever smaller Hhat truncations resulted in 
progressively less stable protein products. The shortest truncates – Hhat-4/5, Hhat-5/6 and 
Hhat-6/7 – were very poorly expressed and were not detectable by immunofluorescence, 
hampering the utility of topology analysis by epitope mapping. As TM helices interact with 
each other to attain correct folding and stabilise it, it is unsurprising that their removal leads 
to lower protein stability. Selection of HEK293A cells stably expressing detectable levels of 
Hhat truncates is suggested in order to achieve better expression of less stable truncates. 
The approach proved successful when epitope mapping HA-Hhat-FL (see above), which is a 
poorly expressed protein probably due to its N-terminal HA epitope that precedes the signal 
peptide. The stability and correct folding of Hhat-FL and long Hhat truncates, in particular, 
could be tested by activity measurements using in vivo or in vitro palmitoylation assays of 
Shh. Buglino and Resh have reported an in vitro assay with Hhat solubilised from 
microsomal membranes using octyl glucoside and shown that C-terminally tagged Hhat 
(Hhat-HA-FLAG-His6) is active (Buglino and Resh, 2008, Buglino and Resh, 2010). 
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Unfortunately, they found that by removing only the C-terminal TM region (corresponding 
to Hhat-12/13), the protein lost its activity (Buglino and Resh, 2010). Therefore, this 
approach to confirm protein stability would be limited to analysis of Hhat-FL and HA-Hhat-
FL. 
While semi-permeabilisation of untreated cells appeared to work successfully when staining 
only calnexin in untransfected cells, epitope mapping of transiently expressed Hhat using 
anti-V5 antibody appeared to suffer from partial ER membrane permeabilisation in 
digitonin-treated cells (Figure 5.9 and Figure 5.10). All digitonin-treated samples expressing 
detectable levels of Hhat truncates contained a fraction of cells which were stained for V5. 
As none of the truncates was expected to have their C-termini in the cytosol, this suggested 
that some cells were fully permeabilised even after digitonin-treatment only. These cells 
were frequently stained by antibodies both against anti-V5 and the luminal marker anti-
calnexin-C and often appeared rounded and detached (Figure 5.10). Three explanations are 
possible: 1. The used digitonin concentration may be high enough to permeabilise a 
minority of cells, most likely those experiencing ER stress. Overexpression of proteins in the 
ER can lead to aggregation of unfolded protein inducing the unfolded protein response 
(UPR) in the cell (Walter and Ron, 2011). Activation of the UPR is a sign of ER stress, which 
results in cells either slowing down their ER protein expression or expanding their ER to 
cope with the demand. If ER stress persists, the UPR will result in apoptosis which will 
ultimately compromise the membrane integrity of cells, allowing luminal proteins to be 
stained in a sub-population of apoptotic digitonin-treated cells. 2. Treatment with 
transfection reagents is commonly known to contribute to rounding, detachment and death 
in a small sub-population of cells. 3. The V5 staining in both digitonin- and Triton X-100-
treated cells may be due to mixed protein topologies induced by destabilising protein 
truncations. This case is less likely as mixed topology should be equal in all cells and result in 
comparable numbers of stained cells in digitonin- and Triton-X100-treated samples, but with 
reduced staining intensity, which is not the case for any Hhat truncate (apart from Hhat-FL). 
A solution to circumvent permeabilisation problems due to ER stress and cell death may be 
the same as previously suggested to improve protein expression levels – to make HEK293A 
cell clones stably expressing each truncate. This would eliminate the need to treat cells with 
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harsh transfection reagents and allow selection of clones which are able to express 
detectable levels of truncates and at the same time avoid ER stress. 
A complementary method to N-glycosylation and epitope mapping not attempted in this 
thesis is Cys mapping with PEG-maleimide which is commonly used to determine the 
orientation of cysteine residues in a membrane protein. An advantage of cysteine mapping 
is that it does not rely on truncation mutants of epitope insertions, but the full-length native 
protein can be used. The method relies on semi-permeabilisation of living cells and 
modification of accessible cysteine residues with PEG-maleimide. However, dependent on 
the number and the position of Cys residues in the protein, mutation of all but one Cys may 
be necessary to identify the position of each individual residue in turn. Human Hhat 
contains 14 Cys residues. According to the proposed topology model, two Cys appear to be 
freely available in cytosolic and four in luminal loops, of which three are potentially buried 
inside membrane re-entering regions (model B in Figure 5.14). Mutation of some of the Cys 
residues may well be necessary for use of this method on Hhat which could negatively affect 
the structure and/or the function of the protein. Nonetheless, this approach may provide 
valuable validation of current data, as well as offering insight into whether TM7 and TM12 
are membrane re-entrant regions or not, and is currently in use in the Magee lab to confirm 
my topology model of Hhat. 
5.3.2 Implications of Hhat topology on its function 
As acylation of Hh occurs in the ER, the active site of Hhat is expected to reside on the 
luminal side of the protein. In the topology model of Hhat, the conserved His residue which 
is the proposed catalytic site for the MBOAT protein superfamily is located away from the 
ER lumen. Protein topology analyses of other MBOAT family members have been reported 
for human ACAT1 (Guo et al., 2005, Lin et al., 1999), ACAT2 (Lin et al., 2003), DGAT1 (McFie 
et al., 2010), Ale1 – a yeast lysophospholipid acyltransferase (LPLAT), and Gup1 – a yeast 
enzyme homologous to human Hhat and Gup1 which acylates GPI-anchored proteins (Pagac 
et al., 2011). Although very variable in their overall topologies, all but one have their 
conserved His on the luminal side of the protein. Only His in ACAT2 is imbedded in the 
cytosolic lattice of the ER membrane; however, these experiments suggest that most of the 
MBOAT domain is only dipping into the cytosolic side of the membrane spanning it only 
twice close to its N- terminus. To complicate the picture further, a recent functional study of  
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Figure 5.17 Membrane topology model of yeast Gup1. Adapted from Pagac et al. 2011. 
Reprinted with permission from the American Society for Biochemistry and Molecular Biology. 
DGAT1 performed in microsomal membranes of HepG2 cells reports that DGAT1 is 
functional on both sides of the membrane suggesting that the enzyme is able to adopt dual 
topologies (Wurie et al., 2011). As would be expected from sequence similarity, the 
topology model of yeast Gup1 is most similar to Hhat (Figure 5.17). However, the 
orientation of the conserved His in Gup1 is luminal, which possibly could reflect the 
antagonising role of mammalian Gup1 on Shh palmitoylation (Abe et al., 2008). 
Mutagenic substitution of the conserved histidine in mammalian DGAT1, ACAT1, ACAT2 and 
GOAT fully deactivated the proteins (McFie et al., 2010, Guo et al., 2005, Lin et al., 2003, 
Yang et al., 2008a), but substitution of H379 in human Hhat only reduced activity by about 
50% when assayed in vitro using detergent-solubilised enzyme (Buglino and Resh, 2010, 
Buglino and Resh, 2008). The same study revealed a number of other conserved residues 
important for catalysis (highlighted in Figure 5.14). Mutation of the conserved residue D339 
had the most profound effect on the activity of Hhat reducing it to only about 7% (Buglino 
and Resh, 2010). The effect of this mutation was first discovered in Drosophila where a 
double mutant corresponding to D339 and H379 in the human gene lost all detectable 
activity (Chamoun et al., 2001). His and Asp residues are able to form a diad which is 
commonly found in catalytic site of enzymes. Although the luminal localisation of D339 in 
my topology model of Hhat speaks in favour of it being directly involved in the catalysis, it 
does not seem to partner with H379 as this residue is located on the opposite side of the 
membrane. Another His highly conserved in Hhat, H267, is found in loop 7 on the luminal 
side of the membrane which by conservation and its localisation could possibly be involved 
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in the catalytic site. This, however, remains to be elucidated in future functional studies of 
Hhat. 
C324 is the only highly conserved Cys residue in Hhat (Figure 5.14) and has not yet been 
tested for its role in Hhat activity. As autopalmitoylation of a Cys residue in DHHC PATs 
results in a catalytic intermediate (Fukata et al., 2004), by analogy, it may be possible that 
C324 has a similar function in Hhat. Buglino and Resh were not able to detect palmitoylation 
of Hhat using radioactive probes (Buglino and Resh, 2010). Nonetheless, it may be of 
interest to assess the role of C324 in mutational activity and palmitoylation studies in vivo 
using click-chemistry reagents.  
While synthesis of acyl-CoA takes place in the cytosol, PATs of the secretory pathway, Hhat, 
Porc and GOAT, use acyl-CoA to acylate their protein targets in the ER lumen (Buglino and 
Resh, 2008, Willert et al., 2003, Takada et al., 2006, Gutierrez et al., 2008, Yang et al., 
2008a). There is as yet no clear evidence for how acyl chains are translocated across the ER 
membrane for this to occur. A well documented process is transport of long acyl-CoA across 
the mitochondrial matrix where fatty acid degradation (β-oxidation) takes place (Kunau et 
al., 1995). This process occurs in three steps. Carnitine acyltransferase I (CAT1) firstly 
converts acyl-CoA to acyl-carnitine upon which carnitine-acylcarnitine transporter (CACT), in 
exchange for a carnitine, transports acyl-carnitine across the inner membrane into the 
mitochondrial lumen by facilitated diffusion. In the lumen, CAT2 converts acyl-carnitine back 
to acyl-CoA which can be used in β-oxidation. There are several reports of CATs being 
localised in the ER involved in triacylglycerol synthesis for production of LDL particles in the 
secretory pathway (Khaled et al., 1999, Washington et al., 2003, Gooding et al., 2004, Sierra 
et al., 2008) implying that a similar mechanism of acyl-CoA transfer is present in the ER. 
Also, transport of free fatty acids into the ER (Rys-Sikora and Gill, 1998) and the presence of 
palmitoyl-CoA hydrolase activity in the ER (Mentlein et al., 1988, Berge and Dossland, 1979) 
have been documented. Based on this circumstantial evidence, Buglino and Resh have 
proposed that the ER is indeed a source of palmitoyl-CoA (Buglino and Resh, 2008). In the 
light of my finding of H379 in Hhat being located close to the cytosolic interface of the 
protein, another possibility remains, that Hhat itself is able to recruit palmitoyl-CoA directly 
from the cytosol. The string of positive residues across the membrane-spanning regions may 
play a role in binding and translocating palmitoyl-CoA across the membrane. The closest 
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homologue of Hhat in yeast, Gup1, has been implicated in a variety of cellular functions 
including glycerol uptake (Holst et al., 2000) and remodelling of GPI anchors (Bosson et al., 
2006). Although the exact mechanism of glycerol uptake by Gup1 remains to be seen, the 
diversity of its actions is enough to encourage the idea that Hhat, apart from having an 
acyltransferase activity, also may have additional functions, such as recruiting palmitoyl-CoA 
from the cytosol and thus too acting as a type of transporter. However, kinetic studies of 
Hhat showed that the H379A mutant at limiting palmitoyl-CoA concentrations had almost 
the same activity as wild type Hhat, while the activity was markedly reduced when Shh was 
the limiting factor (Buglino and Resh, 2010). This led to the conclusion that H379 was more 
likely to be involved in Hh protein binding than binding of palmitoyl-CoA. As these functional 
studies were performed in vitro with Hhat solubilised in detergent where palmitoyl-CoA and 
Shh are freely available in the solution, there is a possibility that the kinetics experiment do 
not reflect the behaviour of Hhat in its native membrane. To clarify these findings and to 
address the possibility of Hhat acting as a palmitoyl-CoA transporter, it will be necessary to 
perform Hhat activity studies in a system where Hhat is located in its native membrane. This 
could be achieved by preparing semi-permeabilised cells transfected with Hhat or its 
mutants for use in in vitro transcription/translation of Shh. Using a click-chemistry palmitoyl-
CoA analogue (e.g. YnC15-CoA available from Dr. Ed Tate) would allow for quantification of 
palmitoylated Shh by SDS-PAGE and subsequent in-gel fluorescence or Western blotting of 
the Shh band-shift induced by the click-chemistry capture reagent. The involvement of CAT1 
in palmitoylation of Hh proteins could further be tested by use of specific inhibitors, e.g. 
etomoxir, a potent inhibitor of CAT enzymes (Rufer et al., 2009). This experimental set-up 
could also be used to conduct mutational studies to assess the role of highly conserved 
positively charged residues outlined in Figure 5.14 in the recruitment of palmitoyl-CoA to 
the ER lumen by Hhat.  
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6 Conclusion and outlook 
The Hh signalling pathway plays an important role during embryonic development as well as 
tissue maintenance and regeneration in adults. Upregulation of Shh signalling found in 
subsets of various types of cancer have prompted an intense search for Shh pathway 
inhibitors. While most efforts have been targeted towards identifying potent inhibitors of 
Smo, this thesis describes some of the first steps towards establishing an alternative 
pharmaceutical target in cancers. Hh signal transduction is highly dependent on 
palmitoylation of its ligands and the PAT responsible for catalysing this reaction, Hhat, 
represents an alternative route to Hh pathway inhibition in cancer. To provide a basis for 
further studies of Hhat as a therapeutic target, the work in this thesis has been focused on 
the effect of Hhat KD on Shh signalling in lung cancer cell lines and on determining the 
membrane topology of Hhat in order to obtain functional information of this important 
enzyme. 
Recent developments in the field of chemical biology include the development of 
bioorthogonal reagents for detection and identification of post-translationally modified 
proteins. These reagents include palmitate analogues, alkynyl- and azidopalmitate, and their 
click chemistry partners – biotin- or fluorescence-labelled tags used to detect or enrich 
palmitoylated proteins. In Chapter 3, I demonstrated the use of click chemistry to study 
both palmitoylation and cholesteroylation of Shh in cell culture. These studies served to 
implement and optimise click reaction as a standard tool for detection of both lipid 
modifications in the lab. In addition, cell tolerance of the first bioorthogonal cholesterol tag 
is described.  
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Click reaction using alkynyl-palmitoyl was shown to be a reliable procedure for detection of 
Shh palmitoylation ready to be used in functional assays of Hhat in vivo with the aim to 
directly measure the effect of Hhat KD on Shh palmitoylation. Due to high background 
palmitoylation in whole cell lysates, palmitoylation of Shh was preferably detected by anti-
Shh Western blotting and mobility shift of tagged proteins, while cholesteroylation was 
readily detected over background using in-gel fluorescence imaging. Moreover, our dual 
labelling experiments provide one of the first demonstrations that it is be possible to 
simultaneously tag the same protein with two different click chemistry tags and detect them 
individually by in-gel fluorescence imaging using two different fluorescent tags. 
The assessment of the first bioorthogonal cholesterol tag for protein labelling, although not 
ideal for in vivo applications due to its high toxicity, opened up doors towards 
cholesteroylome studies by confirming that more proteins than just Hh may be 
cholesteroylated and providing a tag to pull down and identify cholesteroylated proteins. 
This is the first report of a tag for isolation of cholesteroylated proteins. However, due to 
the high toxicity of the cholesterol analogue, a second generation of cholesterol analogues 
has been developed with properties that greatly exceed those of the analogue studied here 
(Paulina Ciepla, unpublished results).  
Much effort in the past has been put into trying to show autocrine Shh ligand dependence in 
human cancer cell lines. In Chapter 4, I used a small panel of lung cancer cell lines 
expressing Shh pathway components to assess the role of Shh signalling on cell growth with 
the aim of finding cell lines dependent on Shh for growth. The results showed that lung 
cancer cell lines H209, H82 and A549 in particularly, are not dependent on autocrine Hh 
signalling for their growth. I also demonstrated that cyclopamine treatment leads to off-
target effects resulting in growth inhibition independent of Shh signalling. Therefore, 
cyclopamine as a tool to determine Hh signalling dependence in cancers should be treated 
with caution.  
Recent studies have shown that Shh signalling in some cancer types, rather than acting in an 
autocrine fashion, signals to the surrounding stroma in a paracrine fashion. Therefore, the 
possibility arises that upregulated Shh signalling in lung cancer also has a paracrine signalling 
role. In line with this, while A549 cells failed to respond to autocrine Shh pathway 
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modulation, they were able to induce a Shh signal response in a juxtacrine/paracrine fashion 
in mouse osteoblast progenitor cells C3H10T½. This mode of signalling was successfully 
inhibited by use of Hh inhibitors demonstrating an ability of lung cancer cells to induce a Shh 
signal response in neighbouring cells in a juxtacrine/paracrine fashion. Most importantly, 
siRNA KD of Hhat reduced the level of intracellular Shh as well as Shh signal response in 
neighbouring cells, confirming that palmitoylation is necessary for proper membrane 
anchoring and function of Shh and that Hhat inhibition is a viable way forward to achieve 
inhibition of Shh juxtacrine/paracrine signalling. While the role of this type of signalling in 
the progression of lung cancer remains to be determined, other cancer types which show 
evidence of both autocrine and paracrine Shh signalling modes, e.g. PDAC, may serve as 
models in order to continue Hhat studies in cell culture. Nonetheless, Hhat/Shh signalling 
could still be an inhibition target in lung cancer if a similar paracrine Shh signal-dependence 
can be confirmed.  
Having provided evidence that Hhat KD can reduce juxtacrine/paracrine Shh signalling in 
cancer cell lines, the next step onwards would be to develop a high throughput screen in 
order to find candidate inhibitors of Hhat. Efforts have already been made in the lab 
towards a cell-based paracrine signalling assay which will allow high throughput screening of 
inhibitors using Gli1 promoter-dependent activation of a reporter gene as a read-out. These 
studies are based on a small panel of Shh-expressing PDAC cell lines in co-culture with 
stromal cells able to respond to Shh signalling. Ongoing collaboration with Dr. Ed Tate at the 
Chemistry Department at Imperial College London aims to provide the team with candidate 
compounds for Hhat inhibition.  
While cell cultures are indispensable to assess the efficacy of novel Hh pathway inhibitors at 
the molecular level, in order to find out what impact Hh signalling has on cancer 
development and sustainment as a whole, it is crucial that we study Hh inhibition in vivo. If 
lead molecules able to inhibit Hh palmitoylation in cells are identified, the compounds 
should be tested in mice such as the PDAC mouse model where inhibition of paracrine Shh 
signalling is crucial for successful treatment of the tumour (Olive et al., 2009). 
In Chapter 5, I proposed a membrane topology model of Hhat based on N-glycosylation and 
epitope mapping combined with topology prediction. In this model, Hhat consists of 11 
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transmembrane regions with the signal peptide retained as a TM region in the mature 
protein and two regions which due to their hydrophobicity may be membrane-associated. 
N-glycosylation mapping of Hhat truncates proved to be the more robust technique for 
topology determination, although results unconfirmed by other means should be 
interpreted with caution. Recently obtained data (by Dr. Antonio Konitsiotis) suggest that 
the N-terminus of Hhat is localised on the cytosolic side of the membrane. This finding 
suggests that N-glycosylation of loop 4 may be an experimental artefact requiring further 
investigation using alternative means.  
The alternative strategy for determination of Hhat topology used to confirm N-glycosylation 
results was epitope mapping in semi-permeabilised cells. This method proved problematic 
and requires optimisation to produce reliable results. Two problems are evident; firstly, this 
method pointed out weaknesses in using protein truncation by showing that expression 
levels of shorter truncates are too low to be detected by immunofluorescence. Secondly, 
transient transfection or high expression levels appear to fully permeabilise a portion of 
digitonin-treated cells. To circumvent these problems, stable clones of cells expressing each 
Hhat truncate should be made, eliminating the use of transfection reagents and selecting 
clones which express detectable levels of Hhat truncates. 
By mapping the localisation of conserved residues within the current topology model, 
several leads for further investigation of the function and topology of Hhat were identified. 
Although the cytosolic localisation of loop 10 located closely to the conserved H379 has not 
been experimentally verified, TM prediction strongly suggests that H379 appears to be 
imbedded in a TM helix close to the cytosolic side of the membrane. As this localisation is 
contradictory to the His orientation in most other known MBOAT family protein topologies, 
and as Hh protein palmitoylation occurs in the ER lumen, these results question the role of 
H379 as the catalytic site of Hhat. The deviating localisation of H379 is not entirely surprising 
as mutational replacement of H379 with Ala does not entirely abolish its activity. Based on 
the topology model, several other conserved residues with potential catalytic importance 
emerged instead. These include D339 known to be indispensible for Hhat function, and 
H267 and C324 which reside on the luminal side of the protein and have as yet not been 
tested for their role in catalysis. In addition, mapping of Cys residues within the proposed 
topology models allows for rational design of further experiments to confirm the topology 
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of Hhat. The method of choice to do so is PEG-maleimide mapping of cytosolic Cys residues 
in semi-permeabilised cells. Using the current topology model, site-directed mutagenesis of 
Cys residues in selected Hhat truncates or full-length Hhat can be used to strategically 
replace them with the aim to minimise the effort needed to confirm the localisation of loops 
of interest. A complete model of Hhat topology would provide the basis for rational 
mutational studies of Hhat and serve to identify regions likely to be involved in substrate 
binding and catalysis. 
In summary, data presented in this thesis confirm the importance of palmitoylation for 
proper Shh signalling, specifically, Shh signal transduction from lung cancer cells to their 
surroundings. Combined with the proposed model of Hhat topology, these studies provide a 
firm basis for further investigation of the mechanism of action of Hhat and its role as a 
potential drug target in multiple human cancers. 
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